<SEC-DOCUMENT>0001104659-24-002065.txt : 20240108
<SEC-HEADER>0001104659-24-002065.hdr.sgml : 20240108
<ACCEPTANCE-DATETIME>20240108073607
ACCESSION NUMBER:		0001104659-24-002065
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240102
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240108
DATE AS OF CHANGE:		20240108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROCKWELL MEDICAL, INC.
		CENTRAL INDEX KEY:			0001041024
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				383317208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23661
		FILM NUMBER:		24518349

	BUSINESS ADDRESS:	
		STREET 1:		30142 WIXOM ROAD
		CITY:			WIXOM
		STATE:			MI
		ZIP:			48393
		BUSINESS PHONE:		8004493353

	MAIL ADDRESS:	
		STREET 1:		30142 WIXOM ROAD
		CITY:			WIXOM
		STATE:			MI
		ZIP:			48393

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20120530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL, INC.
		DATE OF NAME CHANGE:	20120525

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19970722
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm242195d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:rmti="http://rockwellmed.com/20240102">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_rmti_rockwellmed.com_20240102 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20240102_20240102 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001041024 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-01-02" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-01-02" name="dei:EntityCentralIndexKey">0001041024</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="rmti-20240102.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-01-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-02</xbrli:startDate>
        <xbrli:endDate>2024-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 18pt"><b>UNITED STATES</b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 18pt"><b>SECURITIES AND
EXCHANGE COMMISSION</b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 18pt"><b>Washington,
D.C. 20549</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: capitalize; text-align: center"><span style="text-transform: capitalize"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: capitalize; text-align: center"><span style="text-transform: capitalize"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_905_edei--DocumentType_c20240102__20240102_zYEn6otB7E98"><ix:nonNumeric contextRef="AsOf2024-01-02" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or
15(d) of</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Date of Report (Date of earliest event
reported)<b>: <span id="xdx_90D_edei--DocumentPeriodEndDate_c20240102__20240102_z0WmoS51P9Vk"><ix:nonNumeric contextRef="AsOf2024-01-02" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">January 2, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90D_edei--EntityRegistrantName_c20240102__20240102_zZ5MK4ogpce8" style="text-transform: uppercase"><b><ix:nonNumeric contextRef="AsOf2024-01-02" name="dei:EntityRegistrantName">Rockwell
Medical, Inc.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its
charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20240102__20240102_zRHbktPvp9hl"><ix:nonNumeric contextRef="AsOf2024-01-02" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center; width: 34%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_907_edei--EntityFileNumber_c20240102__20240102_zpt5SdTawLi8"><ix:nonNumeric contextRef="AsOf2024-01-02" name="dei:EntityFileNumber">000-23661</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20240102__20240102_zVsvbQaqvLQ7"><ix:nonNumeric contextRef="AsOf2024-01-02" name="dei:EntityTaxIdentificationNumber">38-3317208</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: center">(State or other jurisdiction <br />
    of incorporation)</td>
    <td style="vertical-align: middle; font-size: 10pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0"></p>
                                                                         <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
File Number)</span></p></td>
    <td style="vertical-align: top; text-align: center">(IRS Employer<br />
    Identification No.)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_903_edei--EntityAddressAddressLine1_c20240102__20240102_z73u5aBRN9U6"><b><ix:nonNumeric contextRef="AsOf2024-01-02" name="dei:EntityAddressAddressLine1">30142
S. Wixom Road</ix:nonNumeric></b></span><b>, <span id="xdx_902_edei--EntityAddressCityOrTown_c20240102__20240102_z9XlgCdloPI4"><ix:nonNumeric contextRef="AsOf2024-01-02" name="dei:EntityAddressCityOrTown">Wixom</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20240102__20240102_zNSkWmebscc8"><ix:nonNumeric contextRef="AsOf2024-01-02" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Michigan</ix:nonNumeric></span></b> <b><span id="xdx_901_edei--EntityAddressPostalZipCode_c20240102__20240102_zR9yGO2iwlEf"><ix:nonNumeric contextRef="AsOf2024-01-02" name="dei:EntityAddressPostalZipCode">48393</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices, including
zip code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_905_edei--CityAreaCode_c20240102__20240102_zKGtJ3zG59f7"><ix:nonNumeric contextRef="AsOf2024-01-02" name="dei:CityAreaCode">248</ix:nonNumeric></span>) <span id="xdx_90F_edei--LocalPhoneNumber_c20240102__20240102_zvwUXXSYvuqj"><ix:nonNumeric contextRef="AsOf2024-01-02" name="dei:LocalPhoneNumber">960-9009</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_90B_edei--WrittenCommunications_c20240102__20240102_zOE1lFUSptN5" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2024-01-02" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_90C_edei--SolicitingMaterial_c20240102__20240102_zQGJLLDRzqo4" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2024-01-02" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_908_edei--PreCommencementTenderOffer_c20240102__20240102_zgDyJCqggTDa" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2024-01-02" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_905_edei--PreCommencementIssuerTenderOffer_c20240102__20240102_zwA09gs04O41" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2024-01-02" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 38%; text-align: center; padding-bottom: 1pt; padding-left: 1.5pt">Title&#160;of&#160;Each&#160;Class</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 20%; text-align: center; padding-bottom: 1pt; padding-left: 1.5pt">Trading&#160;
    Symbol</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 38%; text-align: center; padding-left: 1.5pt">Name&#160;of&#160;Each&#160;exchange&#160;on&#160;which<br />
 registered</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 1.5pt"><span id="xdx_90D_edei--Security12bTitle_c20240102__20240102_z5OQGlmkhnl2"><ix:nonNumeric contextRef="AsOf2024-01-02" name="dei:Security12bTitle">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 1.5pt"><span id="xdx_90F_edei--TradingSymbol_c20240102__20240102_zjG8AuudlWHj"><ix:nonNumeric contextRef="AsOf2024-01-02" name="dei:TradingSymbol">RMTI</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 1.5pt"><span id="xdx_90B_edei--SecurityExchangeName_c20240102__20240102_zHKTqTUREcid"><ix:nonNumeric contextRef="AsOf2024-01-02" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2
of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Emerging
growth company <span style="font-family: Wingdings"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20240102__20240102_zy6SKMpbHEqg"><ix:nonNumeric contextRef="AsOf2024-01-02" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.
</span><span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b><span style="text-decoration: underline">Item 1.01</span></b></td><td><b><span style="text-decoration: underline">Entry into a Material Definitive Agreement</span>.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January&#160;2, 2024,
Rockwell Medical,&#160;Inc. (the &#8220;Company&#8221;) and Rockwell Transportation,&#160;Inc., a wholly-owned subsidiary of the Company
(&#8220;RTI&#8221;), entered into the Third Amendment to and Restatement of Loan and Security Agreement (the &#8220;A&amp;R Loan Agreement&#8221;)
with Innovatus Life Sciences Lending Fund I, LP (&#8220;Innovatus&#8221;), a Delaware limited partnership, as collateral agent and the
Lenders listed on Schedule 1.1 thereto, dated January&#160;1, 2024 (the &#8220;Effective Date&#8221;), which amended and restated the
Loan and Security Agreement, dated March&#160;16, 2020 (the &#8220;Original Effective Date&#8221;), as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The A&amp;R Loan Agreement
provides for the continuation of term loans initially borrowed on or after the Original Effective Date, in an aggregate outstanding principal
amount as of the Effective Date of $8.0 million (the &#8220;Term Loans&#8221;). The Company will make interest-only payments on the Term
Loans for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans will mature on the fifth anniversary
of the Effective Date, unless earlier repaid. The Term Loans will bear interest at the greater of (i)&#160;Prime Rate (as defined in the
A&amp;R Loan Agreement) and (ii)&#160;7.50%, plus 3.50%. At the Company&#8217;s option, 2.00% of the interest due on any applicable interest
payment date during the interest-only period may be paid in-kind by adding such amount to the then outstanding principal balance of the
Term Loans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Term Loans may be voluntarily prepaid in full
(but not partially) at any time, upon at least seven business days&#8217; prior notice. In connection with any voluntary prepayment or
satisfaction of the Term Loans prior to the maturity date (including any acceleration), the Company will pay all accrued and unpaid interest
and all other amounts due in connection with the Term Loans, together with (x)&#160;a prepayment fee (the &#8220;Prepayment Fee&#8221;)
equal to: (i)&#160;6.0% of the principal amount of the Term Loans prepaid if the payment is made before the first anniversary of the Effective
Date; (ii)&#160;2.0% of the principal amount of the Term Loans prepaid if the payment is made after the first anniversary of the Effective
Date but on or before the second anniversary of the Effective Date; (iii)&#160;1.0% of the principal amount of the Term Loans prepaid
if the payment is made after the second anniversary of the Effective Date but on or before the third anniversary of the Effective Date;
or (iv)&#160;0% of the principal amount of the Term Loans prepaid if the payment is made after the third anniversary of the Effective
Date through maturity, and (y)&#160;an additional fee equal to 4.375% of the funded amount of the Term Loans (such additional fee, the
&#8220;Final Fee&#8221;). The Term Loans will be mandatorily prepaid upon a change in control of the Company, or upon any early termination/acceleration
of the Term Loans. In the event of a mandatory prepayment of the Term Loans, the Company shall be required to pay the Prepayment Fee (if
applicable), as well as the Final Fee. The Final Fee shall be due and payable at maturity if it has not previously been paid in full in
connection with a prepayment of the Term Loans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The A&amp;R Loan Agreement
is secured by all assets of the Company and RTI. Proceeds were used for working capital purposes. The A&amp;R Loan Agreement contains
customary representations and warranties and affirmative and negative covenants, subject to exceptions as described in the A&amp;R Loan
Agreement. The A&amp;R Loan Agreement includes a financial covenant that requires actual consolidated revenue from the sale and supply
of hemodialysis products for the trailing six-month period (ended on the date when tested), to be not less than 85.0% of the projections
for the same period and, beginning with the quarter ending September&#160;30, 2024, actual consolidated revenue from the sale and supply
of hemodialysis products for the trailing six-month period (ended on the date when tested), to be not less than 80.0% of the projections
for the same period. The A&amp;R Loan Agreement also includes a liquidity covenant that requires that the Company to maintain minimum
liquidity of the greater of (x)&#160;the Company&#8217;s three-month cash burn or (y)&#160;the sum of $1.5 million and the aggregate amount
of capital lease payments required to be made during the succeeding 12 months (or during a continuing event of default, the aggregate
amount of capital lease payments required to be made during the entire term of such capital leases).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with the execution
of the A&amp;R Loan Agreement, on January&#160;2, 2024, the Company issued to Innovatus a warrant (the &#8220;Warrant&#8221;) to purchase
191,096 shares of the Company&#8217;s common stock with an exercise price of $1.83 per share. The Warrant may be exercised on a cashless
basis, and is immediately exercisable through the January&#160;2, 2029. The number of shares of common stock for which the Warrant is
exercisable and the exercise price are subject to certain proportional adjustments as set forth in the Warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The descriptions of the A&amp;R
Loan Agreement and the Warrant contained herein do not purport to be complete and are qualified in their entirety by reference to the
complete text of the A&amp;R Loan Agreement and the form of Warrant, which are attached to this Current Report on Form&#160;8-K as Exhibit&#160;10.1
and Exhibit&#160;4.1, respectively, and are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b><span style="text-decoration: underline">Item 2.02</span></b></td><td><b><span style="text-decoration: underline">Results of Operations and Financial Condition</span>.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The information set forth in Item 8.01 below regarding
the press release issued on January&#160;8, 2024 is incorporated by reference into this Item 2.02.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b><span style="text-decoration: underline">Item 2.03</span></b></td><td><b><span style="text-decoration: underline">Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant</span>.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The information set forth
in Item 1.01 above regarding the A&amp;R Loan Agreement is incorporated by reference into this Item 2.03.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b><span style="text-decoration: underline">Item 3.02</span></b></td><td><b><span style="text-decoration: underline">Unregistered Sales of Equity Securities</span>.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The information set forth
in Item 1.01 above regarding the Warrant is incorporated by reference into this Item 3.02. The issuance of shares of the Company&#8217;s
common stock underlying the Warrant will be made in reliance on the exemption from registration contained in Section&#160;4(a)(2)&#160;of
the Securities Act of 1933, as amended, and Rule&#160;506 of Regulation D thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b><span style="text-decoration: underline">Item 8.01</span></b></td><td><b><span style="text-decoration: underline">Other Events</span>.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January&#160;8, 2024,
the Company issued a press release announcing certain corporate updates. The press release is attached to this Current Report on Form&#160;8-K
as Exhibit&#160;99.1 and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b><span style="text-decoration: underline">Item 9.01</span></b></td><td><b><span style="text-decoration: underline">Financial Statements and Exhibits</span>.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;<i>Exhibits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">EXHIBIT&#160;INDEX</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><b>Exhibit&#160;<br />
No.</b></td>
    <td style="padding-bottom: 1.25pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Description</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 9%"><a href="tm242195d1_ex4-1.htm" style="-sec-extract: exhibit">4.1</a></td>
    <td style="width: 2%">&#160;</td>
    <td><a href="tm242195d1_ex4-1.htm" style="-sec-extract: exhibit">Form&#160;of January&#160;2024 Warrant to Purchase Common Stock issued to Innovatus.</a></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm242195d1_ex10-1.htm" style="-sec-extract: exhibit">10.1</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm242195d1_ex10-1.htm" style="-sec-extract: exhibit">Third Amendment to and Restatement of Loan and Security Agreement, dated January&#160;1, 2024, by and among the Company, Rockwell Transportation,&#160;Inc.,&#160;Innovatus Life Sciences Lending Fund I, LP and the lenders party thereto. </a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="tm242195d1_ex99-1.htm">99.1</a></td>
    <td>&#160;</td>
    <td><a href="tm242195d1_ex99-1.htm">Press Release, dated January&#160;8, 2024.</a></td></tr>
  <tr>
    <td style="vertical-align: top">104</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">Cover Page&#160;Interactive Data File, formatted in INline XBRL and included as Exhibit&#160;101.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">SIGNATURE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2"><b>ROCKWELL MEDICAL,&#160;INC.</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 50%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 46%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Date: January&#160;8, 2024</td>
    <td>By:&#160;</td>
    <td style="border-bottom: black 1pt solid">/s/&#160;Mark Strobeck</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Mark Strobeck</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Chief Executive Officer</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwkAMhU/QO4RZi05/dNGdFhWxihQRt0ObymA7KZnx70je0rFFDIGQvPflCTESa1rpBhnOiyKHI7ZdoxxCgTUymhK9I9tsU/CzwIu2jpVx/foDM/IMemY6jkt/7513bbFKQc4mMplEEmSSxiHMdyL46hmZWldonFYNKFPBgaljjU7xa/hwVE8y1L76pBOy1WRSCMdykN8QyTCCPd3Vg/hqIc8zEYz6CsSa6dZ9Y27WUQvLBlufZQf038EH0vxJBg== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>tm242195d1_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 4.1</B></FONT></P>

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;<U>ACT</U>&rdquo;), OR THE SECURITIES LAWS OF ANY STATE
AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY&#8239;NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED (I)&#8239;UNLESS
AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR (II)&#8239;WITHOUT AN OPINION OF COUNSEL,&#8239;IN FORM&#8239;AND SUBSTANCE REASONABLY SATISFACTORY
TO THE COMPANY, THAT SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&#8239;OF WARRANT TO PURCHASE STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="width: 85%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Company</I></FONT></TD>
    <TD STYLE="width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROCKWELL MEDICAL, INC.</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">191,096</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Type/Series of Stock</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Warrant Price</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.83 per share</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Issue Date</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 2, 2024</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Expiration Date</I></FONT></TD>
    <TD>January 2, 2029 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(See also Section 5.1(b))</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Credit Facility</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Warrant to Purchase Stock (&ldquo;<U>Warrant</U>&rdquo;) is issued in </FONT><FONT STYLE="font-size: 10pt">connection with that certain Loan and Security Agreement, dated March 16, 2020, among Innovatus Life Sciences Lending Fund I, LP, as Lender and Collateral Agent, the Lenders from time to time party thereto, and the Company (as modified, amended and/or restated from time to time, the &ldquo;<U>Loan Agreement</U>&rdquo;).</FONT></TD></TR>
  </TABLE><BR STYLE="clear: both">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS WARRANT CERTIFIES THAT,
for good and valuable consideration,&#8239;INNOVATUS LIFE SCIENCES LENDING FUND I, LP (&ldquo;<U>Innovatus</U>&rdquo;), a Delaware limited
partnership with an office located at 777 Third Avenue, 25th Floor, New York, NY 10017 (together with any successor or permitted assignee
or transferee of this Warrant or of any shares issued upon exercise hereof, &ldquo;<U>Holder</U>&rdquo;) is entitled to purchase the number
of fully paid and non-assessable shares (the &ldquo;<U>Shares</U>&rdquo;) of the above-stated Type/Series&#8239;of Stock (the &ldquo;<U>Class</U>&rdquo;)
of the above-named company (the &ldquo;<U>Company</U>&rdquo;) at the above-stated Warrant Price, all as set forth above and as adjusted
pursuant to Section&#8239;2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">SECTION&#8239;1. <U>EXERCISE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Method
of Exercise</U>. Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the Company
the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1
and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in Section&#8239;1.2, a check, wire transfer of
same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant
Price for the Shares being purchased.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Cashless
Exercise</U>. On any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified in Section&#8239;1.1
above, but otherwise in accordance with the requirements of Section&#8239;1.1, Holder may elect to receive Shares equal to the value of
this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the Company shall issue to the Holder such number
of fully paid and non-assessable Shares as are computed using the following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1.5in">&#8239;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X =</FONT></TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Y(A-B)/A</FONT></TD>
    </TR>
</TABLE>

<P STYLE="margin: 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where:</FONT></TD>
    </TR>
</TABLE>

<P STYLE="margin: 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1.5in">&#8239;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X =</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of Shares to be issued to the Holder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">Y =</TD><TD STYLE="text-align: justify">the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered
to the Company in payment of the aggregate Warrant Price);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">A =</TD><TD STYLE="text-align: justify">the Fair Market Value (as determined pursuant to Section&#8239;1.3 below) of one Share; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1.5in; font-size: 10pt">&#8239;</TD>
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B =</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Warrant Price.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Fair
Market Value</U>. If the Company&rsquo;s common stock is then traded or quoted on a nationally recognized securities exchange, inter-dealer
quotation system or over-the-counter market (a &ldquo;<U>Trading Market</U>&rdquo;) and the Class&#8239;is common stock, the fair market
value of a Share shall be the closing price or last sale price of a share of common stock reported for the Business Day immediately before
the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Company&rsquo;s common stock
is not traded or quoted on a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in
its reasonable good faith judgment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Delivery
of Certificate and New Warrant</U>. Promptly after Holder exercises this Warrant in the manner set forth in Section&#8239;1.1 or 1.2 above,
the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has
not been fully exercised and has not expired, a new warrant of like tenor representing the Shares not so acquired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Replacement
of Warrant</U>. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant
and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount
to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for cancellation, the Company shall, within
a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Treatment
of Warrant Upon Acquisition of Company</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Acquisition</U>.
For the purpose of this Warrant, &ldquo;<U>Acquisition</U>&rdquo; means any transaction or series of related transactions involving: (i)&#8239;the
sale, lease, exclusive license or other disposition of all or substantially all of the assets of the Company; (ii)&#8239;any merger or
consolidation of the Company into or with another person or entity (other than a merger or consolidation effected exclusively to change
the Company&rsquo;s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such
immediately prior to such merger, consolidation or reorganization, own less than a majority of the Company&rsquo;s (or the surviving or
successor entity&rsquo;s) outstanding voting power immediately after such merger, consolidation or reorganization; or (iii)&#8239;any sale
or other transfer by the stockholders of the Company of shares representing a majority of the Company&rsquo;s then-total outstanding combined
voting power.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Treatment
of Warrant at Acquisition</U>. In the event of an Acquisition in which the consideration to be received by the Company&rsquo;s stockholders
consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a &ldquo;<U>Cash/Public Acquisition</U>&rdquo;),
either (i)&#8239;Holder shall exercise this Warrant pursuant to Section&#8239;1.1 and/or 1.2 and such exercise will be deemed effective
immediately prior to and contingent upon the consummation of such Acquisition or (ii)&#8239;if Holder elects not to exercise the Warrant,
this Warrant will expire immediately prior to the consummation of such Acquisition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company shall provide Holder with written notice of its request relating to the Cash/Public Acquisition (together with such reasonable
information as Holder may reasonably require regarding the treatment of this Warrant in connection with such contemplated Cash/Public
Acquisition giving rise to such notice), which is to be delivered to Holder not less than ten (10)&#8239;Business Days prior to the closing
of the proposed Cash/Public Acquisition. Notwithstanding the foregoing, if, immediately prior to the Cash/Public Acquisition, the fair
market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section&#8239;1.3 above
would be greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date
to be exercised pursuant to Section&#8239;1.2 above as to all Shares (or such other securities) for which it shall not previously have
been exercised, and the Company shall promptly notify the Holder of the number of Shares (or such other securities) issued upon such exercise
to the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Upon
the closing of any Acquisition other than a Cash/Public Acquisition defined above, the acquiring, surviving or successor entity shall
assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property
as would have been paid for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding
on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the provisions of this
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
used in this Warrant, &ldquo;<U>Marketable Securities</U>&rdquo; means securities meeting all of the following requirements: (i)&#8239;the
issuer thereof is then subject to the reporting requirements of Section&#8239;13 or Section&#8239;15(d)&#8239;of the Securities Exchange
Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), and is then current in its filing of all required reports and other information
under the Act and the Exchange Act; (ii)&#8239;the class and series of shares or other security of the issuer that would be received by
Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing thereof is then traded in Trading
Market; and (iii)&#8239;Holder would be able to publicly re-sell, within six (6)&#8239;months following the closing of such Acquisition,
all of the issuer&rsquo;s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise
this Warrant in full on or prior to the closing of such Acquisition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">SECTION&#8239;2. <U>ADJUSTMENTS TO THE SHARES AND WARRANT
PRICE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Stock
Dividends, Splits, Etc</U>. If the Company declares or pays a dividend or distribution on the outstanding shares of the Class&#8239;payable
in common stock or other securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder
shall receive, without additional cost to Holder, the total number and kind of securities and property which Holder would have received
had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding
shares of the Class&#8239;by reclassification or otherwise into a greater number of shares, the number of Shares purchasable hereunder
shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Class&#8239;are
combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately
increased and the number of Shares shall be proportionately decreased.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Reclassification,
Exchange, Combinations or Substitution</U>. Upon any event whereby all of the outstanding shares of the Class&#8239;are reclassified, exchanged,
combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the
consummation of such event, this Warrant will be exercisable for the number, class and series of Company securities that Holder would
have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter
from time to time in accordance with the provisions of this Warrant. The provisions of this Section&#8239;2.2 shall similarly apply to
successive reclassifications, exchanges, combinations substitutions, replacements or other similar events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intentionally
Omitted</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intentionally
Omitted</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Fractional Share</U>. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued shall
be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall
eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the fractional interest by (a)&#8239;the
fair market value (as determined in accordance with Section&#8239;1.3 above) of a full Share, less (b)&#8239;the then-effective Warrant
Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notice/Certificate
as to Adjustments</U>. Upon each adjustment of the Warrant Price, Class&#8239;and/or number of Shares, the Company, at the Company&rsquo;s
expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, Class&#8239;and/or
number of Shares and facts upon which such adjustment is based. The Company shall, upon written request from Holder, furnish Holder with
a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, Class&#8239;and number of
Shares in effect upon the date of such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">SECTION&#8239;3. <U>REPRESENTATIONS AND COVENANTS OF THE COMPANY</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties</U>. The Company represents and warrants to, and agrees with, the Holder as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
initial Warrant Price referenced on the first page&#8239;of this Warrant is not greater than the lower of (i)&#8239;the volume weighted
average closing price of Rockwell&rsquo;s stock for the 30-trading day period ending on the last trading day immediately preceding the
execution of the Loan Agreement or (ii)&#8239;the closing price on the last trading day immediately preceding the execution of the Loan
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
Shares which may be issued upon the exercise of this Warrant, and all securities, if any, issuable upon conversion of the Shares, shall,
upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions
on transfer provided for herein or under applicable federal and state securities laws. The Company covenants that it shall at all times
cause to be reserved and kept available out of its authorized and unissued capital stock such number of shares of the Class, common stock
and other securities as will be sufficient to permit the exercise in full of this Warrant and the conversion of the Shares into common
stock or such other securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company&rsquo;s capitalization table attached hereto as Schedule 1 is true and complete, in all material respects, as of the Issue Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notice
of Certain Events</U>. If the Company proposes at any time to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">declare
any dividend or distribution upon the outstanding shares of the Class&#8239;or common stock, whether in cash, property, stock, or other
securities and whether or not a regular cash dividend;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">offer
for subscription or sale pro rata to the holders of the outstanding shares of the Class&#8239;any additional shares of any class or series
of the Company&rsquo;s stock (other than pursuant to contractual pre-emptive rights);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">effect
any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the Class;
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">effect
an Acquisition or to liquidate, dissolve or wind up; then, in connection with each such event, the Company shall give Holder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">at
least seven (7)&#8239;Business Days prior written notice of the date on which a record will be taken for such dividend, distribution, or
subscription rights (and specifying the date on which the holders of outstanding shares of the Class&#8239;will be entitled thereto) or
for determining rights to vote, if any, in respect of the matters referred to in (a)&#8239;and (b)&#8239;above; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">in
the case of the matters referred to in (c)&#8239;and (d)&#8239;above at least seven (7)&#8239;Business Days prior written notice of the date
when the same will take place (and specifying the date on which the holders of outstanding shares of the Class&#8239;will be entitled to
exchange their shares for the securities or other property deliverable upon the occurrence of such event).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reference is made to Section&#8239;1.6(c)&#8239;whereby
this Warrant will be deemed to be exercised pursuant to Section&#8239;1.2 hereof if the Company does not give written notice to Holder
of a Cash/Public Acquisition as required by the terms hereof. Company will also provide information requested by Holder that is reasonably
necessary to enable Holder to comply with Holder&rsquo;s accounting or reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Registration
Rights</U>. In the event that the Company files a resale registration statement at any time after the Issue Date, the Company will use
reasonable efforts to include the securities to be acquired upon exercise of this Warrant in such resale registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">SECTION&#8239;4. REPRESENTATIONS, WARRANTIES OF THE HOLDER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Holder represents and warrants to the Company as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Purchase
for Own Account.</U> This Warrant and the securities to be acquired upon exercise of this Warrant by Holder are being acquired for investment
for Holder&rsquo;s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of
the Act. Holder also represents that it has not been formed for the specific purpose of acquiring this Warrant or the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclosure
of Information.</U> Holder is aware of the Company&rsquo;s business affairs and financial condition and has received or has had full access
to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of
this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and receive answers from the Company
regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information
(to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify
any information furnished to Holder or to which Holder has access.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investment
Experience.</U> Holder understands that the purchase of this Warrant and its underlying securities involves substantial risk. Holder has
experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk
of such Holder&rsquo;s investment in this Warrant and its underlying securities and has such knowledge and experience in financial or
business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities
and/or has a preexisting personal or business relationship with the Company and certain of its officers, directors or controlling persons
of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Accredited
Investor Status.</U> Holder is an &ldquo;accredited investor&rdquo; within the meaning of Regulation D promulgated under the Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>The
Act.</U> Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under the Act in reliance
upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder&rsquo;s investment
intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any exercise hereof must be held indefinitely
unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration
and qualification are otherwise available. Holder is aware of the provisions of Rule&#8239;144 promulgated under the Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Voting Rights</U>. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">SECTION&#8239;5. <U>MISCELLANEOUS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Term
and Automatic Conversion Upon Expiration</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Term</U>.
Subject to the provisions of Section&#8239;1.6 above, this Warrant is exercisable in whole or in part at any time and from time to time
on or before 6:00 P.M., Eastern time, on the Expiration Date and shall be void thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Automatic
Cashless Exercise upon Expiration</U>. In the event that, upon the Expiration Date, the fair market value of one Share (or other security
issuable upon the exercise hereof) as determined in accordance with Section&#8239;1.3 above is greater than the Warrant Price in effect
on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section&#8239;1.2 above
as to all Shares (or such other securities) for which it shall not previously have been exercised, and the Company shall, within a reasonable
time, deliver a certificate representing the Shares (or such other securities) issued upon such exercise to Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Legends</U>.
The Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend
in substantially the following form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify">THE SHARES EVIDENCED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;<U>ACT</U>&rdquo;), OR THE SECURITIES LAWS OF ANY STATE
AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO INNOVATUS LIFE SCIENCES LENDING FUND I, LP
DATED MARCH&#8239;16, 2020, MAY&#8239;NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED (I)&#8239;UNLESS AND UNTIL REGISTERED UNDER
SAID ACT AND LAWS OR (II)&#8239;WITHOUT AN OPINION OF COUNSEL,&#8239;IN FORM&#8239;AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER, THAT
SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Securities Laws on Transfer</U>. This Warrant and the Shares issuable upon exercise of this Warrant (and the securities issuable,
directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part except in compliance
with applicable federal and state securities laws by the transferor and the transferee (including, without limitation, the delivery of
investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company).
The Company shall not require Holder to provide an opinion of counsel if the transfer is to an affiliate of Holder. Additionally, the
Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule&#8239;144 promulgated
under the Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transfer
Procedure.</U> Subject to the provisions of Section&#8239;5.3 and upon providing the Company with written notice, Holder may transfer all
or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable directly or indirectly, upon
conversion of the Shares, if any) to any transferee, <U>provided</U>, <U>however</U>, in connection with any such transfer, Holder will
give the Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification number of the
transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s)&#8239;(and Holder if applicable);
and <U>provided further</U>, that any subsequent transferee shall agree in writing with the Company to be bound by all of the terms and
conditions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
All notices and other communications hereunder from the Company to </FONT>the Holder, or vice versa, shall be deemed delivered and
effective (i)&#8239;when given personally, (ii)&#8239;on the third (3<SUP>rd</SUP>) Business Day after being mailed by first-class
registered or certified mail, postage prepaid, (iii)&#8239;upon actual receipt if given by facsimile or electronic mail and such
receipt is confirmed in writing by the recipient, or (iv)&#8239;on the first Business Day following delivery to a reliable overnight
courier service, courier fee prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case
may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section&#8239;5.5. All
notices to Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a
transfer or otherwise:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">INNOVATUS LIFE SCIENCES LENDING FUND I, LP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">777 Third Avenue, 25th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">New York, NY 10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: Claes Ekstrom</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notice to the Company shall
be addressed as follows until Holder receives notice of a change in address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">ROCKWELL MEDICAL,&#8239;INC.<BR>
30142 S. Wixom Road<BR>
Wixom, MI 48393</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attn: Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">With a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Gibson, Dunn&#8239;&amp; Crutcher LLP<BR>
One Embarcadero Center, Suite&#8239;2600<BR>
San Francisco, CA 94111</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attn: Ryan A. Murr</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Waiver</U>.
This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular instance and either
retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver,
discharge or termination is sought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Attorneys&rsquo;
Fees</U>. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in
such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys&rsquo;
fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Counterparts;
Facsimile/Electronic Signatures</U>. This Warrant may be executed in counterparts, all of which together shall constitute one and the
same agreement. Any signature page&#8239;delivered electronically or by facsimile shall be binding to the same extent as an original signature
page&#8239;with regards to any agreement subject to the terms hereof or any amendment thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. This Warrant shall be governed by and construed in accordance </FONT>with the laws of the State of New York, without giving
effect to its principles regarding conflicts of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning of any provision of
this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Business
Days</U>. &ldquo;<U>Business Day</U>&rdquo; is any day that is not a Saturday, Sunday or a day on which banks in New York, New York are
closed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature page&#8239;follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">IN WITNESS WHEREOF, the parties
have caused this Warrant to Purchase Stock to be executed by their duly authorized representatives effective as of the Issue Date written
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;COMPANY&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ROCKWELL MEDICAL, INC.</B></FONT></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 45%">&#8239;</TD>
    <TD STYLE="width: 50%">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print)</FONT></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;HOLDER&rdquo;</FONT></TD>
    <TD>&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INNOVATUS LIFE SCIENCES LENDING FUND I, LP</B></FONT></TD>
    <TD>&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Innovatus Life Sciences GP, LP </FONT></TD>
    <TD STYLE="width: 50%">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General Partner</FONT></TD>
    <TD>&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&#8239;</TD>
    <TD STYLE="width: 5%">&#8239;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print)</FONT></TD>
    <TD STYLE="width: 50%">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White">[Signature
Page&#8239;to Warrant]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&#8239;</FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>NOTICE OF EXERCISE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
undersigned Holder hereby exercises its right purchase</FONT>____________ shares of the Common
Stock of ROCKWELL MEDICAL,&#8239;INC. (the &ldquo;<U>Company</U>&rdquo;) in accordance with the attached Warrant To Purchase Stock, and
tenders payment of the aggregate Warrant Price for such shares as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">check
in the amount of $_______ payable to order of the Company enclosed herewith</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
                            <TD STYLE="text-align: left"> <FONT STYLE="font-size: 10pt"> </FONT>Wire transfer of immediately available funds to the
                            Company&rsquo;s account</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD>
                            <TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Cashless
Exercise pursuant to Section&#8239;1.2 of the Warrant</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Other [Describe]</FONT></TD>
                                                                                                                                                                                                      <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 3.25in">&#8239;</TD>
                                                                                                                                                                                                      <TD STYLE="text-align: justify; width: 3.25in">&#8239;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Please
issue a certificate or certificates representing the Shares in the name specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD>&#8239;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#8239;</TD>
                            <TD STYLE="text-align: left">&#8239;</TD></TR>
                                                                                                                                      <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15%"></TD><TD STYLE="width: 40%; text-align: left"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Name</FONT></TD>
                            <TD STYLE="text-align: left">&#8239;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&#8239;</TD><TD STYLE="text-align: left">&#8239;</TD>
                            <TD STYLE="text-align: left">&#8239;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&#8239;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#8239;</TD>
                            <TD STYLE="text-align: left">&#8239;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&#8239;</TD><TD STYLE="text-align: left">&#8239;</TD>
                            <TD STYLE="text-align: left">&#8239;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
                            <TD STYLE="text-align: left">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15%"></TD><TD STYLE="width: 36%; text-align: left">(Address)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">By
its execution below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in
Section&#8239;4 of the Warrant to Purchase Stock as of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.65in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">HOLDER:<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&#8239;</TD>
    <TD STYLE="font-size: 10pt; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 45%">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD STYLE="font-size: 10pt">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD STYLE="font-size: 10pt">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD STYLE="font-size: 10pt">(Date):</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 261pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White">Appendix
1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Company Capitalization Table</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of common stock outstanding
as of November&#8239;14, 2023 was 28,489,663 (as set forth in the Company&rsquo;s quarterly report on Form&#8239;10-Q filed with the SEC).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White">Schedule
1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>tm242195d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THIRD AMENDMENT TO AND RESTATEMENT OF LOAN AND
SECURITY AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THIS THIRD AMENDMENT TO AND RESTATEMENT OF
LOAN AND SECURITY AGREEMENT </B>(as the same may be amended, restated, modified, or supplemented from time to time, this &ldquo;<B>Agreement</B>&rdquo;),
dated as of January&#8239;1, 2024 (the &ldquo;<B>Effective Date</B>&rdquo;), among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware
limited partnership, as collateral agent (in such capacity, together with its successors and assigns in such capacity, &ldquo;<B>Collateral
Agent</B>&rdquo;), and the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including INNOVATUS LIFE
SCIENCES LENDING FUND I, LP, in its capacity as a Lender, and ROCKWELL MEDICAL,&#8239;INC., a Delaware corporation (&ldquo;<B>Parent</B>&rdquo;)
and ROCKWELL TRANSPORTATION,&#8239;INC., a Michigan corporation and a wholly owned Subsidiary of Parent (&ldquo;<B>RTI</B>&rdquo;) (individually
and collectively, jointly and severally, &ldquo;<B>Borrower</B>&rdquo;), provides the terms on which the Lenders shall agree to maintain
outstanding Term Loans to Borrower and Borrower shall repay the Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, Borrower, Collateral Agent and
the Lenders party thereto are parties to that certain Loan and Security Agreement, dated as of March&#8239;16, 2020 (such date, the &ldquo;<B>Original
Effective Date</B>&rdquo;; and such agreement, the &ldquo;<B>Original Loan and Security Agreement</B>&rdquo;; and, as amended by that
certain First Amendment to Loan and Security Agreement, dated as of September&#8239;24, 2021, and that certain Second Amendment to Loan
and Security Agreement, dated as of November&#8239;14, 2022, the &ldquo;<B>Existing Loan and Security Agreement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, Borrower has requested that the
Lenders agree to amend and restate the Existing Loan and Security Agreement in the form of this Agreement and waive any prior noncompliance
by the Borrower with the Existing Loan and Security Agreement as a result of the Borrower&rsquo;s having incurred Indebtedness in respect
of capital lease obligations in excess of the Two Hundred Fifty Thousand Dollars ($250,000.00) cap set forth in Section&#8239;7.4 of the
Existing Loan and Security Agreement (the &ldquo;<B>Waiver</B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, the Lenders have agreed to such
amendment and restatement and Waiver upon the terms and subject to the conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accordingly, in consideration of the mutual conditions
and agreements set forth in this Agreement, and for good and valuable consideration, the receipt of which is hereby acknowledged, the
parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>DEFINITIONS, ACCOUNTING AND OTHER TERMS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B>Capitalized
terms used herein shall have the meanings set forth in <U>Section&#8239;13</U> to the extent defined therein. All other capitalized terms
used but not defined herein shall have the meaning given to such terms in the Code. Any accounting term used but not defined herein shall
be construed in accordance with GAAP and all calculations shall be made in accordance with GAAP. The term &ldquo;financial statements&rdquo;
shall include the accompanying notes and schedules. Any section, subsection, schedule or exhibit references are to this Agreement unless
otherwise specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>LOANS AND TERMS OF PAYMENT</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Promise
to Pay</B>. Borrower hereby unconditionally promises to pay each Lender the outstanding principal amount of the Term Loans advanced to
Borrower by such Lender and accrued and unpaid interest thereon and any other amounts due hereunder as and when due in accordance with
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Term
Loans</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Outstanding
Term Loans</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;On
or after the Original Effective Date, pursuant to the Existing Loan and Security Agreement, the Lenders made Term Loans (as defined in
the Existing Loan and Security Agreement) to Borrower, the aggregate principal outstanding amount of which on the Effective Date is set
forth on <U>Schedule 1.1</U> hereto (the &ldquo;<B>Existing Term Loans</B>&rdquo;). Subject to the terms and conditions of this Agreement
and the other Loan Documents, and in reliance upon the representations and warranties set forth in this Agreement and the other Loan Documents,
each Lender severally agrees to continue its portion of the Existing Term Loans (such Existing Term Loans as continued hereunder, collectively,
the &ldquo;<B>Term Loans</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Repayment</U>.
Borrower shall make monthly payments of interest only commencing on the first (1<SUP>st</SUP>) Payment Date following the Effective Date,
and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the
Amortization Date. Borrower agrees to pay, on the first Payment Date after the Effective Date, any initial partial monthly interest payment
otherwise due for the period between the Effective Date and such Payment Date. Commencing on the Amortization Date, and continuing on
the Payment Date of each month thereafter, Borrower shall make equal monthly payments of principal, together with applicable interest,
in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based
upon: (1)&#8239;the amount of such Lender&rsquo;s Term Loan, (2)&#8239;the effective rate of interest, as determined in Section&#8239;2.3(a),
and (3)&#8239;a repayment schedule equal to the number of months remaining between the Amortization Date and the Maturity Date. All unpaid
principal and accrued and unpaid interest with respect to the Term Loans is due and payable in full on the Maturity Date. The Term Loans
may only be prepaid in accordance with Sections 2.2(c)&#8239;and 2.2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Mandatory
Prepayments</U>. If an event described in Section&#8239;7.2(c)(ii)&#8239;occurs or the Term Loans are accelerated following the occurrence
of an Event of Default, Borrower shall immediately pay to Lenders, payable to each Lender in accordance with its respective Pro Rata Share,
an amount equal to the sum of: (i)&#8239;all outstanding principal of the Term Loans plus accrued and unpaid interest thereon through the
prepayment date, (ii)&#8239;the Final Fee, (iii)&#8239;the Prepayment Fee, plus (iv)&#8239;all other Obligations that are due and payable,
including, without limitation, Lenders&rsquo; Expenses and interest at the Default Rate with respect to any past due amounts. Notwithstanding
(but without duplication with) the foregoing, on the Maturity Date, if the Final Fee had not previously been paid in full in connection
with the prepayment of the Term Loans in full, Borrower shall pay to each Lender in accordance with its respective Pro Rata Share, the
Final Fee in respect of the Term Loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Permitted
Prepayment of Term Loan</U>. Borrower shall have the option to prepay all (but not less than all) of the Term Loans outstanding under
this Agreement, provided Borrower (i)&#8239;provides written notice to Collateral Agent of its election to prepay the Term Loans at least
seven (7)&#8239;Business Days prior to such prepayment, (ii)&#8239;pays to the Lenders on the date of such prepayment, payable to each Lender
in accordance with its respective Pro Rata Share, an amount equal to the sum of (A)&#8239;all outstanding principal of such Term Loans
plus accrued and unpaid interest thereon through the prepayment date, (B)&#8239;the Final Fee, (C)&#8239;the Prepayment Fee, plus (D)&#8239;all
other Obligations that are due and payable, including, without limitation, Lenders&rsquo; Expenses and interest at the Default Rate with
respect to any past due amounts, and, (iii)&#8239;in the case of any such prepayment occurring on or prior to the first anniversary of
the Effective Date with the proceeds of Indebtedness provided by a Person or Persons other than the Lenders (such Indebtedness, &ldquo;<B>Third
Party Refinancing Indebtedness</B>&rdquo;), such prepayment shall only be permitted if, prior to incurring such Third Party Refinancing
Indebtedness and applying the proceeds thereof to such prepayment, Borrower shall have provided Lenders notice and a reasonable opportunity
to provide Indebtedness to Borrower on the same terms as those governing the Third Party Refinancing Indebtedness and the Lenders shall
have declined to so provide such Indebtedness on such terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Payment
of Interest on the Term Loan</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Interest
Rate</U>. Subject to Section&#8239;2.3(b), the principal amount outstanding under the Term Loans shall accrue interest at a floating rate
per annum equal to the Basic Rate (which shall be determined on the Effective Date and then from time to time thereafter by Collateral
Agent) which interest shall be payable monthly in arrears in accordance with Sections 2.2(b)&#8239;and 2.3(e); provided that during the
PIK Option Period, at the election of Borrower (which option Borrower must make prior to the Effective Date and, if made, it shall be
considered effective as of the Effective Date) 2.00% of such Basic Rate may be payable in-kind by adding such amount to the then outstanding
principal balance of the applicable Term Loans on each applicable Payment Date so as to increase the outstanding principal balance of
such Term Loans on each Payment Date and which amount shall be payable when the principal amount of the Term Loan is payable in accordance
with Sections 2.2(b)&#8239;and 2.3(e)&#8239;and on which principal amount interest shall be owed pursuant to Section&#8239;2.3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interest shall accrue on the
Term Loan commencing on, and including, the Effective Date, and shall accrue on the principal amount outstanding under the Term Loan through
and including the day on which the Term Loan is paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Default
Rate</U>. Immediately upon the occurrence and during the continuance of an Event of Default, Obligations shall accrue interest at a floating
per annum rate equal to the rate that is otherwise applicable thereto plus five percentage points (5.00%) (the &ldquo;<B>Default Rate</B>&rdquo;).
Payment or acceptance of the increased interest rate provided in this Section&#8239;2.3(b)&#8239;is not a permitted alternative to timely
payment and shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights or remedies of Collateral
Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>365
Day Year</U>. Interest shall be computed on the basis of a three hundred sixty-five (365) day year and the actual number of days elapsed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Debit
of Accounts</U>. Collateral Agent and each Lender may debit (or ACH) any deposit accounts maintained by Borrower or any of its Subsidiaries
for principal and interest payments or any other amounts Borrower owes the Lenders under the Loan Documents when due. Any such debits
(or ACH activity) shall not constitute a set off.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Payments</U>.
Except as otherwise expressly provided herein, all payments by Borrower under the Loan Documents shall be made to the respective Lender
to which such payments are owed, at such Lender&rsquo;s office in immediately available funds on the date specified herein. Unless otherwise
provided, interest is payable monthly on the Payment Date of each month. Payments of principal and/or interest received after 2:00 pm
Eastern time are considered received at the opening of business on the next Business Day. When a payment is due on a day that is not a
Business Day, the payment is due the next Business Day and additional fees or interest, as applicable, shall continue to accrue until
paid. All payments to be made by Borrower hereunder or under any other Loan Document, including payments of principal and interest, and
all fees, expenses, indemnities and reimbursements, shall be made without set off, recoupment or counterclaim, in lawful money of the
United States and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Application
of Payments</U>. Unless otherwise agreed or required by applicable law, payments will be applied first to any accrued unpaid interest
as shown on the most recent version of <U>Annex Y </U>hereto; then to principal; then to any late charges; and then to any unpaid collection
costs. Borrower will pay Collateral Agent at Collateral Agent&rsquo;s address shown above or at such other place as Collateral Agent may
designate in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Changes
in Prime Rate</U>. In the event the Prime Rate is changed from time to time hereafter and because of any such change the Basic Rate changes,
the Basic Rate shall be increased or decreased, effective as of the day of such change in the Prime Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Fees</B>.
Borrower shall pay to Collateral Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendment
Fee</U>. The Amendment Fee, which shall be due on the Effective Date, to be shared among the Lenders in accordance with their respective
Pro Rata Shares; it being understood and agreed that, in lieu of payment of the Amendment Fee in cash, Borrower may elect to pay the Amendment
Fee in kind by (i)&#8239;adding it to the principal balance of the Term Loan or (ii)&#8239;adding it to the amount of Warrants; provided
that Borrower has notified Collateral Agent of its intention to do so in writing prior to the Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Final
Fee</U>. The Final Fee, when due hereunder, to be shared among the Lenders in accordance with their respective Pro Rata Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Prepayment
Fee</U>. The Prepayment Fee, when due hereunder, to be shared among the Lenders in accordance with their respective Pro Rata Shares; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Lenders&rsquo;
Expenses</U>. All Lenders&rsquo; Expenses (including reasonable attorneys&rsquo; fees and expenses for due diligence, investigation, documentation
and negotiation of this Agreement) incurred through and after the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Withholding</B>.
Payments received by the Collateral Agent or the Lenders from Borrower hereunder will be made free and clear of and without deduction
for any and all present or future taxes, levies, imposts, duties, deductions, withholdings, assessments, fees or other charges imposed
by any governmental authority (including any interest, additions to tax or penalties applicable thereto). Specifically, however, if at
any time any Governmental Authority, applicable law, regulation or international agreement requires Borrower to make any withholding or
deduction from any such payment or other sum payable hereunder to the Lenders (other than any withholding or deduction attributable to
taxes imposed on or measured by net income (however denominated), franchise taxes, and branch profits taxes, in each case, imposed as
a result of such Lender being organized under the laws of, or having its principal office or its applicable lending office located in,
the jurisdiction imposing such tax (or any political subdivision thereof)), Borrower hereby covenants and agrees that the amount due from
Borrower with respect to such payment or other sum payable hereunder will be increased to the extent necessary to ensure that, after the
making of such required withholding or deduction, each Lender receives a net sum equal to the sum which it would have received had no
withholding or deduction been required and Borrower shall pay the full amount withheld or deducted to the relevant Governmental Authority;
provided, however, that Borrower shall not be required to make such increased payment to a Lender who is not a U.S. Person or who has
not provided a duly executed original IRS Form&#8239;W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax.
Borrower will, upon request, furnish the Lenders with proof reasonably satisfactory to the Lenders indicating that Borrower has made such
withholding payment; provided, however, that Borrower need not make any withholding payment if the amount or validity of such withholding
payment is contested in good faith by appropriate and timely proceedings and as to which payment in full is bonded or reserved against
by Borrower. The agreements and obligations of Borrower contained in this Section&#8239;2.5 shall survive the termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Secured
Promissory Notes</B>. If not already so evidenced, the Term Loans shall be evidenced by a Secured Promissory Note or Notes in the form
attached as <U>Exhibit&#8239;D</U> hereto (each a &ldquo;<B>Secured Promissory Note</B>&rdquo;), and shall be repayable as set forth in
this Agreement. Borrower irrevocably authorizes each Lender to make or cause to be made, on or about the Effective Date or at the time
of receipt of any payment of principal on such Lender&rsquo;s Secured Promissory Note, an appropriate notation on such Lender&rsquo;s
Secured Promissory Note Record reflecting the aggregate outstanding amount of such Term Loan or (as the case may be) the receipt of such
payment. The outstanding amount of each Term Loan set forth on such Lender&rsquo;s Secured Promissory Note Record shall be prima facie
evidence of the principal amount thereof owing and unpaid to such Lender, but the failure to record, or any error in so recording, any
such amount on such Lender&rsquo;s Secured Promissory Note Record shall not limit or otherwise affect the obligations of Borrower under
any Secured Promissory Note or any other Loan Document to make payments of principal of or interest on any Secured Promissory Note when
due. Upon receipt of an affidavit of an officer of a Lender as to the loss, theft, destruction, or mutilation of its Secured Promissory
Note, Borrower shall issue, in lieu thereof, a replacement Secured Promissory Note in the same principal amount thereof and of like tenor.
In addition, if any Lender shall desire to replace a secured promissory note received by such Lender under the Existing Loan and Security
Agreement, Borrower shall execute and deliver a Secured Promissory Note in replacement of such existing promissory note, which existing
promissory note shall be marked canceled and returned to Borrower upon receipt of the replacement Secured Promissory Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>CONDITIONS TO EFFECTIVE DATE</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Conditions
Precedent to Initial Term Loan</B>. Each Lender&rsquo;s obligation to maintain its Term Loans and for this Agreement to become effective
is subject to the condition precedent that Collateral Agent and each Lender shall consent to or shall have received, in form and substance
satisfactory to Collateral Agent and each Lender, such documents, and completion of such other matters, as Collateral Agent and each Lender
may reasonably deem necessary or appropriate, including, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Agreement and any other Loan Documents or amendments to Loan Documents, each duly executed by Borrower (with the wet ink original signature
of Borrower to the Warrant to be issued on the Effective Date to be delivered to Collateral Agent in advance of the Effective Date, the
wet ink original signature of Borrower to each Secured Promissory Note (if any) to be issued on the Effective Date to be delivered to
Collateral Agent within three days of the Effective Date and the balance of Borrower&rsquo;s original wet signatures to the Loan Documents
to be delivered to Collateral Agent within one week of the Effective Date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Operating Documents and good standing certificates of Borrower and its Subsidiaries certified, in the case of the formation documents
and good standing certificates, by the Secretary of State (or equivalent agency) of Borrower&rsquo;s and such Subsidiary&rsquo;s jurisdiction
of organization or formation, each as of a date no earlier than thirty (30) days prior to the Effective Date; provided that the deliverables
under this clause (d)&#8239;shall not be required as to Rockwell Medical India Private Limited (the &ldquo;<B>Indian Subsidiary</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
copy of resolutions of the governing body for Borrower evidencing approval of the terms of this Agreement and the other transactions evidenced
by the Loan Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;duly
executed officer&rsquo;s certificate for Borrower certifying as to (i)&#8239;the incumbency of each Responsible Officer executing each
Loan Document and (ii)&#8239;the documents delivered pursuant to Section&#8239;3.1(b)&#8239;and 3.1(c), in a form reasonably acceptable to
Collateral Agent and the Lenders (original wet signatures to such officer&rsquo;s certificate to be delivered to Collateral Agent within
one week of the Effective Date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;certified
copies, dated as of date no earlier than thirty (30) days prior to the Effective Date, of financing statement searches of the Borrower,
as Collateral Agent shall request, accompanied by written evidence (including any UCC termination statements) that the Liens indicated
in any such financing statements either constitute Permitted Liens or have been or, in connection with the transactions to be effected
on the Effective Date, will be terminated or released;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
duly executed legal opinion of counsel to Borrower dated as of the Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;payment
of the Amendment Fee and Lenders&rsquo; Expenses then due as specified in Section&#8239;2.4 hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
representations and warranties in Section&#8239;5 hereof shall be true, accurate and complete in all material respects on the Effective
Date; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are
qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring
to a specific date shall be true, accurate and complete in all material respects as of such date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;no
Event of Default or an event that with the passage of time could result in an Event of Default shall have occurred and be continuing or
result from the occurrence of the Effective Date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
such Lender&rsquo;s reasonable discretion, there has not been any Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>CREATION OF SECURITY INTEREST</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Grant
of Security Interest</B>. Borrower hereby grants, and ratifies and confirms its prior grant under the Existing Loan and Security Agreement,
to Collateral Agent, for the ratable benefit of the Lenders, to secure the payment and performance in full of all of the Obligations,
a continuing security interest in, and pledges, and ratifies and confirms its prior pledge under the Existing Loan and Security Agreement,
to Collateral Agent, for the ratable benefit of the Lenders, the Collateral, wherever located, whether now owned or hereafter acquired
or arising, and all proceeds and products thereof. If Borrower shall acquire a commercial tort claim (as defined in the Code) having a
value in excess of $100,000 (other than unasserted commercial tort claims), Borrower shall grant to Collateral Agent, for the ratable
benefit of the Lenders, a security interest therein and in the proceeds thereof, all upon the terms of this Agreement, with such writing
to be in form and substance reasonably satisfactory to Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this Agreement is terminated,
Collateral Agent&rsquo;s Lien in the Collateral shall continue until the Obligations (other than inchoate indemnity obligations) are repaid
in full in cash. Upon payment in full in cash of the Obligations (other than inchoate indemnity obligations) and at such time as the Lenders&rsquo;
obligation to extend the Term Loan has terminated, Collateral Agent shall, at the sole cost and expense of Borrower, release its Liens
in the Collateral and all rights therein shall revert to Borrower, and Collateral Agent shall, at the sole cost and expense of Borrower,
execute and deliver (and authorize Borrower and any of its designees to file) such terminations, releases and other documentation as necessary
and requested by Borrower to evidence such release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Authorization
to File Financing Statements</B>. Borrower hereby authorizes Collateral Agent, and ratifies and confirms its prior authorization under
the Existing Loan and Security Agreement of Collateral Agent, to file financing statements or take any other action required to perfect
Collateral Agent&rsquo;s security interests in the Collateral, without notice to Borrower, with all appropriate jurisdictions to perfect
or protect Collateral Agent&rsquo;s interest or rights under the Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Pledge
of Collateral</B>. Borrower hereby pledges, assigns and grants, and ratifies and confirms its prior pledge, assignment and grant pursuant
to the Existing Loan and Security Agreement of, to Collateral Agent, for the ratable benefit of the Lenders, a security interest in all
the Shares, together with all proceeds and substitutions thereof, all cash, stock and other moneys and property paid thereon, all rights
to subscribe for securities declared or granted in connection therewith, and all other cash and noncash proceeds of the foregoing, as
security for the performance of the Obligations. On the Effective Date, or, to the extent not certificated as of the Effective Date, within
ten (10)&#8239;days of the certification of any such Shares, the certificate or certificates for such Shares will be delivered to Collateral
Agent, accompanied by an instrument of assignment duly executed in blank by Borrower. To the extent required by the terms and conditions
governing such Shares, Borrower shall cause the books of each entity whose Shares are part of the Collateral and any transfer agent to
reflect the pledge of the Shares. Upon the occurrence and during the continuance of an Event of Default hereunder, Collateral Agent may
effect the transfer of any securities included in the Collateral (including but not limited to the Shares) into the name of Collateral
Agent and cause new (as applicable) certificates representing such securities to be issued in the name of Collateral Agent or its transferee.
Borrower will execute and deliver such documents, and take or cause to be taken such actions, as Collateral Agent may reasonably request
to perfect or continue the perfection of Collateral Agent&rsquo;s security interest in the Shares. Unless an Event of Default shall have
occurred and be continuing, Borrower shall be entitled to exercise any voting rights with respect to the Shares and to give consents,
waivers and ratifications in respect thereof, provided that no vote shall be cast or consent, waiver or ratification given or action taken
which would be inconsistent with any of the terms of this Agreement or which would constitute or create any violation of any of such terms.
All such rights to vote and give consents, waivers and ratifications shall terminate upon the occurrence and continuance of an Event of
Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>REPRESENTATIONS AND WARRANTIES</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrower represents and warrants to Collateral
Agent and the Lenders as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Due
Organization, Authorization: Power and Authority</B>. Borrower and each of its Subsidiaries is duly existing and in good standing as a
Registered Organization in its jurisdictions of organization or formation and Borrower and each of its Subsidiaries is qualified and licensed
to do business and is in good standing in any jurisdiction in which the conduct of its businesses or its ownership of property requires
that it be qualified except where the failure to do so could not reasonably be expected to have a Material Adverse Change. In connection
with this Agreement, Borrower and each of its Subsidiaries has delivered to Collateral Agent a completed perfection certificate on or
prior to the Effective Date (the &ldquo;<B>Perfection Certificate</B>&rdquo; and collectively with each updated Perfection Certificate
previously delivered pursuant to Section&#8239;6.2(b)(vi)&#8239;of the Existing Loan and Security Agreement or delivered pursuant to section
6.2(b)(iv)&#8239;hereof, the &ldquo;<B>Perfection Certificates</B>&rdquo;). Borrower represents and warrants that all the information set
forth on the Perfection Certificates pertaining to Borrower and each Guarantor is accurate and complete in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The execution, delivery and performance by Borrower
of the Loan Documents to which it is a party have been duly authorized, and do not (i)&#8239;conflict with any of Borrower&rsquo;s organizational
documents, including its Operating Documents, (ii)&#8239;contravene, conflict with, constitute a default under or violate any material
Requirement of Law applicable thereto, (iii)&#8239;contravene, conflict or violate any applicable order, writ, judgment, injunction, decree,
determination or award of any Governmental Authority by which Borrower, or any of its property or assets may be bound or affected, (iv)&#8239;require
any action by, filing, registration, or qualification with, or Governmental Approval from, any Governmental Authority (except such Governmental
Approvals which have already been obtained and are in full force and effect) or are being obtained pursuant to Section&#8239;6.1(b), or
(v)&#8239;constitute an event of default under any material agreement by which Borrower or any of such Subsidiaries, or their respective
properties, is bound. Neither Borrower nor any of its Subsidiaries is in default under any agreement to which it is a party or by which
it or any of its assets is bound in which such default could reasonably be expected to have a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Collateral</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower
has good title to, has rights in, and the power to transfer each item of the Collateral upon which it purports to grant a Lien under the
Loan Documents, free and clear of any and all Liens except Permitted Liens, and Borrower has no Deposit Accounts, Securities Accounts,
Commodity Accounts or other investment accounts other than the Collateral Accounts or the other investment accounts, if any, described
in the Perfection Certificates delivered to Collateral Agent in connection with the Existing Loan and Security Agreement or in connection
herewith with respect of which Borrower has given Collateral Agent notice and taken such actions as are necessary to give Collateral Agent
a perfected security interest therein. To the Borrower&rsquo;s Knowledge, the Accounts are bona fide, existing obligations of the Account
Debtors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
security interest granted under the Existing Loan and Security Agreement and the security interest granted herein has been, is and shall
at all times continue to be a first priority perfected security interest in the Collateral, subject only to Permitted Liens that are permitted
by the terms of this Agreement to have priority to Collateral Agent&rsquo;s Lien.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;On
the Effective Date, and except as disclosed on the Perfection Certificate (i)&#8239;the Collateral is not in the possession of any third
party bailee, and (ii)&#8239;no such third party bailee possesses components of the Collateral with a book value in excess of Three Hundred
Fifty Thousand Dollars ($350,000.00).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
Inventory and Equipment is in all material respects of good and marketable quality, free from material defects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower
and each of its Subsidiaries is the sole owner, except as specified on the most recent Perfection Certificate, of the Intellectual Property
each respectively purports to own, free and clear of all Liens other than Permitted Liens. Except as noted on the Perfection Certificates,
Borrower is not a party to, nor is bound by, any material license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Litigation</B>.
Except as disclosed on the most recently delivered Perfection Certificate, there are no actions, suits, investigations, or proceedings
pending or, to the Knowledge of the Responsible Officers, threatened in writing by or against Borrower or any of its Subsidiaries involving
more than One Hundred Fifty Thousand Dollars ($150,000.00) or a claim for infringement of any intellectual property. Except as disclosed
on the Perfection Certificate, there are no actions, suits, investigations or proceedings pending or, to the Knowledge of the Responsible
Officers, threatened in writing by or against Borrower or any Subsidiaries involving challenges to the validity of the Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Material Adverse Change; Financial Statements</B>. All consolidated financial statements for Borrower and its Subsidiaries, delivered
to Collateral Agent fairly present, in conformity with GAAP, in all material respects the consolidated financial condition of Borrower
and its Subsidiaries, and the consolidated results of operations of Borrower and its Subsidiaries for the periods covered thereby, subject,
in the case of unaudited financial statements, for the year end adjustments and the absence of footnotes. Since the date of the most recent
financial statements submitted to any Lender, there has not been a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Solvency</B>.
Borrower is Solvent and Borrower and its Subsidiaries, when taken as a whole, are Solvent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Regulatory
Compliance</B>. Neither Borrower nor any of its Subsidiaries is an &ldquo;investment company&rdquo; or a company &ldquo;controlled&rdquo;
by an &ldquo;investment company&rdquo; under the Investment Company Act of 1940, as amended. Neither Borrower nor any of its Subsidiaries
is engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve
Board of Governors). Borrower and each of its Subsidiaries has complied in all material respects with the Federal Fair Labor Standards
Act. Neither Borrower nor any of its Subsidiaries is a &ldquo;holding company&rdquo; or an &ldquo;affiliate&rdquo; of a &ldquo;holding
company&rdquo; or a &ldquo;subsidiary company&rdquo; of a &ldquo;holding company&rdquo; as each term is defined and used in the Public
Utility Holding Company Act of 2005. Neither Borrower nor any of its Subsidiaries has violated any laws, ordinances or rules, the violation
of which could reasonably be expected to have a Material Adverse Change. Neither Borrower&rsquo;s nor any of its Subsidiaries&rsquo; properties
or assets has been used by Borrower or such Subsidiary or, to Borrower&rsquo;s Knowledge, by previous Persons, in disposing, producing,
storing, treating, or transporting any hazardous substance other than in material compliance with applicable laws. Borrower and each of
its Subsidiaries has obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices
to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of Borrower, any of its Subsidiaries, or
any of Borrower&rsquo;s or its Subsidiaries&rsquo; Affiliates or any of their respective agents acting or benefiting in any capacity in
connection with the transactions contemplated by this Agreement, is (i)&#8239;in violation of any Anti Terrorism Law, (ii)&#8239;engaging
in or conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate,
any of the prohibitions set forth in any Anti Terrorism Law, or (iii)&#8239;is a Blocked Person. None of Borrower, any of its Subsidiaries,
or, to the Knowledge of Borrower, any of their Affiliates or agents acting or benefiting in any capacity in connection with the transactions
contemplated by this Agreement, (x)&#8239;conducts any business or engages in making or receiving any contribution of funds, goods or services
to or for the benefit of any Blocked Person, or (y)&#8239;deals in, or otherwise engages in any transaction relating to, any property or
interest in property blocked pursuant to Executive Order No.&#8239;13224, any similar executive order or other Anti Terrorism Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments</B>.
Neither Borrower nor any of its Subsidiaries owns any stock, shares, partnership interests or other equity securities except for Permitted
Investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tax
Returns and Payments; Pension Contributions</B>. Borrower and each of its Subsidiaries has timely filed all required tax returns and reports,
and Borrower and each of its Subsidiaries, has timely paid all foreign, federal, state, and local taxes, assessments, tax deposits and
tax contributions owed by Borrower and such Subsidiaries in an amount greater than Twenty-Five Thousand Dollars ($25,000.00), in all jurisdictions
in which Borrower or any such Subsidiary is subject to taxes, including the United States, unless such taxes are being contested in accordance
with the next sentence. Borrower and each of its Subsidiaries, may defer payment of any contested taxes, provided that Borrower or such
Subsidiary in good faith contests its obligation to pay the taxes by appropriate proceedings promptly and diligently instituted and conducted.
Neither Borrower nor any of its Subsidiaries is aware of any claims or adjustments proposed for any of Borrower&rsquo;s or such Subsidiaries&rsquo;
prior tax years which could result in additional taxes becoming due and payable by Borrower or its Subsidiaries. Borrower and each of
its Subsidiaries have paid all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance
with their terms, and neither Borrower nor any of its Subsidiaries have, withdrawn from participation in, and have not permitted partial
or complete termination of, or permitted the occurrence of any other event with respect to, any such plan which could reasonably be expected
to result in any material liability of Borrower or its Subsidiaries, including any liability to the Pension Benefit Guaranty Corporation
or its successors or any other Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Use
of Proceeds</B>. Borrower shall use the proceeds of the Term Loans solely as working capital and to fund its general business requirements
in accordance with the provisions of this Agreement, and not for personal, family, household or agricultural purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Full
Disclosure</B>. No written representation, warranty or other statement of Borrower or any of its Subsidiaries in any certificate or written
statement given to Collateral Agent or any Lender, as of the date such representation, warranty, or other statement was made, taken together
with all such written certificates and written statements given to Collateral Agent or any Lender, contains any untrue statement of a
material fact or omits to state a material fact necessary to make the statements contained in the certificates or statements not misleading
(it being recognized that projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions are not viewed
as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the projected
or forecasted results and any failure to meet such projections shall not be deemed to be a breach of any representation herein; provided,
however, such failure may constitute a breach of one or more specific covenants herein that based on such projections).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Shares</B>.
Borrower has full power and authority to create a first lien on the Shares and no disability or contractual obligation exists that would
prohibit Borrower from pledging the Shares pursuant to this Agreement. To Borrower&rsquo;s knowledge, there are no subscriptions, warrants,
rights of first refusal or other restrictions on transfer relative to, or options exercisable with respect to the Shares. The Shares have
been and will be duly authorized and validly issued, and are fully paid and non assessable. To Borrower&rsquo;s knowledge, the Shares
are not the subject of any present or threatened suit, action, arbitration, administrative or other proceeding, and Borrower knows of
no reasonable grounds for the institution of any such proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>AFFIRMATIVE COVENANTS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrower shall, and shall cause each of its Subsidiaries
to, do all of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Government
Compliance</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Maintain
its and all its Subsidiaries&rsquo; legal existence and good standing in their respective jurisdictions of organization and maintain qualification
in each jurisdiction in which the failure to so qualify could reasonably be expected to have a Material Adverse Change. Comply with all
laws, ordinances and regulations to which Borrower or any of its Subsidiaries is subject, the noncompliance with which could reasonably
be expected to have a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Obtain
and keep in full force and effect, all of the material Governmental Approvals necessary for the performance by Borrower and its Subsidiaries
of their respective businesses and obligations under the Loan Documents and the grant of a security interest to Collateral Agent for the
ratable benefit of the Lenders, in all of the Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Financial
Statements, Reports, Certificates; Notices</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Deliver
to Collateral Agent and each Lender:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
soon as available, but no later than thirty (30) days after the last day of each fiscal month (other than the last fiscal month of any
fiscal quarter) of Borrower, a company prepared summary consolidated balance sheet and income statement covering the consolidated operations
of Borrower and its Subsidiaries for such fiscal month certified by a Responsible Officer and in a form reasonably acceptable to Collateral
Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
soon as available, but no later than forty-five (45) days after the last day of each fiscal quarter or, if earlier, within five (5)&#8239;days
of filing its quarterly report on Form&#8239;10-Q with the Securities and Exchange Commission, a company prepared consolidated balance
sheet, income statement, statement of operations and cash flow statement covering the consolidated operations of Borrower and its Subsidiaries
for such fiscal quarter certified by a Responsible Officer and in a form reasonably acceptable to Collateral Agent (the form thereof delivered
to Collateral Agent prior to the Original Effective Date being acceptable to Collateral Agent);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
soon as available, but no later than ninety (90) days after the last day of Borrower&rsquo;s fiscal year or within five (5)&#8239;days
of filing with the Securities and Exchange Commission, audited consolidated financial statements of Borrower and its Subsidiaries prepared
under GAAP, consistently applied, together with an unqualified opinion on the financial statements from EisnerAmper LLP or such other
independent certified public accounting firm acceptable to Collateral Agent in its reasonable discretion;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
soon as available after approval thereof by Borrower&rsquo;s board of directors, but no later than the earlier of ten (10)&#8239;days after
such approval and sixty (60) days after the last day of Borrower&rsquo;s fiscal year, Borrower&rsquo;s annual (A)&#8239;financial projections
and (B)&#8239;budget, in each case, for the entire current fiscal year as approved by Borrower&rsquo;s board of directors; provided that,
any board approved revisions to such projections and/or budget approved by Borrower&rsquo;s board of directors shall be delivered to Collateral
Agent and the Lenders no later than seven (7)&#8239;days after such approval;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;within
five (5)&#8239;days of delivery, copies of all non-ministerial statements, reports and notices made available to Borrower&rsquo;s board
of directors, security holders generally or holders of Subordinated Debt; provided, notwithstanding anything set forth in this Section&#8239;6.2(a)(v),
Borrower shall not be required to deliver any such statements, reports or notices (i)&#8239;if Borrower determines in good faith and upon
the advice of counsel that the receipt of such materials by Collateral Agent or the Lenders would jeopardize the attorney-client privilege
between Borrower and its counsel, or any Subsidiary of Borrower and its counsel, (ii)&#8239;if and to the extent necessary, to protect
highly confidential proprietary information of Borrower or any of its Subsidiaries or (iii)&#8239;if information that is being disclosed
in such materials relate to Borrower or Subsidiary&rsquo;s strategy, negotiating positions or similar matters relating to Collateral Agent
or the Lenders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
the event that Borrower becomes subject to the reporting requirements under the Securities Exchange Act of 1934, as amended, within five
(5)&#8239;days of filing, all reports on Form&#8239;10 K, 10 Q and 8 K filed with the Securities and Exchange Commission;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;prompt
notice of any amendments of or other changes to the Operating Documents of Borrower or any of its Subsidiaries (other than the Indian
Subsidiary), together with any copies reflecting such amendments or changes with respect thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
soon as available, but no later than thirty (30) days after the last day of each month, copies of the month end account statements for
each Collateral Account maintained by Borrower or its Subsidiaries, which statements may be provided to Collateral Agent and each Lender
by Borrower or directly from the applicable institution(s);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ix)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;prompt
delivery of (and in any event within five (5)&#8239;days after the same are sent or received) copies of all material correspondence, reports,
documents and other filings with any Governmental Authority that could reasonably be expected to have a material adverse effect on any
of the Governmental Approvals material to Borrower&rsquo;s business or otherwise could reasonably be expected to have a Material Adverse
Change;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
prompt notice of any event that (A)&#8239;could reasonably be expected to materially and adversely affect the Borrower&rsquo;s
Intellectual Property and (B)&#8239;could reasonably be expected to result in a Material Adverse Change;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;written notice at least (10)&#8239;days prior to Borrower&rsquo;s creation of a New Subsidiary in accordance with the terms of
Section&#8239;6.10;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;written notice at least fifteen (15) days&rsquo; prior to Borrower&rsquo;s (A)&#8239;adding any new offices or business locations,
including warehouses (unless such new offices or business locations contain less than Three Hundred Fifty Thousand Dollars
($350,000.00) of book value in assets or property of Borrower), (B)&#8239;changing its jurisdiction of organization,
(C)&#8239;changing its organizational structure or type, (D)&#8239;changing its legal name, or (E)&#8239;changing any organizational
number (if any) assigned by its jurisdiction of organization;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;upon
Borrower becoming aware of the existence of any Event of Default or event which, with the giving of notice or passage of time, or both,
would constitute an Event of Default, prompt (and in any event within three (3)&#8239;Business Days) written notice of such occurrence,
which such notice shall include a reasonably detailed description of such Event of Default or event which, with the giving of notice or
passage of time, or both, would constitute an Event of Default;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;immediate
notice if Borrower or such Subsidiary has Knowledge that Borrower, or any Subsidiary or Affiliate of Borrower, is listed on the OFAC Lists
or (a)&#8239;is convicted on, (b)&#8239;pleads <I>nolo contendere </I>to, (c)&#8239;is indicted on, or (d)&#8239;is arraigned and held over
on charges involving money laundering or predicate crimes to money laundering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;notice of any commercial tort claim in excess of $100,000 (other than unasserted commercial tort claims) and of the general details
thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[reserved];
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;other
information as reasonably requested by Collateral Agent or any Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, documents required
to be delivered pursuant to the terms hereof (to the extent any such documents are included in materials otherwise filed with the Securities
and Exchange Commission) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which
Borrower posts such documents, or provides a link thereto, on Borrower&rsquo;s website on the internet at Borrower&rsquo;s website address.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Concurrently
with the delivery of the financial statements specified in Section&#8239;6.2(a)(ii)&#8239;above but no later than forty-five (45) days after
the last day of each fiscal quarter, deliver to Collateral Agent and each Lender:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
a duly completed Compliance Certificate signed by a Responsible Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;copies
of any material Governmental Approvals obtained by Borrower or any of its Subsidiaries;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;written
notice of the commencement of, and any material development in, the proceedings contemplated by Section&#8239;5.8 hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;written
notice of any litigation or governmental proceedings pending or threatened (in writing) against Borrower or any of its Subsidiaries,
which could reasonably be expected to result in damages or costs to Borrower or any of its Subsidiaries of more than Five Hundred Thousand
Dollars ($500,000.00) (not paid or covered by independent third party insurance);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;written
notice of all returns, recoveries, disputes and claims regarding Inventory that involve more than Two Hundred Fifty Thousand Dollars ($250,000.00)
individually or in the aggregate in any calendar year;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;an
updated Perfection Certificate to reflect any amendments, modifications and updates to information set forth in the Perfection Certificate
after the Effective Date to the extent such amendments, modifications and updates are permitted by one or more specific provisions in
this Agreement; in each case, subject to the review and approval of Collateral Agent and each Lender; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
the extent not included in the materials provided with the updated Perfection Certificate provided pursuant to Section&#8239;6.2(b)(vi)&#8239;above,
a written notice of any registrations or applications for Intellectual Property, to the extent not previously disclosed to Collateral
Agent and Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Keep
proper, complete and true books of record and account in accordance with GAAP in all material respects. Borrower shall, and shall cause
each of its Subsidiaries to, allow, at the sole cost of Borrower, Collateral Agent or any Lender, during regular business hours upon reasonable
prior notice (provided that no notice shall be required when an Event of Default has occurred and is continuing), to visit and inspect
any of its properties, to examine and make abstracts or copies from any of its books and records, and to conduct a collateral audit and
analysis of its operations and the Collateral. Such audits shall be conducted no more often than twice every year unless (and more frequently
if) an Event of Default has occurred and is continuing, provided that unless an Event of Default has occurred and is continuing, only
one such audit in any year shall be at the cost of Borrower. Notwithstanding the foregoing, upon request of any Lender, Borrower agrees
to permit such Lender to communicate with Borrower&rsquo;s accounting firm with respect to the consolidated financial statements delivered
pursuant to this Section&#8239;6.2, provided such communication shall be in the presence of an authorized representative of Borrower, and
provided further than the inability of Borrower to provide access to such accounting firm when requested by such lender shall not constitute
an Event of Default hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Inventory;
Returns</B>. Keep all Inventory in good and marketable condition, free from material defects. Returns and allowances between Borrower,
or any of its Subsidiaries, and their respective Account Debtors shall follow Borrower&rsquo;s, or such Subsidiary&rsquo;s, customary
practices as they exist at the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Taxes;
Pensions</B>. Timely file and require each of its Subsidiaries to timely file, all required tax returns and reports and timely pay, and
require each of its Subsidiaries to timely pay, all foreign, federal, state, and local taxes, assessments, deposits and contributions
owed by Borrower or its Subsidiaries, except as otherwise permitted pursuant to the terms of Section&#8239;5.8 hereof, and shall deliver
to Collateral Agent and each Lender, on demand, appropriate certificates attesting to such payments, and pay all amounts necessary to
fund all present pension, profit sharing and deferred compensation plans in accordance with the terms of such plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Insurance</B>.
Keep Borrower&rsquo;s and its Subsidiaries&rsquo; business and the Collateral insured for risks and in amounts standard for companies
in Borrower&rsquo;s and its Subsidiaries&rsquo; industry and location and as Collateral Agent may reasonably request, including, but not
limited to, D&amp;O insurance reasonably satisfactory to Collateral Agent. Insurance policies shall be in a form, with companies, and
in amounts that are reasonably satisfactory to Collateral Agent and Lenders. All property policies shall have a lender&rsquo;s loss payable
endorsement showing Collateral Agent as lender loss payee and waive subrogation against Collateral Agent, and all liability policies shall
show, or have endorsements showing, Collateral Agent, as additional insured. The Collateral Agent shall be named as lender loss payee
and/or additional insured with respect to any such insurance providing coverage in respect of any Collateral, and each provider of any
such insurance shall agree, by endorsement upon the policy or policies issued by it or by independent instruments furnished to the Collateral
Agent, that it will give the Collateral Agent thirty (30) days&rsquo; prior written notice before any such policy or policies shall be
materially altered or canceled (other than cancellation for non-payment of premiums, for which ten (10)&#8239;days&rsquo; prior written
notice shall be required). At Collateral Agent&rsquo;s request, Borrower shall deliver certified copies of policies and evidence of all
premium payments. Proceeds payable under any policy shall, at Collateral Agent&rsquo;s option, be payable to Collateral Agent, for the
ratable benefit of the Lenders, on account of the Obligations. Notwithstanding the foregoing, (a)&#8239;so long as no Event of Default
has occurred and is continuing, Borrower shall have the right to apply the proceeds of any casualty policy within 180 days of receipt
thereof (subject, in the case of replacement or repair of destroyed or damaged property of Borrower, to a cap of One Million Two Hundred
Fifty Thousand Dollars ($1,250,000.00) with respect to any loss, but not exceeding One Million Two Hundred Fifty Thousand Dollars ($1,250,000.00),
in the aggregate for all losses under all casualty policies in any one year; provided that any such replaced or repaired property (i)&#8239;shall
be of equal or like value as the replaced or repaired Collateral and (ii)&#8239;shall be deemed Collateral in which Collateral Agent has
been granted a first priority security interest, and (b)&#8239;after the occurrence and during the continuance of an Event of Default,
all proceeds payable under such casualty policy shall, at the option of Collateral Agent, be payable to Collateral Agent, for the ratable
benefit of the Lenders, on account of the Obligations). If Borrower or any of its Subsidiaries fails to obtain insurance as required under
this Section&#8239;6.5 or to pay any amount or furnish any required proof of payment to third persons, Collateral Agent and/or any Lender
may make (but has no obligation to do so), at Borrower&rsquo;s expense, all or part of such payment or obtain such insurance policies
required in this Section&#8239;6.5, and take any action under the policies Collateral Agent or such Lender deems prudent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Operating
Accounts</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower
shall provide Collateral Agent ten (10)&#8239;days&rsquo; prior written notice before Borrower or any of its Subsidiaries establishes any
Collateral Account. In addition, for each Collateral Account that Borrower at any time maintains, Borrower shall cause the applicable
bank or financial institution at or with which such Collateral Account is maintained to execute and deliver a Control Agreement or other
appropriate instrument with respect to such Collateral Account to perfect Collateral Agent&rsquo;s Lien in such Collateral Account in
accordance with the terms hereunder prior to the establishment of such Collateral Account, which Control Agreement may not be terminated
without prior written consent of Collateral Agent. The provisions of this Section&#8239;6.6(a)&#8239;shall not apply to deposit accounts
exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of Borrower&rsquo;s, or
any of its Subsidiaries&rsquo;, employees (which accounts shall be identified as such in the Perfection Certificate).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Neither
Borrower nor any of its Subsidiaries shall maintain any Collateral Accounts except Collateral Accounts maintained in accordance with Section&#8239;6.6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Protection
of Intellectual Property Rights</B>. Borrower and each of its Subsidiaries shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;protect,
defend and maintain the validity and enforceability of its Intellectual Property that is material to its business; (b)&#8239;promptly advise
Collateral Agent in writing of a challenge to the validity, or material infringement by a third party of its Intellectual Property; and
(c)&#8239;not allow any Intellectual Property material to its business to be abandoned, forfeited or dedicated to the public without Collateral
Agent&rsquo;s prior written consent. If Borrower (i)&#8239;obtains any patent, registered trademark or servicemark, registered copyright,
registered mask work, or any pending application for any of the foregoing, whether as owner, licensee or otherwise, or (ii)&#8239;applies
for any patent or the registration of any trademark or servicemark, then Borrower shall provide written notice thereof to Collateral Agent
and each Lender concurrently with the delivery of each Compliance Certificate, pursuant to an updated Perfection Certificate, and shall
execute such intellectual property security agreements and other documents and take such other actions as Collateral Agent shall reasonably
request in its good faith business judgment to perfect and maintain a first priority perfected security interest in favor of Collateral
Agent, for the ratable benefit of the Lenders, in such property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Litigation
Cooperation</B>. Commencing on the Effective Date and continuing through the termination of this Agreement, make available to Collateral
Agent and the Lenders, without expense to Collateral Agent or the Lenders, Borrower and each of Borrower&rsquo;s officers, employees and
agents and Borrower&rsquo;s Books, to the extent that Collateral Agent or any Lender may reasonably deem them necessary to prosecute or
defend any third party suit or proceeding instituted by or against Collateral Agent or any Lender with respect to any Collateral or relating
to Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Waivers
</B>In the event that Borrower or any of its Subsidiaries, after the Effective Date, intends to add any new offices or business locations,
including warehouses, or otherwise store any portion of the Collateral with, or deliver any portion of the Collateral to, a bailee, in
each case pursuant to Section&#8239;7.2, then Borrower or such Subsidiary will first notify Collateral Agent and, in the event that the
Collateral at any new location has a book value in excess of Three Hundred Fifty Thousand Dollars ($350,000.00) in the aggregate or such
new office constitutes Borrower&rsquo;s headquarter, Borrower shall obtain from such bailee or landlord, as applicable, must execute and
deliver a bailee waiver or landlord waiver, as applicable, in form and substance reasonably satisfactory to Collateral Agent prior to
the addition of any new offices or business locations, or any such storage with or delivery to any such bailee, as the case may be; provided,
however, the aggregate value of the Collateral that is not stored at locations subject bailee waiver or a landlord waiver in favor of
Collateral Agent shall not exceed One Million Dollars ($1,000,000.00).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Creation/Acquisition of Subsidiaries</B>. In the event any Borrower or any Subsidiary of any Borrower creates or acquires any
Subsidiary after the Effective Date, Borrower or such Subsidiary shall promptly notify Collateral Agent of such creation or
acquisition, and Borrower or such Subsidiary shall take all actions reasonably requested by Collateral Agent to achieve any of the
following (as determined by Collateral Agent in its reasonable discretion) with respect to such &ldquo;<B>New Subsidiary</B>&rdquo;
(defined as a Subsidiary formed after the date hereof during the term of this Agreement): (i)&#8239;to cause such New Subsidiary to
become either a co-Borrower hereunder, if such New Subsidiary is organized under the laws of the United States, or a secured
guarantor with respect to the Obligations; and (ii)&#8239;to grant and pledge to Collateral Agent a perfected security interest in
the Shares of such New Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Further
Assurances</B>. Execute any further instruments and take further action as Collateral Agent or any Lender reasonably requests to perfect
or continue Collateral Agent&rsquo;s Lien in the Collateral or to effect the purposes of this Agreement, including without limitation,
subject to the terms of Section&#8239;6.2(c), permitting Collateral Agent or any Lender to discuss Borrower&rsquo;s financial condition
with Borrower&rsquo;s accountants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Financial
Covenant. </B>Borrower shall achieve the following, as determined by Collateral Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
tested on the last date of each quarter, beginning with the quarter ending on December&#8239;31, 2023, actual consolidated revenue (as
measured in accordance with GAAP) from the sale and supply of Borrower&rsquo;s hemodialysis products (a/k/a concentrate products) for
the trailing six-month period (ended on the date when tested), in an amount not less than 85.00% of the projections for the same period
as set forth in the Management Plan; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
tested on the last date of each quarter, beginning with the quarter ending September&#8239;30, 2024, actual consolidated revenue (as measured
in accordance with GAAP) from the sale and supply of Borrower&rsquo;s hemodialysis products (a/k/a concentrate products) for the trailing
six-month period (ended on the date when tested), in an amount not less than 80.00% of the projections for the same period as set forth
in the Management Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liquidity
Covenant</B>. Borrower shall at all times maintain in a Collateral Account subject to a Control Agreement in favor of Collateral Agent
a cash balance of not less than an amount equal to the greater of (i)&#8239;the Minimum Cash Amount or (ii)&#8239;the sum of (a)&#8239;One
Million Five Hundred Thousand Dollars ($1,500,000), plus (b)&#8239;an amount equal to the Capital Lease Adjustment in effect at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>7.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>NEGATIVE COVENANTS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrower shall not, and shall not permit any of
its Subsidiaries to, do any of the following without the prior written consent of the Required Lenders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Dispositions</B>.
Convey, sell, lease, transfer, assign, dispose of (collectively, &ldquo;<B>Transfer</B>&rdquo;), or permit any of its Subsidiaries to
Transfer, all or any part of its business or property (including Intellectual Property), except for Transfers (a)&#8239;of Inventory in
the ordinary course of business; (b)&#8239;of worn out or obsolete Equipment or Equipment no longer used or useful in such Person&rsquo;s
business; (c)&#8239;in connection with Permitted Liens, Permitted Investments and Permitted Licenses; (d)&#8239;to the extent constituting
a Transfer, any restricted payment explicitly permitted by Section&#8239;7.7; (e)&#8239;having a fair market value not in excess of $1,000,000
during any fiscal year but not including Intellectual Property; (f)&#8239;from Subsidiary to Borrower; (g)&#8239;from one Borrower to another
Borrower; and (h)&#8239;constituting the sale or discount of Accounts or other rights to payment in connection with the compromise or collection
thereof, not in excess of $100,000 during any fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Changes
in Business, Management, Ownership, or Business Locations</B>. (a)&#8239;Engage in or permit any of its Subsidiaries to engage in any business
other than the businesses engaged in by Borrower as of the Original Effective Date or reasonably related thereto; (b)&#8239;liquidate or
dissolve (provided that any Subsidiary may be liquidated or dissolved provided that its assets are Transferred to Borrower); or (c)&#8239;(i)&#8239;any
Key Person shall cease to be actively engaged in the management of Borrower unless written notice thereof is provided to Collateral Agent
and each Lender within ten (10)&#8239;days of such, or (ii)&#8239;consummating any transaction or series of related transactions in which
(A)&#8239;the stockholders of Borrower who were not stockholders immediately prior to the first such transaction own more than 50% of the
voting stock of Borrower immediately after giving effect to such transaction or related series of such transactions and (B)&#8239;Borrower
ceases to own 100% of the ownership interests of a Subsidiary of Borrower (except pursuant to any Transfer permitted by Section&#8239;7.1
or liquidation or dissolution permitted by clause (b)&#8239;of this Section&#8239;7.2). Borrower shall not, without at least fifteen (15)
days&rsquo; prior written notice to Collateral Agent: (A)&#8239;add any new offices or business locations, including warehouses (unless
such new offices or business locations contain less than Three Hundred Fifty Thousand Dollars ($350,000.00) of book value in assets or
property of Borrower); (B)&#8239;change its jurisdiction of organization, (C)&#8239;change its organizational structure or type, (D)&#8239;change
its legal name, or (E)&#8239;change any organizational number (if any) assigned by its jurisdiction of organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Mergers
or Acquisitions</B>. Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with any other Person, or acquire,
or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock, shares or property of another Person. A Subsidiary
may merge or consolidate into another Subsidiary (provided such surviving Subsidiary is a &ldquo;co Borrower&rdquo; hereunder or has provided
a secured Guaranty of Borrower&rsquo;s Obligations hereunder) or with (or into) Borrower provided Borrower is the surviving legal entity,
and as long as no Event of Default is occurring prior thereto or arises as a result therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness</B>.
Create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to do so, other than Permitted Indebtedness (which,
without limitation, may be in the form of Cure Loan Subordinated Debt that is incurred pursuant to the provisions of Section&#8239;8.2(b)&#8239;or,
if no amount of Cure Loan Subordinated Debt is then outstanding and assuming all other applicable conditions are met, in the form of Qualified
Subordinated Debt).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Encumbrance</B>.
Create, incur, allow, or suffer any Lien on any of its property, or assign or convey any right to receive income, including the sale of
any Accounts, or permit any of its Subsidiaries to do so, except for Permitted Liens, or permit any Collateral not to be subject to the
first priority security interest granted herein (except for Permitted Liens), or enter into any agreement, document, instrument or other
arrangement (except with or in favor of Collateral Agent, for the ratable benefit of the Lenders) with any Person which directly or indirectly
prohibits or has the effect of prohibiting Borrower, or any of its Subsidiaries, from assigning, mortgaging, pledging, granting a security
interest in or upon, or encumbering any of Borrower&rsquo;s or such Subsidiary&rsquo;s Intellectual Property, except as is otherwise permitted
in Section&#8239;7.1 hereof and the definition of &ldquo;<B>Permitted Liens</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Maintenance
of Collateral Accounts</B>. Maintain any Collateral Account except pursuant to the terms of Section&#8239;6.6 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Restricted
Payments</B>. Pay any dividends (other than dividends payable solely in capital stock) or make any distribution or payment in respect
of or redeem, retire or purchase any capital stock (other than (a)&#8239;dividends and distributions paid by Subsidiaries to Borrower;
or (b)&#8239;repurchases pursuant to the terms of employee stock purchase plans, employee restricted stock agreements, stockholder rights
plans, director or consultant stock option plans, or similar plans, provided such repurchases do not exceed One Hundred and Fifty Thousand
Dollars ($150,000.00) in the aggregate per fiscal year).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments</B>.
Directly or indirectly make any Investment other than Permitted Investments, or permit any of its Subsidiaries to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Transactions
with Affiliates</B>. Directly or indirectly enter into or permit to exist any material transaction with any Affiliate of Borrower or any
of its Subsidiaries, except for (a)&#8239;transactions that are in the ordinary course of Borrower&rsquo;s or such Subsidiary&rsquo;s business,
upon fair and reasonable terms that are no less favorable to Borrower or such Subsidiary than would reasonably be obtained in an arm&rsquo;s
length transaction with a non affiliated Person, (b)&#8239;Subordinated Debt or equity investments by Borrower&rsquo;s investors in Borrower
or its Subsidiaries, (c)&#8239;employment and severance arrangements (including equity incentive plans and employee benefit plans and arrangements)
with their respective directors, officers and employees in the ordinary course of business, (d)&#8239;payment of customary fees and reasonable
out of pocket costs to, and indemnities for the benefit of, directors, officers and employees of the Borrower and its Subsidiaries in
the ordinary course of business to the extent attributable to the operation and governance of Borrower and its Subsidiaries, (e)&#8239;transactions
solely among Borrower and its Subsidiaries that are otherwise expressly permitted hereunder and (f)&#8239;transactions among Borrowers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subordinated
Debt</B>. (a)&#8239;Make or permit any payment on any Subordinated Debt, except under the terms of the subordination, intercreditor, or
other similar agreement to which such Subordinated Debt is subject, or (b)&#8239;amend any provision in any document relating to the Subordinated
Debt which would increase the amount thereof or adversely affect the subordination thereof to Obligations owed to the Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Compliance</B>.
Become an &ldquo;investment company&rdquo; or a company controlled by an &ldquo;investment company&rdquo;, under the Investment Company
Act of 1940, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined
in Regulation U of the Board of Governors of the Federal Reserve System), or use the proceeds of any Term Loan for that purpose; fail
to meet the minimum funding requirements of ERISA, permit a Reportable Event or Prohibited Transaction, as defined in ERISA, to occur;
fail to comply with the Federal Fair Labor Standards Act or violate any other law or regulation, if the failure to comply or violation
could reasonably be expected to have a Material Adverse Change, or permit any of its Subsidiaries to do so; withdraw or permit any Subsidiary
to withdraw from participation in, permit partial or complete termination of, or permit the occurrence of any other event with respect
to, any present pension, profit sharing and deferred compensation plan which could reasonably be expected to result in any liability of
Borrower or any of its Subsidiaries, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other
Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Compliance
with Anti Terrorism Laws</B>. Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries permit
any Affiliate to, directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed
on the OFAC Lists. Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries, permit any Affiliate
to, directly or indirectly, (i)&#8239;conduct any business or engage in any transaction or dealing with any Blocked Person, including,
without limitation, the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person,
(ii)&#8239;deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive
Order No.&#8239;13224 or any similar executive order or other Anti Terrorism Law, or (iii)&#8239;engage in or conspire to engage in any
transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth
in Executive Order No.&#8239;13224 or other Anti Terrorism Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Material
Agreements</B>. Neither Borrower nor any of its Subsidiaries shall (i)&#8239;materially amend a Material Agreement in a manner materially
adverse to the Lenders or (ii)&#8239;terminate a Material Agreement without giving prompt written notice within five (5)&#8239;Business
Days of such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>EVENTS OF DEFAULT</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any one of the following shall constitute an event
of default (an &ldquo;<B>Event of Default</B>&rdquo;) under this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Payment Default</B>. Borrower fails to (a)&#8239;make any payment of principal or interest on any Term Loan on its due date, or
(b)&#8239;pay any other Obligations within three (3)&#8239;Business Days after such Obligations are due and payable (which three
(3)&#8239;Business Day grace period shall not apply to payments due on the Maturity Date or the date of acceleration pursuant to
Section&#8239;9.1(a)&#8239;hereof);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
Covenant Default</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower
or any of its Subsidiaries fails or neglects to perform any obligation in Sections 6.2 (Financial Statements, Reports, Certificates),
6.4 (Taxes), 6.5 (Insurance), 6.6 (Operating Accounts), 6.7 (Protection of Intellectual Property Rights), 6.10 (Creation/Acquisition of
Subsidiaries), or 6.13 (Liquidity Covenant), Borrower violates any provision in Section&#8239;7 or Borrower violates any provision of the
Letter Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower
fails or neglects to perform its obligation under Section&#8239;6.12 (Financial Covenant); provided, however, as long as the Borrower
(i)&#8239;within 21 days following a failure to satisfy such Performance Covenant provides a written notification to Collateral Agent
of Borrower&rsquo;s intent to close a Qualified Financing Event within the Cure Period and (ii)&#8239;is proceeding with good faith effort
to consummate a Qualified Financing Event, a breach of Section&#8239;6.12 (Financial Covenant) shall not be deemed an Event of Default
until the lapse of the Cure Period by which time such breach must have been cured as described below. In the event that the Borrower
fails to comply with the requirements of the financial covenant set forth in Section&#8239;6.12, Borrower may cure such breach by means
of submitting a new financial plan under which Borrower is expected to break even on a cash flow basis prior to Maturity Date (which
financial plan shall be subject to the approval of Collateral Agent) and raising such amount of capital from Qualified Financing Event
as required per such new financial plan, no later than sixty (60) days after the occurrence of the breach (the &ldquo;<B>Cure Period</B>&rdquo;),
provided, that upon such cure the parties shall amend the covenant in Section&#8239;6.12 in accordance with such new financial plan which
amendment must be acceptable to Collateral Agent in its discretion;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower,
or any of its Subsidiaries, fails or neglects to perform, keep, or observe any other term, provision, condition, covenant or agreement
contained in this Agreement or any Loan Documents, and as to any default (other than those specified in this Section&#8239;8) under such
other term, provision, condition, covenant or agreement that can be cured, has failed to cure the default within fifteen (15) days after
the occurrence thereof; provided, however, that if the default cannot by its nature be cured within the fifteen (15) day period or cannot
after diligent attempts by Borrower be cured within such fifteen (15) day period, and such default is likely to be cured within a reasonable
time, then Borrower shall have an additional period (which shall not in any case exceed thirty (30) days) to attempt to cure such default,
and within such reasonable time period the failure to cure the default shall not be deemed an Event of Default (but no Term Loan shall
be made during such cure period);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Material
Adverse Change</B>. A Material Adverse Change has occurred;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Attachment;
Levy; Restraint on Business</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&#8239;The
service of process seeking to attach, by trustee or similar process, any funds of Borrower or any of its Subsidiaries or of any entity
under control of Borrower or its Subsidiaries on deposit with any institution at which Borrower or any of its Subsidiaries maintains a
Collateral Account, or (ii)&#8239;a notice of lien, levy, or assessment is filed against Borrower or any of its Subsidiaries or their respective
assets by any government agency, and the same under subclauses (i)&#8239;and (ii)&#8239;hereof are not, within ten (10)&#8239;days after
the occurrence thereof, discharged or stayed (whether through the posting of a bond or otherwise); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&#8239;any
material portion of Borrower&rsquo;s or any of its Subsidiaries&rsquo; assets is attached, seized, levied on, or comes into possession
of a trustee or receiver, or (ii)&#8239;any court order enjoins, restrains, or prevents Borrower or any of its Subsidiaries from conducting
any part of its business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Insolvency</B>.
(a)&#8239;Borrower becomes Insolvent or Borrower and its Subsidiaries (taken as a whole) become Insolvent; (b)&#8239;Borrower or any of
its Subsidiaries begins an Insolvency Proceeding; or (c)&#8239;an Insolvency Proceeding is begun against Borrower or any of its Subsidiaries
and not dismissed or stayed within forty five (45) days (but no Term Loan shall be extended while Borrower or any Subsidiary is Insolvent
and/or until any Insolvency Proceeding is dismissed);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Other
Agreements</B>. There is (a)&#8239;a default in any agreement to which Borrower or any of its Subsidiaries is a party with a third party
or parties resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness
in an amount in excess of One Million Dollars ($1,000,000.00) or that could reasonably be expected to have a Material Adverse Change;
or (b)&#8239;any default under a Material Agreement that permits the counterparty thereto to accelerate the payments owed thereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Judgments</B>.
(a)&#8239;One or more judgments, orders, or decrees for the payment of money in an amount, individually or in the aggregate, of at least
Seven Hundred Fifty Thousand Dollars ($750,000.00) ((i)&#8239;not paid or covered by independent third party insurance and (ii)&#8239;excluding
any judgments, orders or decrees, in an aggregate amount of up to $1,250,000.00, in connection with a dispute with Piramal Healthcare
(Canada) Limited (&ldquo;<B>Piramal</B>&rdquo;), in connection with the Supply Agreement dated November&#8239;2, 2015 (as amended, supplemented
or modified) between Borrower and Piramal) shall be rendered against Borrower or any of its Subsidiaries and shall remain unsatisfied,
unvacated, or unstayed for a period of ten (10)&#8239;consecutive days after the entry thereof or (b)&#8239;any judgments, orders or decrees
rendered against Borrower that could reasonably be expected to result in a Material Adverse Change;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Misrepresentations</B>.
Borrower or any of its Subsidiaries or any Person acting for Borrower or any of its Subsidiaries makes any representation, warranty, or
other statement now or later in this Agreement, any Loan Document or in any writing delivered to Collateral Agent and/or Lenders or to
induce Collateral Agent and/or the Lenders to enter this Agreement or any Loan Document, and such representation, warranty, or other statement,
when taken as a whole, is incorrect in any material respect when made;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subordinated
Debt</B>. A default or breach occurs under any agreement between Borrower or any of its Subsidiaries and any creditor of Borrower or any
of its Subsidiaries that signed a subordination, intercreditor, or other similar agreement with Collateral Agent or the Lenders, or any
creditor that has signed such an agreement with Collateral Agent or the Lenders breaches any terms of such subordination, intercreditor,
or other similar agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[Reserved]</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Governmental
Approvals; FDA Action</B>. (a)&#8239;Any Governmental Approval shall have been revoked, rescinded, suspended, modified in an adverse manner,
or not renewed in the ordinary course for a full term and such revocation, rescission, suspension, modification or non renewal has resulted
in or could reasonably be expected to result in a Material Adverse Change; or (b)&#8239;(i)&#8239;the FDA, DOJ, or other Governmental Authority
initiates a Regulatory Action or any other enforcement action against Borrower or any of its Subsidiaries or any supplier of Borrower
or any of its Subsidiaries that causes Borrower or any of its Subsidiaries to recall, withdraw, remove or discontinue manufacturing, distributing,
and/or marketing any of its products, even if such action is based on previously disclosed conduct; (ii)&#8239;the FDA issues a warning
letter or Regulatory Action to Borrower or any of its Subsidiaries with respect to any of its activities or products which could reasonably
be expected to result in a Material Adverse Change; (iii)&#8239;Borrower or any of its Subsidiaries conducts a mandatory or voluntary recall
which could reasonably be expected to result in liability and expense to Borrower or any of its Subsidiaries of Seven Hundred Fifty Thousand
Dollars ($750,000.00) or more; (iv)&#8239;Borrower or any of its Subsidiaries enters into a settlement agreement with the FDA, DOJ, or
other Governmental Authority that results in aggregate liability as to any single or related series of transactions, incidents or conditions,
of Seven Hundred Fifty Thousand Dollars ($750,000.00) or more, or that could reasonably be expected to result in a Material Adverse Change
even if such settlement agreement is based on previously disclosed conduct; or (v)&#8239;Borrower or any of its Subsidiaries fails to remediate
observations identified in an FDA Form&#8239;483 notice of inspection observation to Collateral Agent&rsquo;s reasonable satisfaction within
six months of receipt; or (vi)&#8239;the FDA revokes any authorization or permission granted under any Registration, or Borrower or any
of its Subsidiaries withdraws any Registration, that could reasonably be expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Lien
Priority; Intellectual Property</B>. Any Lien created hereunder or by any other Loan Document shall at any time fail to constitute a valid
and perfected Lien on any of the Collateral purported to be secured thereby, subject to no prior or equal Lien, other than Permitted Liens
arising as a matter of applicable law. Any Intellectual Property material to Borrower&rsquo;s business shall cease to be validly owned
or licensed by Borrower free and clear of any Liens other than Permitted Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Delisting</B>.
The shares of common stock of Parent are delisted from NASDAQ Global Market because of failure to comply with continued listing standards
thereof or due to a voluntary delisting which results in such shares not being listed within ninety (90) days on any other nationally
recognized stock exchange in the United States having listing standards at least as restrictive as the NASDAQ Global Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>RIGHTS AND REMEDIES</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Rights
and Remedies</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
the occurrence and during the continuance of an Event of Default, Collateral Agent may, without notice or demand, do any or all of the
following: (i)&#8239;deliver notice of the Event of Default to Borrower, (ii)&#8239;by notice to Borrower declare all Obligations immediately
due and payable (but if an Event of Default described in Section&#8239;8.5 occurs all Obligations shall be immediately due and payable
without any action by Collateral Agent or the Lenders) or (iii)&#8239;by notice to Borrower suspend or terminate the obligations, if any,
of the Lenders to advance money or extend credit for Borrower&rsquo;s benefit under this Agreement or under any other agreement between
Borrower and Collateral Agent and/or the Lenders (but if an Event of Default described in Section&#8239;8.5 occurs all obligations, if
any, of the Lenders to advance money or extend credit for Borrower&rsquo;s benefit under this Agreement or under any other agreement between
Borrower and Collateral Agent and/or the Lenders shall be immediately terminated without any action by Collateral Agent or the Lenders).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Without
limiting the rights of Collateral Agent and the Lenders set forth in Section&#8239;9.1(a)&#8239;above, upon the occurrence and during the
continuance of an Event of Default, Collateral Agent shall have the right, without notice or demand, to do any or all of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;foreclose
upon and/or sell or otherwise liquidate, the Collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;apply
to the Obligations any (a)&#8239;balances and deposits of Borrower that Collateral Agent or any Lender holds or controls, or (b)&#8239;any
amount held or controlled by Collateral Agent or any Lender owing to or for the credit or the account of Borrower; and/or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;commence
and prosecute an Insolvency Proceeding or consent to Borrower commencing any Insolvency Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Without
limiting the rights of Collateral Agent and the Lenders set forth in Sections 9.1(a)&#8239;and (b)&#8239;above, upon the occurrence and
during the continuance of an Event of Default, Collateral Agent shall have the right, without notice or demand, to do any or all of the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;settle
or adjust disputes and claims directly with Account Debtors for amounts on terms and in any order that Collateral Agent considers advisable,
notify any Person owing Borrower money of Collateral Agent&rsquo;s security interest in such funds, and verify the amount of such account;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;make
any payments and do any acts it considers necessary or reasonable to protect the Collateral and/or its security interest in the Collateral.
Borrower shall assemble the Collateral if Collateral Agent requests and make it available in a location as Collateral Agent reasonably
designates. Collateral Agent may enter premises where the Collateral is located, take and maintain possession of any part of the Collateral,
and pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses
incurred. Borrower grants Collateral Agent a license to enter and occupy any of its premises, without charge, to exercise any of Collateral
Agent&rsquo;s rights or remedies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;ship,
reclaim, recover, store, finish, maintain, repair, prepare for sale, and/or advertise for sale, the Collateral. Collateral Agent is hereby
granted a non exclusive, royalty free license or other right to use, without charge, Borrower&rsquo;s and each of its Subsidiaries&rsquo;
labels, Patents, Copyrights, mask works, rights of use of any name, trade secrets, trade names, Trademarks, service marks, and advertising
matter, or any similar property as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral
and, in connection with Collateral Agent&rsquo;s exercise of its rights under this Section&#8239;9.1, Borrower&rsquo;s and each of its
Subsidiaries&rsquo; rights under all licenses and all franchise agreements inure to Collateral Agent, for the benefit of the Lenders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;place
a &ldquo;hold&rdquo; on any account maintained with Collateral Agent or the Lenders and/or deliver a notice of exclusive control, any
entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any
Collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;demand
and receive possession of Borrower&rsquo;s Books;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;appoint
a receiver to seize, manage and realize any of the Collateral, and such receiver shall have any right and authority as any competent court
will grant or authorize in accordance with any applicable law, including any power or authority to manage the business of Borrower or
any of its Subsidiaries; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;subject
to clauses 9.1(a)&#8239;and (b), exercise all rights and remedies available to Collateral Agent and each Lender under the Loan Documents
or at law or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any provision of this Section&#8239;9.1
to the contrary, upon the occurrence and during the continuance of any Event of Default (that has not been waived by Collateral Agent
and Required Lenders), Collateral Agent shall have the right to exercise any and all remedies referenced in this Section&#8239;9.1 without
the written consent of Required Lenders following the occurrence of an Exigent Circumstance. For the purposes of clarification, an Event
of Default after occurrence shall continue for the purposes of this Agreement unless and until it is waived by Collateral Agent and Required
Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Power
of Attorney</B>. Borrower hereby irrevocably appoints Collateral Agent as its lawful attorney in fact, exercisable upon the occurrence
and during the continuance of an Event of Default, to: (a)&#8239;endorse Borrower&rsquo;s or any of its Subsidiaries&rsquo; name on any
checks or other forms of payment or security; (b)&#8239;sign Borrower&rsquo;s or any of its Subsidiaries&rsquo; name on any invoice or
bill of lading for any Account or drafts against Account Debtors; (c)&#8239;settle and adjust disputes and claims about the Accounts directly
with Account Debtors, for amounts and on terms Collateral Agent determines reasonable; (d)&#8239;make, settle, and adjust all claims under
Borrower&rsquo;s insurance policies; (e)&#8239;pay, contest or settle any Lien, charge, encumbrance, security interest, and adverse claim
in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same; and (f)&#8239;transfer
the Collateral into the name of Collateral Agent or a third party as the Code or any applicable law permits. Borrower hereby appoints
Collateral Agent as its lawful attorney in fact to sign Borrower&rsquo;s or any of its Subsidiaries&rsquo; name on any documents necessary
to perfect or continue the perfection of Collateral Agent&rsquo;s security interest in the Collateral during the continuance of an Event
of Default until all Obligations (other than inchoate indemnity obligations) have been satisfied in full and Collateral Agent and the
Lenders are under no further obligation to extend the Term Loan hereunder. Collateral Agent&rsquo;s foregoing appointment as Borrower&rsquo;s
or any of its Subsidiaries&rsquo; attorney in fact, and all of Collateral Agent&rsquo;s rights and powers, coupled with an interest, are
irrevocable until all Obligations (other than inchoate indemnity obligations) have been fully repaid and performed and Collateral Agent&rsquo;s
and the Lenders&rsquo; obligation to provide the Term Loan terminates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<!-- Field: Split-Segment; Name: 01 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Protective
Payments</B>. If Borrower or any of its Subsidiaries fail to obtain the insurance called for by Section&#8239;6.5 or fails to pay any premium
thereon or fails to pay any other amount which Borrower or any of its Subsidiaries is obligated to pay under this Agreement or any other
Loan Document, Collateral Agent may obtain such insurance or make such payment, and all amounts so paid by Collateral Agent are Lenders&rsquo;
Expenses and immediately due and payable, bearing interest at the Default Rate, and secured by the Collateral. Collateral Agent will make
reasonable efforts to provide Borrower with notice of Collateral Agent obtaining such insurance or making such payment at the time it
is obtained or paid or within a reasonable time thereafter. No such payments by Collateral Agent are deemed an agreement to make similar
payments in the future or Collateral Agent&rsquo;s waiver of any Event of Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Application
of Payments and Proceeds</B>. Notwithstanding anything to the contrary contained in this Agreement, upon the occurrence and during the
continuance of an Event of Default, (a)&#8239;Borrower irrevocably waives the right to direct the application of any and all payments at
any time or times thereafter received by Collateral Agent from or on behalf of Borrower or any of its Subsidiaries of all or any part
of the Obligations, and, as between Borrower on the one hand and Collateral Agent and Lenders on the other, Collateral Agent shall have
the continuing and exclusive right to apply and to reapply any and all payments received against the Obligations in such manner as Collateral
Agent may deem advisable notwithstanding any previous application by Collateral Agent, and (b)&#8239;the proceeds of any sale of, or other
realization upon all or any part of the Collateral shall be applied: first, to the Lenders&rsquo; Expenses; second, to accrued and unpaid
interest on the Obligations (including any interest which, but for the provisions of the United States Bankruptcy Code, would have accrued
on such amounts); third, to the principal amount of the Obligations outstanding; and fourth, to any other indebtedness or obligations
of Borrower owing to Collateral Agent or any Lender under the Loan Documents. Any balance remaining shall be delivered to Borrower or
to whoever may be lawfully entitled to receive such balance or as a court of competent jurisdiction may direct. In carrying out the foregoing,
(x)&#8239;amounts received shall be applied in the numerical order provided until exhausted prior to the application to the next succeeding
category, and (y)&#8239;each of the Persons entitled to receive a payment in any particular category shall receive an amount equal to its
pro rata share of amounts available to be applied pursuant thereto for such category. Any reference in this Agreement to an allocation
between or sharing by the Lenders of any right, interest or obligation &ldquo;ratably,&rdquo; &ldquo;proportionally&rdquo; or in similar
terms shall refer to Pro Rata Share unless expressly provided otherwise. Collateral Agent, or if applicable, each Lender, shall promptly
remit to the other Lenders such sums as may be necessary to ensure the ratable repayment of each Lender&rsquo;s portion of any Term Loan
and the ratable distribution of interest, fees and reimbursements paid or made by Borrower. Notwithstanding the foregoing, a Lender receiving
a scheduled payment shall not be responsible for determining whether the other Lenders also received their scheduled payment on such date;
provided, however, if it is later determined that a Lender received more than its ratable share of scheduled payments made on any date
or dates, then such Lender shall remit to Collateral Agent or other Lenders such sums as may be necessary to ensure the ratable payment
of such scheduled payments, as instructed by Collateral Agent. If any payment or distribution of any kind or character, whether in cash,
properties or securities, shall be received by a Lender in excess of its ratable share, then the portion of such payment or distribution
in excess of such Lender&rsquo;s ratable share shall be received by such Lender in trust for and shall be promptly paid over to the other
Lender for application to the payments of amounts due on the other Lenders&rsquo; claims. To the extent any payment for the account of
Borrower is required to be returned as a voidable transfer or otherwise, the Lenders shall contribute to one another as is necessary to
ensure that such return of payment is on a pro rata basis. If any Lender shall obtain possession of any Collateral, it shall hold such
Collateral for itself and as agent and bailee for Collateral Agent and other Lenders for purposes of perfecting Collateral Agent&rsquo;s
security interest therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liability
for Collateral</B>. So long as Collateral Agent and the Lenders comply with reasonable banking practices regarding the safekeeping of
the Collateral in the possession or under the control of Collateral Agent and the Lenders, Collateral Agent and the Lenders shall not
be liable or responsible for: (a)&#8239;the safekeeping of the Collateral; (b)&#8239;any loss or damage to the Collateral; (c)&#8239;any
diminution in the value of the Collateral; or (d)&#8239;any act or default of any carrier, warehouseman, bailee, or other Person. Borrower
bears all risk of loss, damage or destruction of the Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Waiver; Remedies Cumulative</B>. Failure by Collateral Agent or any Lender, at any time or times, to require strict performance by Borrower
of any provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of Collateral Agent or any
Lender thereafter to demand strict performance and compliance herewith or therewith. No waiver hereunder shall be effective unless signed
by Collateral Agent and the Required Lenders and then is only effective for the specific instance and purpose for which it is given. The
rights and remedies of Collateral Agent and the Lenders under this Agreement and the other Loan Documents are cumulative. Collateral Agent
and the Lenders have all rights and remedies provided under the Code, any applicable law, by law, or in equity. The exercise by Collateral
Agent or any Lender of one right or remedy is not an election, and Collateral Agent&rsquo;s or any Lender&rsquo;s waiver of any Event
of Default is not a continuing waiver. Collateral Agent&rsquo;s or any Lender&rsquo;s delay in exercising any remedy is not a waiver,
election, or acquiescence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Demand
Waiver</B>. Borrower waives, to the fullest extent permitted by law, demand, notice of default or dishonor, notice of payment and nonpayment,
notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments,
chattel paper, and guarantees held by Collateral Agent or any Lender on which Borrower or any Subsidiary is liable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.</B></FONT></TD><TD><B><U>NOTICES</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All notices, consents, requests, approvals, demands,
or other communication (collectively, &ldquo;<B>Communication</B>&rdquo;) by any party to this Agreement or any other Loan Document must
be in writing and shall be deemed to have been validly served, given, or delivered: (a)&#8239;upon the earlier of actual receipt and three
(3)&#8239;Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt requested, with proper
postage prepaid; (b)&#8239;upon transmission, when sent by facsimile transmission; (c)&#8239;one (1)&#8239;Business Day after deposit with
a reputable overnight courier with all charges prepaid; or (d)&#8239;when delivered, if hand delivered by messenger, all of which shall
be addressed to the party to be notified and sent to the address, facsimile number, or email address indicated below. Any of Collateral
Agent, Lender or Borrower may change its mailing address or facsimile number by giving the other party written notice thereof in accordance
with the terms of this Section&#8239;10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">If to Borrower:</TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: -0.125in">ROCKWELL MEDICAL,&#8239;INC.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: -0.125in">ROCKWELL TRANSPORTATION,&#8239;INC.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">30142 Wixom Road <BR>
Wixom, MI 48393</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">Attn: Jesse Neri</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">with a copy (which shall<BR>
not constitute notice) to: </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">Gibson, Dunn&#8239;&amp; Crutcher LLP<BR>
One Embarcadero Center Suite&#8239;2600</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">San Francisco, CA 94111</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">Attn: Ryan A. Murr </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">Fax: (415) 374-8430</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 50%">If to Collateral Agent:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in; width: 50%">INNOVATUS LIFE SCIENCES<BR>
LENDING FUND I, LP</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">777 Third Avenue, 25th Floor</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">New York, NY 10017</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">Attn: Claes Ekstrom<BR>
</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">with a copy (which shall<BR>
not constitute notice) to:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">Kramer Levin Naftalis&#8239;&amp; Frankel LLP<BR>
1177 Avenue of the Americas</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">New York, NY 10036</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">Attn: Mark Ramsey</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">Fax: (212) 715-8213</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>11.</B></FONT></TD><TD><B><U>CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Waiver
of Jury Trial</B>. EACH OF BORROWER, COLLATERAL AGENT AND LENDERS UNCONDITIONALLY WAIVES ANY AND ALL RIGHT TO A JURY TRIAL OF ANY CLAIM
OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, ANY OF THE OTHER LOAN DOCUMENTS, ANY OF THE INDEBTEDNESS SECURED HEREBY,
ANY DEALINGS AMONG BORROWER, COLLATERAL AGENT AND/OR LENDERS RELATING TO THE SUBJECT MATTER OF THIS TRANSACTION OR ANY RELATED TRANSACTIONS,
AND/OR THE RELATIONSHIP THAT IS BEING ESTABLISHED AMONG BORROWER, COLLATERAL AGENT AND/OR LENDERS. THE SCOPE OF THIS WAIVER IS INTENDED
TO BE ALL ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY&#8239;BE FILED IN ANY COURT. THIS WAIVER IS IRREVOCABLE. THIS WAIVER MAY&#8239;NOT
BE MODIFIED EITHER ORALLY OR IN WRITING. THE WAIVER ALSO SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS
TO THIS AGREEMENT, ANY OTHER LOAN DOCUMENTS, OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THIS TRANSACTION OR ANY RELATED TRANSACTION.
THIS AGREEMENT MAY&#8239;BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Governing
Law and Jurisdiction</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;THIS
AGREEMENT, THE OTHER LOAN DOCUMENTS (EXCLUDING THOSE LOAN DOCUMENTS THAT BY THEIR OWN TERMS ARE EXPRESSLY GOVERNED BY THE LAWS OF ANOTHER
JURISDICTION) AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER AND THEREUNDER SHALL IN ALL RESPECTS BE GOVERNED BY AND CONSTRUED
IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES THAT WOULD RESULT IN
THE APPLICATION OF ANY LAWS OTHER THAN THE LAWS OF THE STATE OF NEW YORK),&#8239;INCLUDING ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE,
REGARDLESS OF THE LOCATION OF THE COLLATERAL, PROVIDED, HOWEVER, THAT IF THE LAWS OF ANY JURISDICTION OTHER THAN NEW YORK SHALL GOVERN
IN REGARD TO THE VALIDITY, PERFECTION OR EFFECT OF PERFECTION OF ANY LIEN OR IN REGARD TO PROCEDURAL MATTERS AFFECTING ENFORCEMENT OF
ANY LIENS IN COLLATERAL, SUCH LAWS OF SUCH OTHER JURISDICTIONS SHALL CONTINUE TO APPLY TO THAT EXTENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Submission
to Jurisdiction</U>. Any legal action or proceeding with respect to the Loan Documents shall be brought exclusively in the courts of the
State of New York located in the City of New York, Borough of Manhattan, or of the United States of America for the Southern District
of New York and, by execution and delivery of this Agreement, Borrower hereby accepts for itself and in respect of its Property, generally
and unconditionally, the jurisdiction of the aforesaid courts. Notwithstanding the foregoing, Collateral Agent and Lenders shall have
the right to bring any action or proceeding against Borrower (or any property of Borrower) in the court of any other jurisdiction Collateral
Agent or Lenders deem necessary or appropriate in order to realize on the Collateral or other security for the Obligations. The parties
hereto hereby irrevocably waive any objection, including any objection to the laying of venue or based on the grounds of forum non conveniens,
that any of them may now or hereafter have to the bringing of any such action or proceeding in such jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Service
of Process</U>. Borrower irrevocably waives personal service of any and all legal process, summons, notices and other documents and other
service of process of any kind and consents to such service in any suit, action or proceeding brought in the United States of America
with respect to or otherwise arising out of or in connection with any Loan Document by any means permitted by applicable requirements
of law, including by the mailing thereof (by registered or certified mail, postage prepaid) to the address of Borrower specified herein
(and shall be effective when such mailing shall be effective, as provided therein). Borrower agrees that a final judgment in any such
action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Non-exclusive
Jurisdiction</U>. Nothing contained in this Section&#8239;11.2 shall affect the right of Collateral Agent or Lenders to serve process in
any other manner permitted by applicable requirements of law or commence legal proceedings or otherwise proceed against Borrower in any
other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>12.</B></FONT></TD><TD><B><U>GENERAL PROVISIONS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Successors
and Assigns</B>. This Agreement binds and is for the benefit of the successors and permitted assigns of each party. Borrower may not transfer,
pledge or assign this Agreement or any rights or obligations under it without Collateral Agent&rsquo;s prior written consent (which may
be granted or withheld in Collateral Agent&rsquo;s discretion, subject to Section&#8239;12.5). The Lenders have the right, without the
consent of or notice to Borrower, to sell, transfer, assign, pledge, negotiate, or grant participation in (any such sale, transfer, assignment,
negotiation, or grant of a participation, a &ldquo;<B>Lender Transfer</B>&rdquo;) all or any part of, or any interest in, the Lenders&rsquo;
obligations, rights, and benefits under this Agreement and the other Loan Documents. Borrower and Collateral Agent shall be entitled to
continue to deal solely and directly with such Lender in connection with the interests so assigned until Collateral Agent shall have received
and accepted an effective assignment agreement in form satisfactory to Collateral Agent executed, delivered and fully completed by the
applicable parties thereto, and shall have received such other information regarding such transferee as Collateral Agent reasonably shall
require. Notwithstanding anything to the contrary contained herein, so long as no Event of Default has occurred and is continuing, no
Lender Transfer (other than a Lender Transfer in connection with (i)&#8239;assignments by a Lender due to a forced divestiture at the request
of any regulatory agency; or (ii)&#8239;upon the occurrence of a default, event of default or similar occurrence with respect to a Lender&rsquo;s
own financing or securitization transactions) shall be permitted, without Borrower&rsquo;s consent, to any Person which is a direct competitor
of Borrower or a vulture hedge fund, each as determined by Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indemnification</B>.
Borrower agrees to indemnify, defend and hold Collateral Agent and the Lenders and their respective directors, officers, employees, consultants,
agents, attorneys, or any other Person affiliated with or representing Collateral Agent or the Lenders (each, an &ldquo;<B>Indemnified
Person</B>&rdquo;) harmless against: (a)&#8239;all obligations, demands, claims, and liabilities (collectively, &ldquo;<B>Claims</B>&rdquo;)
asserted by any other party in connection with; related to; following; or arising from, out of or under, the transactions contemplated
by the Loan Documents; and (b)&#8239;all losses or Lenders&rsquo; Expenses incurred, or paid by Indemnified Person in connection with;
related to; following; or arising from, out of or under, the transactions contemplated by the Loan Documents between Collateral Agent,
and/or the Lenders and Borrower (including reasonable documented attorneys&rsquo; fees and expenses), except for Claims and/or losses
directly caused by such Indemnified Person&rsquo;s gross negligence or willful misconduct. Borrower hereby further indemnifies, defends
and holds each Indemnified Person harmless from and against any and all liabilities, obligations, losses, damages, penalties, actions,
judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever (including the fees and disbursements of
counsel for such Indemnified Person) in connection with any investigative, response, remedial, administrative or judicial matter or proceeding,
whether or not such Indemnified Person shall be designated a party thereto and including any such proceeding initiated by or on behalf
of Borrower, and the reasonable and documented expenses of investigation by engineers, environmental consultants and similar technical
personnel and any commission, fee or compensation claimed by any broker (other than any broker retained by Collateral Agent or Lenders)
asserting any right to payment for the transactions contemplated hereby which may be imposed on, incurred by or asserted against such
Indemnified Person as a result of or in connection with the transactions contemplated hereby and the use or intended use of the proceeds
of the loan proceeds except for liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses
and disbursements directly caused by such Indemnified Person&rsquo;s gross negligence or willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Severability
of Provisions</B>. Each provision of this Agreement is severable from every other provision in determining the enforceability of any provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Correction
of Loan Documents</B>. Collateral Agent may correct patent errors and fill in any blanks in this Agreement and the other Loan Documents
consistent with the agreement of the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Amendments
in Writing; Integration</B>. (a)&#8239;No amendment, modification, termination or waiver of any provision of this Agreement or any other
Loan Document, no approval or consent thereunder, or any consent to any departure by Borrower or any of its Subsidiaries therefrom, shall
in any event be effective unless the same shall be in writing and signed by Borrower, Collateral Agent and the Required Lenders provided
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;no
such amendment, waiver or other modification that would have the effect of increasing or reducing a Lender&rsquo;s Term Loan Commitment
or Commitment Percentage shall be effective as to such Lender without such Lender&rsquo;s written consent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;no
such amendment, waiver or modification that would affect the rights and duties of Collateral Agent shall be effective without Collateral
Agent&rsquo;s written consent or signature; and (iii)&#8239;no such amendment, waiver or other modification shall, unless signed by all
the Lenders directly affected thereby, (A)&#8239;reduce the principal of, rate of interest on or any fees with respect to any Term Loan
or forgive any principal, interest (other than default interest) or fees (other than late charges) with respect to any Term Loan (B)&#8239;postpone
the date fixed for, or waive, any payment of principal of any Term Loan or of interest on any Term Loan (other than default interest)
or any fees provided for hereunder (other than late charges or for any termination of any commitment); (C)&#8239;change the definition
of the term &ldquo;Required Lenders&rdquo; or the percentage of Lenders which shall be required for the Lenders to take any action hereunder;
(D)&#8239;release all or substantially all of any material portion of the Collateral, authorize Borrower to sell or otherwise dispose of
all or substantially all or any material portion of the Collateral, except, in each case with respect to this clause (D), as otherwise
may be expressly permitted under this Agreement or the other Loan Documents (including in connection with any disposition permitted hereunder);
(E)&#8239;amend, waive or otherwise modify this Section&#8239;12.5 or the definitions of the terms used in this Section&#8239;12.5 insofar
as the definitions affect the substance of this Section&#8239;12.5; (F)&#8239;consent to the assignment, delegation or other transfer by
Borrower of any of its rights and obligations under any Loan Document or release Borrower of its payment obligations under any Loan Document,
except, in each case with respect to this clause (F), pursuant to a merger or consolidation permitted pursuant to this Agreement; (G)&#8239;amend
any of the provisions of Section&#8239;9.4 or amend any of the definitions of Pro Rata Share, Term Loan Commitment, Commitment Percentage
or that provide for the Lenders to receive their Pro Rata Shares of any fees, payments, setoffs or proceeds of Collateral hereunder; (H)&#8239;subordinate
the Liens granted in favor of Collateral Agent securing the Obligations; or (I)&#8239;amend any of the provisions of Section&#8239;12.5.
It is hereby understood and agreed that all Lenders shall be deemed directly affected by an amendment, waiver or other modification of
the type described in the preceding clauses (C), (D), (E), (F), (G)&#8239;and (H)&#8239;of the immediately preceding sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Other
than as expressly provided for in Section&#8239;12.5(a)(i)&#8239;(iii), Collateral Agent may, if requested by the Required Lenders, from
time to time designate covenants in this Agreement less restrictive by notification to a representative of Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Agreement and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements
with respect to such subject matter. All prior agreements, understandings, representations, warranties, and negotiations between the parties
about the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Counterparts</B>.
This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed
and delivered, is an original, and all taken together, constitute one Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Survival</B>.
All covenants, representations and warranties made in this Agreement continue in full force and effect until this Agreement has terminated
pursuant to its terms and all Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms,
are to survive the termination of this Agreement) have been satisfied. The obligation of Borrower in Section&#8239;12.2 to indemnify each
Lender and Collateral Agent, as well as the confidentiality provisions in Section&#8239;12.8 below, shall survive until the statute of
limitations with respect to such claim or cause of action shall have run.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Confidentiality</B>.
In handling any confidential information of Borrower, the Lenders and Collateral Agent shall exercise the same degree of care that it
exercises for their own proprietary information, but disclosure of information may be made: (a)&#8239;subject to the terms and conditions
of this Agreement, to the Lenders&rsquo; and Collateral Agent&rsquo;s Subsidiaries or Affiliates, who have been advised about the confidential
nature of such information and directed to keep such information confidential; (b)&#8239;to prospective transferees (other than those identified
in (a)&#8239;above) or purchasers of any interest in the Term Loan (provided, however, (i)&#8239;if, at the applicable time, an Event of
Default has occurred and is outstanding, the Lenders and Collateral Agent shall advise such prospective transferee or purchaser about
the confidential nature of such information and (ii)&#8239;if, at the applicable time, no Event of Default has occurred and is continuing,
obtain such prospective transferee&rsquo;s or purchaser&rsquo;s agreement to the terms of this provision or to similar confidentiality
terms); (c)&#8239;as required by law, regulation, subpoena, or other order; (d)&#8239;to Lenders&rsquo; or Collateral Agent&rsquo;s regulators
or as otherwise required in connection with an examination or audit (provided such regulatory authority shall be advised about the confidential
nature of such information); (e)&#8239;as Collateral Agent reasonably considers appropriate in exercising remedies under the Loan Documents;
and (f)&#8239;to third party service providers of the Lenders and/or Collateral Agent so long as such service providers have executed a
confidentiality agreement or have agreed to similar confidentiality terms with the Lenders and Collateral Agent with terms no less restrictive
than those contained herein. Confidential information does not include information that either: (i)&#8239;is in the public domain or in
the Lenders&rsquo; and/or Collateral Agent&rsquo;s possession when disclosed to the Lenders and/or Collateral Agent, or becomes part of
the public domain after disclosure to the Lenders and/or Collateral Agent at no fault of the Lenders or the Collateral Agent; or (ii)&#8239;is
disclosed to the Lenders and/or Collateral Agent by a third party, if the Lenders and/or Collateral Agent does not know that the third
party is prohibited from disclosing the information. Collateral Agent and the Lenders may use confidential information for any purpose,
including, without limitation, for the development of client databases, reporting purposes, and market analysis. The provisions of the
immediately preceding sentence shall survive the termination of this Agreement. The agreements provided under this Section&#8239;12.8 supersede
all prior agreements, understanding, representations, warranties, and negotiations between the parties about the subject matter of this
Section&#8239;12.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Right
of Set Off</B>. Borrower hereby grants to Collateral Agent and to each Lender, a lien, security interest and right of set off as security
for all Obligations to Collateral Agent and each Lender hereunder, whether now existing or hereafter arising upon and against all deposits,
credits, collateral and property, now or hereafter in the possession, custody, safekeeping or control of Collateral Agent or the Lenders
or any entity under the control of Collateral Agent or the Lenders (including a Collateral Agent affiliate) or in transit to any of them.
At any time after the occurrence and during the continuance of an Event of Default, without demand or notice, Collateral Agent or the
Lenders may set off the same or any part thereof and apply the same to any liability or obligation of Borrower even though unmatured and
regardless of the adequacy of any other collateral securing the Obligations. ANY AND ALL RIGHTS TO REQUIRE COLLATERAL AGENT TO EXERCISE
ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES THE OBLIGATIONS, PRIOR TO EXERCISING ITS RIGHT OF SETOFF WITH
RESPECT TO SUCH DEPOSITS, CREDITS OR OTHER PROPERTY OF BORROWER ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVED BY BORROWER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Cooperation
of Borrower</B>. If necessary, Borrower agrees to (i)&#8239;execute any documents reasonably required to effectuate and acknowledge each
assignment of a Term Loan Commitment or Term Loan to an assignee in accordance with Section&#8239;12.1, (ii)&#8239;make Borrower&rsquo;s
management available to meet with Collateral Agent and prospective participants and assignees of Term Loan Commitments (which meetings
shall be conducted no more often than twice every twelve months unless an Event of Default has occurred and is continuing), and (iii)&#8239;assist
Collateral Agent or the Lenders in the preparation of information relating to the financial affairs of Borrower as any prospective participant
or assignee of a Term Loan Commitment or Term Loan reasonably may request. Subject to the provisions of Section&#8239;12.8, Borrower authorizes
each Lender to disclose to any prospective participant or assignee of a Term Loan Commitment, any and all information in such Lender&rsquo;s
possession concerning Borrower and its financial affairs which has been delivered to such Lender by or on behalf of Borrower pursuant
to this Agreement, or which has been delivered to such Lender by or on behalf of Borrower in connection with such Lender&rsquo;s credit
evaluation of Borrower prior to entering into this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Public
Announcement</B>. Borrower hereby agrees that Collateral Agent and each Lender may make a public announcement of the transactions contemplated
by this Agreement, and may publicize the same in marketing materials, newspapers and other publications, and otherwise, and in connection
therewith may use Borrower&rsquo;s name, tradenames and logos.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Collateral
Agent and Lender Agreement</B>. Collateral Agent and each Lender hereby agree to the terms and conditions set forth on Annex I attached
hereto. Borrower acknowledges and agrees to the terms and conditions set forth on Annex I attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;RLOC
Intercreditor Agreement</B>. The parties (a)&#8239;consent to the subordination of Liens provided for in the RLOC Intercreditor Agreement
and (b)&#8239;agree that they will be bound by, and will take no actions contrary to, the provisions of the RLOC Intercreditor Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower
Liability</B>. Each Borrower hereby appoints the other as agent for the other for all purposes hereunder. Each Borrower hereunder shall
be jointly and severally obligated to repay all Credit Extensions made or outstanding hereunder, regardless of which Borrower actually
received said Credit Extension, as if each Borrower hereunder directly received all Credit Extensions. Each Borrower waives (a)&#8239;any
suretyship defenses available to it under the Code or any other applicable law, and (b)&#8239;any right to require Collateral Agent or
any Lender to: (i)&#8239;proceed against any Borrower or any other person; (ii)&#8239;proceed against or exhaust any security; or (iii)&#8239;pursue
any other remedy. Collateral Agent and or any Lender may exercise or not exercise any right or remedy it has against any Borrower or any
security it holds (including the right to foreclose by judicial or non-judicial sale) without affecting any Borrower&rsquo;s liability.
Notwithstanding any other provision of this Agreement or other related document, each Borrower irrevocably waives all rights that it may
have at law or in equity (including, without limitation, any law subrogating Borrower to the rights of Collateral Agent and the Lenders
under this Agreement) to seek contribution, indemnification or any other form of reimbursement from any other Borrower, or any other Person
now or hereafter primarily or secondarily liable for any of the Obligations, for any payment made by Borrower with respect to the Obligations
in connection with this Agreement or otherwise and all rights that it might have to benefit from, or to participate in, any security for
the Obligations as a result of any payment made by Borrower with respect to the Obligations in connection with this Agreement or otherwise.
Any agreement providing for indemnification, reimbursement or any other arrangement prohibited under this Section&#8239;shall be null and
void. If any payment is made to a Borrower in contravention of this Section, such Borrower shall hold such payment in trust for Collateral
Agent and the Lenders and such payment shall be promptly delivered to Collateral Agent for application to the Obligations, whether matured
or unmatured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Amendment
and Restatement; No Novation; Waiver</B>. This Agreement constitutes an amendment and restatement of the Existing Loan and Security Agreement,
effective from and after the Effective Date. The execution and delivery of this Agreement shall not constitute a novation of any indebtedness
or other obligations owing to the Lenders or the Collateral Agent under the Existing Loan and Security Agreement. On the Effective Date,
(a)&#8239;the credit facility described in the Existing Loan and Security Agreement shall be amended, supplemented, modified and restated
in its entirety by this Agreement, and all obligations of Borrower outstanding as of such date under the Existing Loan and Security Agreement
shall continue to exist and shall be subject to the provisions of this Agreement, thereby deemed to be obligations outstanding hereunder,
without any further action by any Person and (b)&#8239;the Waiver shall become effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>13.</B></FONT></TD><TD><B><U>DEFINITIONS</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As used in this Agreement, the following terms
have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Account</B>&rdquo; is any &ldquo;account&rdquo;
as defined in the Code with such additions to such term as may hereafter be made, and includes, without limitation, all accounts receivable
and other sums owing to Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Account Debtor</B>&rdquo; is any &ldquo;account
debtor&rdquo; as defined in the Code with such additions to such term as may hereafter be made under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Affiliate</B>&rdquo; of any Person is
a Person that owns or controls directly or indirectly the Person, any Person that controls or is controlled by or is under common control
with the Person, and each of that Person&rsquo;s senior executive officers, directors, partners if such Person is a partnership and, for
any Person that is a limited liability company, that Person&rsquo;s managers and members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Amendment Fee</B>&rdquo; is a fee due
on the Effective Date equal to Seventy-Five Thousand Dollars ($75,000.00), payable to Lenders in accordance with their Pro Rata Shares
with respect to such Term Loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Amortization Date</B>&rdquo; is (a)&#8239;August&#8239;1,
2026, or (b)&#8239;February&#8239;1, 2027, if the Interest-Only Period has been extended to thirty-six (36) months after the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Anti Terrorism Laws</B>&rdquo; are any
laws relating to terrorism or money laundering, including without limitation Executive Order No.&#8239;13224 (effective September&#8239;24,
2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, and the laws administered by OFAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Basic Rate</B>&rdquo; is with respect
to each Term Loan, the floating per annum rate of interest (based on a year of three hundred sixty five (365) days) equal to the sum of
(a)&#8239;the greater of (i)&#8239;Prime Rate, subject to Section&#8239;2.3(g), and (ii)&#8239;seven and one-half percent (7.50%), plus (b)&#8239;three
and one-half percent (3.50%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Blocked Person</B>&rdquo; is any Person:
(a)&#8239;listed in the annex to, or is otherwise subject to the provisions of, Executive Order No.&#8239;13224, (b)&#8239;a Person owned
or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions
of, Executive Order No.&#8239;13224, (c)&#8239;a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction
by any Anti Terrorism Law, (d)&#8239;a Person that commits, threatens or conspires to commit or supports &ldquo;terrorism&rdquo; as defined
in Executive Order No.&#8239;13224, or (e)&#8239;a Person that is named a &ldquo;specially designated national&rdquo; or &ldquo;blocked
person&rdquo; on the most current list published by OFAC or other similar list.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Borrower&rsquo;s Books</B>&rdquo; are
Borrower&rsquo;s or any of its Subsidiaries&rsquo; books and records including ledgers, federal, and state tax returns, records regarding
Borrower&rsquo;s or its Subsidiaries&rsquo; assets or liabilities, the Collateral, business operations or financial condition, and all
computer programs or storage or any equipment containing such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Business Day</B>&rdquo; is any day that
is not a Saturday, Sunday or a day on which banks in New York are not open for the conduct of their commercial banking business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Capital Lease Adjustment</B>&rdquo;
means, as of any date of determination, an amount equal to aggregate amount of payments during the period of 12 full calendar months next
succeeding such date that are required to be made by the Borrower in respect of capital lease obligations by the terms of the capital
leases to which the Borrower is a party on such date; provided, however, if an Event of Default shall have occurred and be continuing,
 &ldquo;Capital Lease Adjustment&rdquo; shall mean an amount equal to the aggregate amount of all payments that are required to be made
by the Borrower in respect of all capital lease obligations by the terms of the capital leases to which the Borrower is a party, in each
case during the entire term of each such capital lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Cash Equivalents</B>&rdquo; are (a)&#8239;marketable
direct obligations issued or unconditionally guaranteed by the United States or any agency or any State thereof having maturities of not
more than one (1)&#8239;year from the date of acquisition; (b)&#8239;commercial paper maturing no more than one (1)&#8239;year after its
creation and having the highest rating from either Standard&#8239;&amp; Poor&rsquo;s Ratings Group or Moody&rsquo;s Investors Service,&#8239;Inc.,
(c)&#8239;certificates of deposit maturing no more than one (1)&#8239;year after issue provided that the account in which any such certificate
of deposit is maintained is subject to a Control Agreement in favor of Collateral Agent and (d)&#8239;solely with respect to any Subsidiary
not organized in the United States, any equivalent of Cash Equivalents referred to in clauses (a)&#8239;through (c)&#8239;of this definition,
denominated in the foreign currency that is the local currency where such Subsidiary is organized or has its principal place of business
which are comparable in tenor and credit quality to those referred to in clauses (a)&#8239;through (c)&#8239;above and customarily used
in the ordinary course of business by similar companies for cash management purposes in the relevant jurisdiction to the extent reasonably
required in connection with any business conducted by such Subsidiary in such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Cash Burn</B>&rdquo; is the cash used
by Borrower in its operations and in its capital expenditures; provided, however, for any period during which Cash Burn is calculated
or required to be calculated under the Loan Documents, if, during such period, cash used for capital expenditures is less than Five Hundred
Thousand Dollars ($500,000), then cash used for capital expenditures for such period shall be deemed to be Zero Dollars ($0).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Code</B>&rdquo; is the Uniform Commercial
Code, as the same may, from time to time, be enacted and in effect in the State of New York; provided, that, to the extent that the Code
is used to define any term herein or in any Loan Document and such term is defined differently in different Articles or Divisions of the
Code, the definition of such term contained in Article&#8239;or Division 9 shall govern; provided further, that in the event that, by reason
of mandatory provisions of law, any or all of the attachment, perfection, or priority of, or remedies with respect to, Collateral Agent&rsquo;s
Lien on any Collateral is governed by the Uniform Commercial Code in effect in a jurisdiction other than the State of New York, the term
 &ldquo;<B>Code</B>&rdquo; shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes
of the provisions thereof relating to such attachment, perfection, priority, or remedies and for purposes of definitions relating to such
provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Collateral</B>&rdquo; is any and all
properties, rights and assets of Borrower described on <U>Exhibit&#8239;A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Collateral Account</B>&rdquo; is any
Deposit Account, Securities Account, or Commodity Account, or any other bank account maintained by Borrower or any Subsidiary at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Commodity Account</B>&rdquo; is any
 &ldquo;commodity account&rdquo; as defined in the Code with such additions to such term as may hereafter be made under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Compliance Certificate</B>&rdquo; is
that certain certificate in substantially the form attached hereto as <U>Exhibit&#8239;C-1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Contingent Obligation</B>&rdquo; is,
for any Person, any direct or indirect liability, contingent or not, of that Person for (a)&#8239;any indebtedness, lease, dividend, letter
of credit or other obligation of another Person such as an obligation directly or indirectly guaranteed, endorsed, co made, discounted
or sold with recourse by that Person, or for which that Person is directly or indirectly liable; (b)&#8239;any obligations for undrawn
letters of credit for the account of that Person; and (c)&#8239;all obligations from any interest rate, currency or commodity swap agreement,
interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest
rates, currency exchange rates or commodity prices; but &ldquo;Contingent Obligation&rdquo; does not include endorsements in the ordinary
course of business. The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent
Obligation is made or, if not determinable, the maximum reasonably anticipated liability for it determined by the Person in good faith;
but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Control Agreement</B>&rdquo; is any
control agreement entered into among the depository institution at which Borrower maintains a Deposit Account or the securities intermediary
or commodity intermediary at which Borrower maintains a Securities Account or a Commodity Account, Borrower, and Collateral Agent pursuant
to which Collateral Agent, for the benefit of the Lenders, obtains &ldquo;control&rdquo; (within the meaning of the Code) over such Deposit
Account, Securities Account, or Commodity Account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Copyrights</B>&rdquo; are any and all
copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work
thereof, whether published or unpublished and whether or not the same also constitutes a trade secret.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Cure Loan Subordinated Debt</B>&rdquo;
is unsecured Subordinated Debt issued in connection with a Qualified Financing, having terms acceptable to Collateral Agent which terms
shall include certain restrictions including, without limitation, (i)&#8239;a prohibition on cash repayments of principal amount of all
such Subordinated Debt while any of the payment Obligations hereunder remain outstanding and until the Lenders have no further commitment
to make any Term Loans hereunder, (ii)&#8239;a restriction on payment of an aggregate amount of interest on all such Subordinated Debt
in excess of Seven Hundred Fifty Thousand Dollars ($750,000.00) per annum and (iii)&#8239;a restriction on the aggregate amount of all
payments of interest on all such Subordinated Debt in excess of Two Million Two Hundred Fifty Thousand Dollars ($2,250,000.00) while any
of the payment Obligations hereunder are outstanding and until the Lenders have no further commitment to make any Term Loans hereunder;
provided further that no interest payments may be made if Borrower is in breach of any of the provisions of the Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Deposit Account</B>&rdquo; is any &ldquo;deposit
account&rdquo; as defined in the Code with such additions to such term as may hereafter be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>DOJ</B>&rdquo; means the U.S. Department
of Justice or any successor thereto or any other comparable Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Dollars</B>,&rdquo; &ldquo;dollars&rdquo;
and &ldquo;$&rdquo; each mean lawful money of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Equipment</B>&rdquo; is all &ldquo;equipment&rdquo;
as defined in the Code with such additions to such term as may hereafter be made, and includes without limitation all machinery, fixtures,
goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>ERISA</B>&rdquo; is the Employee Retirement
Income Security Act of 1974, as amended, and its regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Exigent Circumstance</B>&rdquo; means
any event or circumstance that, in the reasonable judgment of Collateral Agent, imminently threatens the ability of Collateral Agent to
realize upon all or any material portion of the Collateral, such as, without limitation, fraudulent removal, concealment, or abscondment
thereof, destruction or material waste thereof, or failure of Borrower or any of its Subsidiaries after reasonable demand to maintain
or reinstate adequate casualty insurance coverage, or which, in the judgment of Collateral Agent, could reasonably be expected to result
in a material diminution in value of the Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>FDA</B>&rdquo; means the U.S. Food and
Drug Administration or any successor thereto or any other comparable Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Final Fee</B>&rdquo; is a payment (in
addition to and not a substitution for the regular monthly payments of principal plus accrued interest or any other fee payable hereunder)
due on the earliest to occur of (a)&#8239;the Maturity Date, or (b)&#8239;the acceleration of any Term Loan, or (c)&#8239;the prepayment
of any Term Loan pursuant to Section&#8239;2.2(c)&#8239;or (d), in each case equal to 4.375% <I>multiplied </I>by the aggregate amount of
such Term Loan funded, payable to Lenders in accordance with their respective Pro Rata Shares. For the avoidance of doubt, the calculation
of any Final Payment shall not include the principal amount prepaid in accordance with the second paragraph of Section&#8239;2.2(d)&#8239;if
a Final Payment based on such principal amount was made at the time of such prepayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Foreign Subsidiary</B>&rdquo; is a Subsidiary
that is not an entity organized under the laws of the United States or any state thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>GAAP</B>&rdquo; is generally accepted
accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified
Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other
Person as may be approved by a significant segment of the accounting profession in the United States, which are applicable to the circumstances
as of the date of determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>General Intangibles</B>&rdquo; are all
 &ldquo;general intangibles&rdquo; as defined in the Code in effect on the date hereof with such additions to such term as may hereafter
be made, and includes without limitation, all copyright rights, copyright applications, copyright registrations and like protections in
each work of authorship and derivative work, whether published or unpublished, any patents, trademarks, service marks and, to the extent
permitted under applicable law, any applications therefor, whether registered or not, any trade secret rights, including any rights to
unpatented inventions, payment intangibles, royalties, contract rights, goodwill, franchise agreements, purchase orders, customer lists,
route lists, telephone numbers, domain names, claims, income and other tax refunds, security and other deposits, options to purchase or
sell real or personal property, rights in all litigation presently or hereafter pending (whether in contract, tort or otherwise), insurance
policies (including without limitation key man, property damage, and business interruption insurance), payments of insurance and rights
to payment of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Governmental Approval</B>&rdquo; is
any consent, authorization, approval, order, license, franchise, permit, certificate, accreditation, registration, filing or notice, of,
issued by, from or to, or other act by or in respect of, any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Governmental Authority</B>&rdquo; is
any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality, regulatory body (including,
without limitation, the FDA and any state board of pharmacy or state pharmacy licensing authority), court, central bank or other entity
exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government, any securities
exchange and any self-regulatory organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Guaranty</B>&rdquo; is any guarantee
of all or any part of the Obligations, as the same may from time to time be amended, restated, modified or otherwise supplemented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Indebtedness</B>&rdquo; is (a)&#8239;indebtedness
for borrowed money or the deferred price of property or services, such as reimbursement and other obligations for surety bonds and letters
of credit, (b)&#8239;obligations evidenced by notes, bonds, debentures or similar instruments, (c)&#8239;capital lease obligations, and
(d)&#8239;Contingent Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Insolvency Proceeding</B>&rdquo; is
any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency law, including
assignments for the benefit of creditors, compositions or proceedings seeking reorganization, arrangement, or other relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Insolvent</B>&rdquo; means not Solvent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Intellectual Property</B>&rdquo; means
all of Borrower&rsquo;s or any of its Subsidiaries&rsquo; right, title and interest in and to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;its
Copyrights, Trademarks and Patents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, know how, operating
manuals;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
and all source code;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
and all design rights which may be available to Borrower;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
and all claims for damages by way of past, present and future infringement of any of the foregoing, with the right, but not the obligation,
to sue for and collect such damages for said use or infringement of the Intellectual Property rights identified above;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
licenses, sublicenses or other contracts under which Borrower or any Subsidiary is granted rights by third parties in any Intellectual
Property asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Interest-Only Period</B>&rdquo; means
the period commencing on the Effective Date and ending on the date that is thirty (30) months thereafter; <U>provided</U> that the Interest-Only
Period shall be extended to thirty-six (36) months after the Effective Date if cash flow of Borrower is positive for any two consecutive
fiscal quarters of Borrower during the period from the Effective Date to the date that is thirty (30) months thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Inventory</B>&rdquo; is all &ldquo;inventory&rdquo;
as defined in the Code in effect on the date hereof with such additions to such term as may hereafter be made under the Code, and includes
without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products,
including without limitation such inventory as is temporarily out of any Person&rsquo;s custody or possession or in transit and including
any returned goods and any documents of title representing any of the above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Investment</B>&rdquo; is any beneficial
ownership interest in any Person (including stock, partnership interest or other securities), and any loan, advance or capital contribution
to any Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>IP Security Agreement</B>&rdquo; is
that certain Intellectual Property Security Agreement executed and delivered by Parent to Collateral Agent and dated as of the Original
Effective Date, as may be amended, restated, or otherwise modified or supplemented from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Key Person</B>&rdquo; is each of Borrower&rsquo;s
(i)&#8239;President and Chief Executive Officer, who is Stuart Paul as of the Original Effective Date and (ii)&#8239;Chief Financial Officer,
who is Angus Smith as of the Original Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Knowledge</B>&rdquo; means to the &ldquo;best
of&rdquo; Borrower&rsquo;s knowledge, or with a similar qualification, knowledge or awareness means the actual knowledge, after reasonable
investigation, of the Responsible Officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Lender</B>&rdquo; is any one of the
Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Lenders</B>&rdquo; are the Persons identified
on <U>Schedule 1.1</U> hereto and each assignee that becomes a party to this Agreement pursuant to Section&#8239;12.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Lenders&rsquo; Expenses</B>&rdquo; are
all audit fees and expenses, costs, and expenses (including reasonable and documented attorneys&rsquo; fees and expenses, as well as appraisal
fees, fees incurred on account of lien searches, inspection fees, and filing fees) for preparing, amending, negotiating, administering,
defending and enforcing the Loan Documents (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings)
or otherwise incurred by Collateral Agent and/or the Lenders in connection with the Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Letter Agreement</B>&rdquo; is that
certain Letter Agreement entered into on the Original Effective Date by and among, Borrower, Collateral Agent and Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Lien</B>&rdquo; is a mortgage, deed
of trust, levy, charge, pledge, security interest, or other encumbrance of any kind, whether voluntarily incurred or arising by operation
of law or otherwise against any property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Loan Documents</B>&rdquo; are, collectively,
this Agreement, the IP Security Agreement, each Secured Promissory Note, each Warrant, the Perfection Certificate(s), each Control Agreement,
each Compliance Certificate, each Loan Payment Request Form&#8239;(as defined in the Existing Loan and Security Agreement), each Disbursement
Letter (as defined in the Existing Loan and Security Agreement), the Letter Agreement, any subordination agreements, any note, or notes
or guaranties executed by Borrower or any other Person, and any other present or future agreement entered into by Borrower or any other
Person for the benefit of the Lenders and Collateral Agent in connection with this Agreement; all as amended, restated, or otherwise modified
or supplemented from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Management Plan</B>&rdquo; is Borrower&rsquo;s
projected revenue attached hereto as <U>Annex X</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Material Adverse Change</B>&rdquo; is
(a)&#8239;a material adverse change in the business, operations or condition (financial or otherwise) of Borrower or any Subsidiary, when
taken as a whole; (b)&#8239;a material impairment of the prospect of repayment of any portion of the Obligations, or (c)&#8239;a material
adverse effect on the Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Material Agreement</B>&rdquo; is any
license, agreement or other contractual arrangement with a Person or Governmental Authority whereby Borrower or any of its Subsidiaries
is reasonably likely to be required to transfer, either in-kind or in cash, prior to the Maturity Date, assets or property valued (book
or market) at more than Five Hundred Thousand Dollars ($500,000.00) in the aggregate or any license, agreement or other contractual arrangement
conveying rights in or to any intellectual property necessary to make, use or sell any Inventory, products or services of Borrower or
any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Maturity Date</B>&rdquo; is January&#8239;1,
2029.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Minimum Cash Amount</B>&rdquo; is the
Cash Burn of Borrower in the immediately preceding three months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Obligations</B>&rdquo; are all of Borrower&rsquo;s
obligations to pay when due any debts, principal, interest, Lenders&rsquo; Expenses, the Prepayment Fee, the Final Fee, the Amendment
Fee and other amounts Borrower owes the Lenders now or later, in connection with, related to, following, or arising from, out of or under,
this Agreement or, the other Loan Documents (other than the Warrant), or otherwise, and including interest accruing after Insolvency Proceedings
begin (whether or not allowed) and debts, liabilities, or obligations of Borrower assigned to the Lenders and/or Collateral Agent, and
the performance of Borrower&rsquo;s duties under the Loan Documents (other than the Warrant).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>OFAC</B>&rdquo; is the U.S. Department
of Treasury Office of Foreign Assets Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>OFAC Lists</B>&rdquo; are, collectively,
the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to Executive Order No.&#8239;13224, 66 Fed. Reg.
49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules&#8239;and
regulations of OFAC or pursuant to any other applicable Executive Orders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Operating Documents</B>&rdquo; are,
for any Person, such Person&rsquo;s formation documents, as certified by the Secretary of State (or equivalent agency) of such Person&rsquo;s
jurisdiction of organization on a date that is no earlier than thirty (30) days prior to the Effective Date, and, (a)&#8239;if such Person
is a corporation, its bylaws in current form, (b)&#8239;if such Person is a limited liability company, its limited liability company agreement
(or similar agreement), and (c)&#8239;if such Person is a partnership, its partnership agreement (or similar agreement), each of the foregoing
with all current amendments or modifications thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Patents</B>&rdquo; means all patents,
patent applications and like protections including without limitation improvements, divisions, continuations, renewals, reissues, re-examination
certificates, utility models, extensions and continuations-in-part of the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Payment Date</B>&rdquo; is the first
(1<SUP>st</SUP>) calendar day of each calendar month, commencing on February&#8239;1, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Permitted Indebtedness</B>&rdquo; is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower&rsquo;s
Indebtedness to the Lenders and Collateral Agent under this Agreement and the other Loan Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
existing on the Original Effective Date and disclosed on the Perfection Certificate(s);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subordinated
Debt (including without limitation Cure Loan Subordinated Debt and Qualified Subordinated Debt);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&#8239;unsecured
Indebtedness to trade creditors and (ii)&#8239;Indebtedness in connection with credit cards, in each case incurred in the ordinary course
of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
consisting of capitalized lease obligations and purchase money Indebtedness, in each case incurred by Borrower or any of its Subsidiaries
to finance the acquisition, repair, improvement or construction of fixed or capital assets of such Person, provided that (i)&#8239;the
aggregate outstanding principal amount of all such Indebtedness does not exceed Two Million Three Hundred Fifty Thousand Dollars ($2,350,000.00)
at any time and (ii)&#8239;the principal amount of such Indebtedness does not exceed cost of the property so acquired or built or of such
repairs or improvements financed with such Indebtedness (each measured at the time of such acquisition, repair, improvement or construction
is made);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
incurred as a result of endorsing negotiable instruments received in the ordinary course of Borrower&rsquo;s business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
RLOC;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
consisting of letters of credit, provided that the aggregate outstanding principal amount of all such Indebtedness does not exceed Two
Hundred and Fifty Thousand Dollars ($250,000.00) at any time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
owed to current and former directors, officers and employees pursuant to deferred compensation, severance and retirement plans and similar
obligations in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
constituting Permitted Investments described in clause (i)&#8239;of the definition of Permitted Investments; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;extensions,
refinancings, modifications, amendments and restatements of any items of Permitted Indebtedness (a)&#8239;through (j)&#8239;above, provided
that the principal amount thereof is not increased or the terms thereof are not modified to impose materially more burdensome terms upon
Borrower, or its Subsidiary, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Permitted Investments</B>&rdquo; are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
disclosed on the Perfection Certificate(s)&#8239;and existing on the Original Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of cash and Cash Equivalents, and (ii)&#8239;any Investments permitted by Borrower&rsquo;s investment policy, as amended from
time to time, provided that such investment policy (and any such amendment thereto) has been approved in writing by Collateral Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of Borrower;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of Deposit Accounts in which Collateral Agent has a perfected security interest;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
in connection with Transfers permitted by Section&#8239;7.1;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of (i)&#8239;travel advances and employee relocation loans and other employee loans and advances in the ordinary course of business,
and (ii)&#8239;loans to employees, officers or directors relating to the purchase of equity securities of Borrower or its Subsidiaries
pursuant to employee stock purchase plans or agreements approved by Borrower&rsquo;s board of directors, not to exceed One Hundred and
Fifty Thousand Dollars ($150,000.00) in the aggregate for (i)&#8239;and (ii)&#8239;in any fiscal year;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
(including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement
of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates,
in the ordinary course of business; provided that this paragraph (h)&#8239;shall not apply to Investments of Borrower in any Subsidiary;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
in Subsidiaries not exceed Two Hundred Thousand Dollars ($200,000.00) in any fiscal year and Investments by one Borrower in another Borrower;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;non-cash
Investments in joint ventures or strategic alliances in the ordinary course of Borrower&rsquo;s business consisting of the non exclusive
licensing of technology, the development of technology or the providing of technical support.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Permitted Licenses</B>&rdquo; are (A)&#8239;licenses
of over-the-counter software that is commercially available to the public, and (B)&#8239;non-exclusive and exclusive licenses for the use
of the Intellectual Property of Borrower or any of its Subsidiaries entered into in the ordinary course of business, <U>provided</U>,
that, with respect to each such license described in clause (B), (i)&#8239;no Event of Default has occurred or is continuing at the time
of such license; (ii)&#8239;the license constitutes an arms-length transaction, the terms of which, on their face, do not provide for a
sale or assignment of any Intellectual Property and do not restrict the ability of Borrower or any of its Subsidiaries, as applicable,
to pledge, grant a security interest in or lien on, or assign or otherwise Transfer any Intellectual Property; (iii)&#8239;in the case
of any exclusive license, (x)&#8239;Borrower delivers to Collateral Agent and the Lenders copies of the final executed licensing documents
in connection with the exclusive license promptly upon consummation thereof (an in any event no later than five (5)&#8239;Business Days
after the consummation thereof), and (y)&#8239;any such license could not result in a legal transfer of title of the licensed property
but may be exclusive in respects other than territory and may be exclusive as to territory only as to discrete geographical areas outside
of the United States; and (iv)&#8239;all upfront payments, royalties, milestone payments or other proceeds arising from the licensing agreement
that are payable to Borrower or any of its Subsidiaries are paid to a Deposit Account that is governed by a Control Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Permitted Liens</B>&rdquo; are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
existing on the Original Effective Date and disclosed on the Perfection Certificates or arising under this Agreement and the other Loan
Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
for taxes, fees, assessments or other government charges or levies, either (i)&#8239;not due and payable or (ii)&#8239;being contested in
good faith and for which Borrower maintains adequate reserves on its Books, provided that no notice of any such Lien has been filed or
recorded under the Internal Revenue Code of 1986, as amended, and the Treasury Regulations adopted thereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
securing Indebtedness permitted under clause (e)&#8239;of the definition of &ldquo;Permitted Indebtedness,&rdquo; provided that (i)&#8239;such
liens exist prior to the acquisition of, or attach substantially simultaneous with, or within twenty (20) days after the, acquisition,
lease, repair, improvement or construction of, such property financed or leased by such Indebtedness and (ii)&#8239;such liens do not extend
to any property of Borrower other than the property (and proceeds thereof) acquired, leased or built, or the improvements or repairs,
financed by such Indebtedness;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
on Borrower&rsquo;s accounts receivable and identifiable cash proceeds thereof, securing Indebtedness under the RLOC (if any) that are
subject to the priority and terms set forth in the RLOC Intercreditor Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
of landlords, carriers, warehousemen, suppliers, or other Persons that are possessory in nature arising in the ordinary course of business
so long as such Liens attach only to Inventory, securing liabilities in the aggregate amount not to exceed One Hundred Fifty Thousand
Dollars ($150,000.00), and which are not delinquent or remain payable without penalty or which are being contested in good faith and by
appropriate proceedings which proceedings have the effect of preventing the forfeiture or sale of the property subject thereto;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
to secure payment of workers&rsquo; compensation, employment insurance, old age pensions, social security and other like obligations incurred
in the ordinary course of business (other than Liens imposed by ERISA);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
incurred in the extension, renewal or refinancing of the indebtedness secured by Liens described in (a)&#8239;through (c), but any extension,
renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness
may not increase;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;easements,
rights-of-way, restrictions, covenants, leases or subleases of real property granted in the ordinary course of Borrower&rsquo;s business
(or, if referring to another Person, in the ordinary course of such Person&rsquo;s business), and leases, subleases, non exclusive licenses
or sublicenses of personal property (other than Intellectual Property) granted in the ordinary course of Borrower&rsquo;s business (or,
if referring to another Person, in the ordinary course of such Person&rsquo;s business), in each case not materially interfering with
the ordinary conduct of the business of Borrower or such Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;banker&rsquo;s
liens, rights of setoff and Liens in favor of financial institutions incurred in the ordinary course of business arising in connection
with cash management related activities of Borrower and its Subsidiaries;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
arising from judgments, decrees or attachments in circumstances not constituting an Event of Default under Section&#8239;8.4 or 8.7;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
on a segregated bank account of Borrower securing Indebtedness permitted under clause (h)&#8239;of the definition of &ldquo;Permitted Indebtedness,&rdquo;
provided that the account balance in such bank account shall not exceed Two Hundred Fifty Thousand Dollars ($250,000.00); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Permitted
Licenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Person</B>&rdquo; is any individual,
sole proprietorship, partnership, limited liability company, joint venture, company, trust, unincorporated organization, association,
corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>PIK Option Period</B>&rdquo; means the
period from the Effective Date until the end of the Interest-Only Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Prepayment Fee</B>&rdquo; is, with respect
to any Term Loan subject to prepayment prior to the Maturity Date, whether by mandatory or voluntary prepayment, acceleration or otherwise
(but except as expressly set forth in the last paragraph of Section&#8239;2.2(d)), an additional fee payable to the Lenders in amount equal
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;for
a prepayment made on or after the Effective Date and through and including the date which is the first anniversary of the Effective Date,
six percent (6.00%) of the principal amount of the Term Loans prepaid;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;for
a prepayment made after the date which is the first anniversary of the Effective Date and through and including the date which is the
second anniversary of the Effective Date, two percent (2.00%) of the principal amount of the Term Loans prepaid;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;for
a prepayment made after the date which is the second anniversary of the Effective Date through and including the date which is the third
anniversary of the Effective Date, one percent (1.00%) of the principal amount of the Term Loan prepaid; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;for
a prepayment made after the date which is the third anniversary of the Effective Date and prior to the Maturity Date, zero percent (0.00%)
of the principal amount of the Term Loan prepaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Prime Rate</B>&rdquo; means the prime
rate reported in the Wall Street Journal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Property</B>&rdquo; means any interest
in any kind of property or asset, whether real, personal or mixed, and whether tangible or intangible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Pro Rata Share</B>&rdquo; is, as of
any date of determination, with respect to each Lender, a percentage (expressed as a decimal, rounded to the ninth decimal place) determined
by dividing the outstanding principal amount of the Term Loan held by such Lender by the aggregate outstanding principal amount of the
Term Loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Qualified Financing Event</B>&rdquo;
is the receipt by Borrower within the applicable Cure Period of unrestricted net gross proceeds in such amount as would allow Borrower
to break even on a cash flow basis prior to Maturity Date in accordance with the applicable financial plan provided by Borrower to Collateral
Agent pursuant to Section&#8239;8.2(b)&#8239;(which financial plan shall be subject to the approval of Collateral Agent) from the issuance
and sale by Parent of its equity securities or Cure Loan Subordinated Debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Qualified Subordinated Debt</B>&rdquo;
is a one-time unsecured Subordinated Debt in aggregate amount of up to Twenty Five Million Dollars ($25,000,000.00); provided, however,
at the time of the incurrence of the Qualified Subordinated Debt, (i)&#8239;no Event of Default may have occurred and be continuing and
Borrower must be in compliance with its obligations under Section&#8239;6.12 (Financial Covenant) and Section&#8239;6.13 (Liquidity Covenant)
and (ii)&#8239;Borrower must have a pro forma funded debt (including funded Subordinated Debt and funded RLOC) to market capitalization
(determined based on Parent&rsquo;s volume weighted average stock price for the immediately preceding ten (10)&#8239;trading days) ratio
of less than twenty five percent (25.00%) on the date of the incurrence of the Qualified Subordinated Debt after taking into account the
proceeds of the Qualified Subordinated Debt. Furthermore, Qualified Financing Debt must have terms acceptable to Collateral Agent which
terms shall include certain restrictions including, without limitation, (i)&#8239;a prohibition on amortization and cash repayments of
principal amount of such Subordinated Debt while any of the Obligations hereunder remain outstanding and until the Lenders have no further
commitment to make any Term Loans hereunder, (ii)&#8239;the maturity date of the Qualified Subordinated Debt must be at least six (6)&#8239;months
after the Maturity Date, (iii)&#8239;a restriction on payment of an aggregate amount of interest (that is payable in a form other than
in shares of common stock of Parent) on the Qualified Subordinated Debt in excess of One Million Five Hundred Thousand Dollars ($1,500,000.00)
per annum and a restriction on the aggregate amount of all payments of interest (that is payable in a form other than in shares of common
stock of Parent) on the Qualified Subordinated Debt in excess of Four Million Five Hundred Fifty Thousand Dollars ($4,500,000.00) while
any of the payment Obligations hereunder are outstanding and until the Lenders have no further commitment to make any Term Loans hereunder;
provided further that no interest payments may be made with respect to the Qualified Subordinated Debt if annualized quarterly consolidated
revenue of Borrower (as of the end of the quarter that has then most recently ended) at the time of the incurrence of the Qualified Subordinated
Debt is at least Seventy Million Dollars ($70,000,000.00). Furthermore, no Qualified Subordinated Debt may be incurred while any amount
of Cure Loan Subordinated Debt is outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Registered Organization</B>&rdquo; is
any &ldquo;registered organization&rdquo; as defined in the Code with such additions to such term as may hereafter be made under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Registration</B>&rdquo; means any registration,
authorization, approval, license, permit, clearance, certificate, and exemption issued or allowed by the FDA or state pharmacy licensing
authorities (including, without limitation, new drug applications, abbreviated new drug applications, biologics license applications,
investigational new drug applications, over-the-counter drug monograph, device pre-market approval applications, device pre-market notifications,
investigational device exemptions, product recertifications, manufacturing approvals, registrations and authorizations, CE Marks, pricing
and reimbursement approvals, labeling approvals or their foreign equivalent, controlled substance registrations, and wholesale distributor
permits).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Regulatory Action</B>&rdquo; means an
administrative, regulatory, or judicial enforcement action, proceeding, investigation or inspection, FDA Form&#8239;483 notice of inspectional
observation, warning letter, untitled letter, other notice of violation letter, recall, seizure, Section&#8239;305 notice or other similar
written communication, injunction or consent decree, issued by the FDA or a federal or state court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Related Persons</B>&rdquo; means, with
respect to any Person, each Affiliate of such Person and each director, officer, employee, agent, trustee, representative, attorney, accountant
and each insurance, environmental, legal, financial and other advisor and other consultants and agents of or to such Person or any of
its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Required Lenders</B>&rdquo; means (i)&#8239;for
so long as all of the Persons that are Lenders on the Effective Date (each an &ldquo;<B>Original Lender</B>&rdquo;) have not assigned
or transferred any of their interests in the Term Loan, Lenders holding one hundred percent (100%) of the aggregate outstanding principal
balance of the Term Loan, or (ii)&#8239;at any time from and after any Original Lender has assigned or transferred any interest in its
Term Loan, Lenders holding at least fifty one percent (51%) of the aggregate outstanding principal balance of the Term Loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Requirement of Law</B>&rdquo; is as
to any Person, the organizational or governing documents of such Person, and any law (statutory or common), treaty, rule&#8239;or regulation
or determination of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such Person or
any of its property or to which such Person or any of its property is subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Responsible Officer</B>&rdquo; is any
of the President, Chief Executive Officer, or Chief Financial Officer of Borrower acting alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;RLOC</B>&rdquo; is a formula based revolving
line of credit, based upon Borrower&rsquo;s accounts receivable (in an amount of up to equal to (i)&#8239;Seven Million Five Hundred Thousand
Dollars ($7,500,000.00) minus the (ii)&#8239;sum of (A)&#8239;aggregate amount of Indebtedness then outstanding that is described in clause
(e)&#8239;of the definition of Permitted Indebtedness or that is otherwise incurred in the form of financing lease obligations and permitted
hereunder, (B)&#8239;the aggregate amount of Indebtedness then outstanding that is described in clause (h)&#8239;of the definition of Permitted
Indebtedness and (C)&#8239;the aggregate amount of all interest payments made on Subordinated Debt in accordance with the provisions of
this Agreement) that the Borrower may enter into after the Effective Date, in connection with which the lender(s)&#8239;under the RLOC
(which lender(s)&#8239;must be reasonably acceptable to Collateral Agent) may have first priority security interest in accounts receivable
of Borrower and identifiable proceeds thereof and be subject to RLOC Intercreditor Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>RLOC Intercreditor Agreement</B>&rdquo;
is an agreement between Collateral Agent and lender(s)&#8239;under the RLOC, which agreement shall have such terms and conditions as acceptable
to Collateral Agent in its reasonable discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Secured Promissory Note</B>&rdquo; is
defined in Section&#8239;2.6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Secured Promissory Note Record</B>&rdquo;
is a record maintained by each Lender with respect to the outstanding Obligations owed by Borrower to Lender and credits made thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Securities Account</B>&rdquo; is any
 &ldquo;securities account&rdquo; as defined in the Code with such additions to such term as may hereafter be made under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Shares</B>&rdquo; is one hundred percent
(100%) of the issued and outstanding capital stock, membership units or other securities owned or held of record by Borrower or Borrower&rsquo;s
Subsidiary, in any Subsidiary; provided that, in the event Borrower, demonstrates to Collateral Agent&rsquo;s reasonable satisfaction,
that a pledge of more than sixty five percent (65%) of the Shares of such Subsidiary which is a Foreign Subsidiary, creates a present
and existing adverse tax consequence to Borrower under the U.S. Internal Revenue Code, &ldquo;Shares&rdquo; shall mean sixty-five percent
(65%) of the issued and outstanding capital stock, membership units or other securities owned or held of record by Borrower or its Subsidiary
in such Foreign Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Solvent</B>&rdquo; is, with respect
to any Person: the fair salable value of such Person&rsquo;s consolidated assets (including goodwill minus disposition costs) exceeds
the fair value of such Person&rsquo;s liabilities; such Person is not left with unreasonably small capital after the transactions in this
Agreement; and such Person is able to pay its debts (including trade debts) as they mature in the ordinary course (without taking into
account any forbearance and extensions related thereto).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Subordinated Debt</B>&rdquo; is indebtedness
incurred by Borrower or any of its Subsidiaries subordinated to all Indebtedness of Borrower and/or its Subsidiaries to the Lenders (pursuant
to a subordination, intercreditor, or other similar agreement in form and substance satisfactory to Collateral Agent and the Lenders entered
into between Collateral Agent, Borrower, and/or any of its Subsidiaries, and the other creditor), on terms acceptable to Collateral Agent
and the Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Subsidiary</B>&rdquo; is, with respect
to any Person, any Person of which more than fifty percent (50%) of the voting stock or other equity interests (in the case of Persons
other than corporations) is owned or controlled, directly or indirectly, by such Person or through one or more intermediaries. Unless
otherwise specified, references herein to a Subsidiary means a Subsidiary of Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Term Loan</B>&rdquo; is defined in Section&#8239;2.2(a)(i)&#8239;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Trademarks</B>&rdquo; means any trademark
and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the
entire goodwill of the business of Borrower and each of its Subsidiaries connected with and symbolized by such trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Warrant</B>&rdquo; means any of that
certain Warrant to Purchase Stock dated the Effective Date issued by Parent in favor of each Lender or such Lender&rsquo;s Affiliates
or any other warrant entered into in connection with the Term Loan, all as may be amended, restated, or otherwise modified or supplemented
from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>[Balance of Page&#8239;Intentionally Left
Blank]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, the parties hereto
have caused this Agreement to be executed as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ROCKWELL MEDICAL, INC.</FONT></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%"><FONT STYLE="font-size: 10pt">/s/ Mark Strobeck</FONT></TD>
    <TD STYLE="width: 50%">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Strobeck, Ph.D.</FONT></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ROCKWELL TRANSPORTATION, INC.</FONT></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mark Strobeck</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Strobeck, Ph.D.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">INNOVATUS LIFE SCIENCES LENDING FUND I, LP</FONT></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Innovatus Life Sciences GP, LP</FONT></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Its: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">General Partner</FONT></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Andrew Dym</FONT></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew Dym</FONT></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --> -</FONT>&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>tm242195d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="tm242195d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rockwell Medical Amends Loan and Security Agreement
with<BR>
Innovatus Life Sciences Lending Fund</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Defers
principal payments of $8.0 million up to three years, </I></B></FONT><B><I>reduces Rockwell's need for additional operating capital, and
enhances the Company's cash balance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B><I>Rockwell Medical provides
preliminary projected fourth quarter and full-year 2023 financial results</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Wixom,
Michigan, January&nbsp;8, 2024 </B></FONT>&ndash; Rockwell Medical,&nbsp;Inc. (the &quot;Company&quot;) (Nasdaq: RMTI), <FONT STYLE="background-color: white">a
healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers
worldwide</FONT>, today announced that the Company amended its loan and security agreement with Innovatus Life Sciences Lending Fund I,
LP (&quot;Innovatus&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rockwell Medical and its wholly owned subsidiary, Rockwell Transportation,&nbsp;Inc.,
initially entered into a loan and security agreement with Innovatus on March&nbsp;16, 2020 under which Innovatus agreed to make certain
term loans to the Company, of which the Company drew down approximately $21.0 million. At December&nbsp;31, 2023, the Company's outstanding
balance under those term loans was $8.0 million (the &quot;Term Loans&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the third amended and restated loan and security
agreement (the &quot;Amendment&quot;), Rockwell Medical reduced the interest rate on, and extended the loan maturity date for, the Term
Loans from March&nbsp;2025 to January&nbsp;2029. The Company will make interest-only payments for thirty months, or up to thirty-six months
if certain conditions are met. In connection with the execution of the Amendment, the Company issued to Innovatus a warrant to purchase
191,096 shares of the Company's common stock with an exercise price of $1.83 per share. The warrant is immediately exercisable through
January&nbsp;2, 2029.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;Over
the past 18 months, we significantly reduced the leverage on our business,&quot; said Mark Strobeck, Ph.D.</FONT>, President and CEO
of Rockwell Medical. &quot;As we work towards sustained profitability and positive cash flow, we continue to seek ways to enhance our
financial stability and our cash balance. Based on the amortization schedule under the loan and security agreement prior to the Amendment,
we would have been required to pay off $6.0 million of the outstanding debt in 2024 and $2.0 million in 2025, which would have significantly
reduced our cash balance during this period. While the Amendment extends the maturity date of the Term Loans out to January&nbsp;2029,
it offers us a better interest rate and the financial flexibility we need to help ensure long-term viability and sustainability of our
business.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more details about the Amendment, please reference the Current
Report on Form&nbsp;8-K filed by the Company on January&nbsp;8, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="border-top: Black 2pt solid; vertical-align: top; text-align: left"><TD STYLE="padding-top: 4pt; width: 33%">&nbsp;</TD><TD STYLE="padding-top: 4pt; width: 34%; text-align: center">&nbsp;</TD><TD STYLE="padding-right: 6pt; padding-top: 4pt; width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="tm242195d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Rockwell Medical Preliminary Fourth Quarter and Full-Year 2023 Projected
Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rockwell Medical projects net sales in the fourth quarter of 2023 to
be between $21.3 million and $22.3 million, a 10% to 16% increase over net sales of $19.3 million for the same period in 2022; gross profit
for the fourth quarter of 2023 to be between $1.6 million and $2.6 million, similar to gross profit of $2.3 million for the same period
in 2022; and projects that the Company will report adjusted EBITDA between $(0.9) million and $0.1 million in the fourth quarter of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rockwell Medical is narrowing its full-year 2023 guidance and projects
net sales for the twelve months ended December&nbsp;31, 2023 to be between $82.8 million and $83.8 million, a 14% to 15% increase over
net sales of $72.8 million in 2022, and gross profit for the full-year 2023 to be between $7.4 million and $8.4 million, an 80% to 105%
increase over gross profit of $4.1 million in 2022. The Company projects adjusted EBITDA for the full-year 2023 to be between $(5.5) million
and $(4.5) million. Rockwell Medical projects cash, cash equivalents and investments available-for-sale at December&nbsp;31, 2023 to be
$11.0 million compared to $11.7 million at September&nbsp;30, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fourth quarter 2023 and full-year 2023 net sales, gross profit
and adjusted EBITDA and December&nbsp;31, 2023 cash balance included in this release are preliminary and are therefore subject to adjustment.
The preliminary results are based on management&rsquo;s initial analysis of operations for the quarter and year ended December&nbsp;31,
2023. The Company expects to report fourth quarter and full-year 2023 financial and operational results in March&nbsp;2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Three Months Ended<BR> December&nbsp;31, 2023</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Twelve Months Ended <BR>December&nbsp;31, 2023</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">(In Millions)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Net Sales</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21.3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22.3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">82.8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">83.8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; font: 10pt Times New Roman, Times, Serif; text-align: left">Gross Profit</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.6</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">2.6</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">7.4</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">8.4</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(9.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(8.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Adjusted EBITDA*</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.9</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5.5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(4.5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><I>* See reconciliation to GAAP financial
measures in the tables below.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="border-top: Black 2pt solid; vertical-align: top; text-align: left"><TD STYLE="padding-top: 4pt; width: 33%">&nbsp;</TD><TD STYLE="padding-top: 4pt; width: 34%; text-align: center">&nbsp;</TD><TD STYLE="padding-right: 6pt; padding-top: 4pt; width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="tm242195d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Rockwell Medical<BR>
</B></FONT><FONT STYLE="background-color: white">Rockwell Medical,&nbsp;Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures,
commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to
provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry.
Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the
Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. </FONT>Hemodialysis
is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers,
hospital-based outpatient centers, skilled nursing facilities, or in a patient&rsquo;s home. <FONT STYLE="background-color: white">Rockwell
Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched
reliability and customer service. Rockwell Medical is the second largest supplier of acid and bicarbonate concentrates for dialysis patients
in the United States and has the vision of becoming the leading global supplier of hemodialysis concentrates. Certified as a Great Place
to Work</FONT><SUP>&reg;</SUP> in 2023, <FONT STYLE="background-color: white">Rockwell Medical is </FONT><I>Driven to Deliver Life-Sustaining
Dialysis Solutions<SUP>TM</SUP>. </I>For more information, visit www.RockwellMed.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain
statements in this press release may constitute &quot;forward-looking statements&quot; within the meaning of the federal securities laws.
Words such as, &quot;may,&quot; &quot;might,&quot; &quot;will,&quot; &quot;should,&quot; &quot;believe,&quot; &quot;expect,&quot; &quot;anticipate,&quot;
 &quot;estimate,&quot; &quot;continue,&quot; &quot;could,&quot; &quot;can,&quot; &quot;would,&quot; &quot;develop,&quot; &quot;plan,&quot;
 &quot;potential,&quot; &quot;predict,&quot; &quot;forecast,&quot; &quot;project,&quot; &quot;intend,&quot; &quot;look forward to,&quot;
 &quot;remain confident,&quot; &ldquo;are determined,&rdquo; &ldquo;are on track,&rdquo; &ldquo;has the vision,&rdquo; &quot;work to,&quot;
 &quot;drive towards,&quot; &ldquo;focused on,&rdquo; or the negative of these terms, and similar expressions, or statements regarding
intent, belief, or current expectations, are forward looking statements. These statements include, but are not limited to, Rockwell Medical&rsquo;s
expectations regarding its reduced need for additional operating capital and enhanced cash balance, the Company&rsquo;s ability to achieve
p</FONT>rofitability and positive cash flow, Rockwell Medical&rsquo;s <FONT STYLE="background-color: white">expectations and projections
regarding its future operating results and financial performance, and the Company&rsquo;s vision of becoming the leading global provider
of hemodialysis concentrates. While&nbsp;Rockwell Medical&nbsp;believes these forward-looking statements are reasonable, undue reliance
should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release.
These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including,
without limitation, those set forth in&nbsp;Rockwell Medical's SEC filings), many of which are beyond our control and subject to change.
Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed
in the &quot;Risk Factors&quot; section of our Annual Report on Form&nbsp;10-K for the year ended&nbsp;December&nbsp;31, 2022, as such
description may be amended or updated in any future reports we file with the&nbsp;SEC.&nbsp;Rockwell Medical&nbsp;expressly disclaims
any obligation to update our forward-looking statements, except as may be required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"># # #</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONTACT:<BR>
</B></FONT>Heather R. Hunter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SVP, Chief Corporate Affairs Officer<BR>
<FONT STYLE="background-color: white">(248) 432-1362</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IR@RockwellMed.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Financial Tables Follow</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>###</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="border-top: Black 2pt solid; vertical-align: top; text-align: left"><TD STYLE="padding-top: 4pt; width: 33%">&nbsp;</TD><TD STYLE="padding-top: 4pt; width: 34%; text-align: center">&nbsp;</TD><TD STYLE="padding-right: 6pt; padding-top: 4pt; width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="tm242195d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reconciliation to GAAP Financial Measures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated Adjusted EBITDA</FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">12 Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&nbsp;31, 2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&nbsp;31, 2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(in millions)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Low</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">High</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Low</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">High</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 48%; text-align: left">Net Loss</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(2.2</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(1.2</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(9.1</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(8.1</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Income taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Depreciation and amortization</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1.8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1.8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">EBITDA</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(6.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">One time severance costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.9</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.9</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Wanbang deferred revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Wanbang inventory reserve</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Adjusted EBITDA</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.9</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(5.5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4.5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="border-top: Black 2pt solid; vertical-align: top; text-align: left"><TD STYLE="padding-top: 4pt; width: 33%">&nbsp;</TD><TD STYLE="padding-top: 4pt; width: 34%; text-align: center">&nbsp;</TD><TD STYLE="padding-right: 6pt; padding-top: 4pt; width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>rmti-20240102.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa6IubOdzZR+KYkxtmB8bdlKHyMkdaeEGCZZxh1GkTwP -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:rmti="http://rockwellmed.com/20240102" elementFormDefault="qualified" targetNamespace="http://rockwellmed.com/20240102">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://rockwellmed.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="rmti-20240102_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="rmti-20240102_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>rmti-20240102_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>rmti-20240102_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://rockwellmed.com/role/Cover" xlink:href="rmti-20240102.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://rockwellmed.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm242195d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm242195d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ 28# 2(  A$! Q$!_\0
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M+R4:?JQTZY5L/'%.!M/^Z3D5+8Z7H.@)/)J6N+>>:H\R.YD5U;!R#MY)(/\
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M4(=3BM5AMA"4>(L20S-G@_[5=EK?B"+1);*%K.[NY[QV2**U52Q*J6/WF Z
MU1'C2UAGB34]-U+2XY6"+<7D2"+<>@+*S;<^^!2I\\7S1"?+)<LCRS_AGZ__
M .@_;?\ @.W^-'_#/U__ -!^V_\  =O\:]XZU0TK5[?6([I[=9%%M=2VC^8
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M7[T;": JP]P0"/I7;U$;:!KI;HP1FX5#&LI0;PI()4'K@D X]A50ERNXFKG
M2Z?K6I65_>^(HT5])L9X+?9]V>1D.Z?';*X ';+5U/@W_D1O#_\ V#;;_P!%
M+6S)&DT3Q2HKQN"K(PR&!Z@CN*2&&*V@C@@B2*&-0B1HH544#   Z #M52GS
M*PE&SN>?V#3CQ#XG$7B*'31_:7^J=8R6/D1?-\W/M^%=S;:C973^7;WEO/(!
MDK'(&./7 J";0-&N+B2>?2+"6:0[GD>V1F8XQDDC)X J2TT?3+"4RV>G6EO(
M1M+PP*AQZ9 Z<42DI"2:,+Q-/%;>*_"DL\J11BXN,N[  ?N&[FJWCO5],N_"
M5_I=O/#>WU_"UO:VT+AW>0C@@#H ><]L5U-YIMAJ(C%]96UT(R2GGQ*^TGC(
MR.*@A\/Z+;7<5W!I&GQ7,6?+F2V173(P<,!D<4U.*LWT!Q>OF2:-;SVFAZ?;
M7+;KB&VCCD.<Y8* ?UK"\"_\>FM_]AR^_P#1IKJJB@M;>U#BW@BA$CM(XC0+
MN=CEF..I)Y)[U'-H_,=M4<8]W:^'/B)J-[JZB&#4H8$M+UQ\B% 0T9;^$D\^
MAKH+CQ3HD$]O;_;X9KB>0)%# PD9B>^!V'7/H*OW^FV.J6_V?4+*WNX-P;R[
MB)9%R.AP01FJMOX=T.UO$N[?1M.AN8_N31VJ*Z\8X8#(XJG*+W%9K877-:M-
M TR2]NVP!D1H.LC[20@]S@UP)\)>++C1+M)!8KJ=U>C4!=^:V^*4$%0..B@;
M<>A->D7=A9WZ(EY:07*1N)$6:,.%8=&&>AY/-6*(SY5H-QON9'AK6?[=T2&[
M=/*N5+0W,7_/.9#M=?S'Y8K&T&_L[3Q3XN2YNX(6.H1$"20*2/LT/K756]K;
MV@D%M;Q0B60RR>6@7>YZL<=2>YJK-H.CW-Q)<3Z382SRD&25[9&9R  ,DC)X
M 'X4<T=?,+/0LV][:WF[[-<PS;<;O+<-C/KBBF6>FV.G[_L5E;VV_&_R8E3=
,CIG YZFBH=NA1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139916196210816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 02, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  02,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-23661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Rockwell
Medical, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001041024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-3317208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">30142
S. Wixom Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wixom<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">48393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">960-9009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RMTI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>tm242195d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rmti-20240102.xsd" xlink:type="simple"/>
    <context id="AsOf2024-01-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-01-02">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-01-02">0001041024</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-01-02">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-01-02">2024-01-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-01-02">Rockwell Medical, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-01-02">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-01-02">000-23661</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-01-02">38-3317208</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-01-02">30142 S. Wixom Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-01-02">Wixom</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-01-02">MI</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-01-02">48393</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-01-02">248</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-01-02">960-9009</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-01-02">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-01-02">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-01-02">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-01-02">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-01-02">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-01-02">RMTI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-01-02">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-01-02">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( (,\*%C:G1.P[@   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( (,\
M*%B97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ @SPH6-YU8W1"!   <Q   !@
M ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( (,\
M*%B?H!OPL0(  .(,   -              "  84,  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ @SPH6)>*NQS     $P(   L              ( !80\
M %]R96QS+RYR96QS4$L! A0#%     @ @SPH6*K$(A8S 0  (@(   \
M         ( !2A   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( (,\*%@D
M'INBK0   /@!   :              "  :H1  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( (,\*%AED'F2&0$  ,\#   3
M      "  8\2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
' -D3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm242195d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>rmti-20240102.xsd</File>
    <File>rmti-20240102_lab.xml</File>
    <File>rmti-20240102_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm242195d1_8k.htm">tm242195d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm242195d1_8k.htm": {
   "nsprefix": "rmti",
   "nsuri": "http://rockwellmed.com/20240102",
   "dts": {
    "schema": {
     "local": [
      "rmti-20240102.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "rmti-20240102_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rmti-20240102_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm242195d1_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://rockwellmed.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-02",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm242195d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-01-02",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm242195d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-24-002065-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-002065-xbrl.zip
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M@IH\),7SX#V4@'JWL/38;C(#B -"I]LA0) ,0LTHGR#-6<3%,Z\][C#C6SD
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M^MO :+?,O*E)39H&A0;$V5O\ @0>JD"U.C[49BR?%_/40^,JFQN/GA:/6![
MVVV6JAE4&H.O@G<&.;Z],* !QDV&CHB T!M@$[KAD$>B//0#*H)1+=K3^5EZ
MR )(XL_[>_) A'KO8$EVV6>YHZ>.,XP!L:[/W@8WQSR9ZPT, L*WNH5.]5)4
MKP"MU#-B917H=U4)RFNQ_7YY?=.U_"0WZTWRKQ5.B=SR7U!+ P04    " "#
M/"A803<DZUH'  #;5P  %0   ')M=&DM,C R-# Q,#)?<')E+GAM;,V<2W/;
M-A#'[YWI=V#5L][IPX[=C*U8&4V<V+6<I.TE Y&0A#$(: #0DKY] 5)2]"#
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M#^V@K>6]*TQ]W]DIEV]O;TNWM9+M3LI*J]4JS[!-033:F66VJU8J2OGSZ<E
MG3*3%G7+\ZFELJB3H5O7J^'CVZCIR#7T5%-\$@Y2*R^!AK=:W"'9>*LL7J::
M^IE-&Z*I'S;5/;M>5;;OPD.TB#K,5K55$&>@D'T^Z)_$S?WL]G'3LN]2RQO;
MKDE]F$.$U"A6JL7J5@)(T6-J"A!\+TWLFWOA-(LU)82S-#EI2O'UB'H1QS6V
MP.YP3'@!/:JUL*'+QBO!;I7A;=@P\(H32IVH\9AZ(]Y0ODA!A6>N;3 OLS5_
MDVJNVH'EN_-LC.7+5 ?/]9=!P\,T::8?,\&UU>M;9A@FTTJJ;6+#>D6I5 M<
MOQC5X)/@/WN^[ANLO5<6G_#69#XE"*;(O@7ZS;M"Q[9\9OG%X=P!AJOBV[N"
MSV9^6:AA&?N5)=B]?Q6+Y$AGAK9#!LS?)6?49#MDILUV2>^0_W%5J7:N+@=O
MJH?O]_<OX /I(,7BNKUKAU=([=4"E5<AE0\ 56]%O1[3O=&Z8B!C0 +\?]]D
ME@;_^D<&G5R-J>&QAX#J)D!U+9B/>0=@N=3H61J;';/Y505,6J4.&-8? '?K
M %A]>*5<2?,@!H!'#X%1O1I,J<N\J^H5MX8"B,>?/03.(>)R(6'5EE!:"7QD
M:W/B^7.#O2N,00)WB%)Q?#+436ARQFY)WS:IM2D>; ("KC[FLJ[I-V$_3?<<
M@\YWB&5;C+_49SLHM,Q%;>#?=$UC%M<-_ H-SP(38*E"[&=^'^W'OG<^1EDI
M5A2P?@5B :4 GND[*0DHM+D([)53D!X//%,F"NU8*#)'*J?(PH'!RC$7'"_S
M1 LTICL>]Y*  >&N;V?*+25J63%4B]+,TPKRM0^VX%W!TTW'8$+_Y5!IX&(X
MSP[<<#1HQN=X1]),=&V)YM VA4T9)SQZ&CW7-7PSUIE+./HLT^UT>L=I)BUV
MCH<K9XXG1W. I[:VC 7X?M<_I#YKQR2$D.)W2]U 4%9T"M\LHI5"('PHV9CF
M;6#I@K&@4DO<-!GU I>UI>[M0)L06/@J/01"6P%?*/+*(203>*-'CQ$;C*5Q
M0+EA&I=YBWVY$E#?=A.O'\Z#11RSH"8&/626;>K6?</>SY?%<;, A^]37%AB
MJ-3*A X*DQ#:O;TR](=/_-^>$]I*D[H3W=HAE4+[O_]6MBJ[>V6GO;))]#+A
M _J!P8H7=,)=8-(,BWY%WW:@KP..0CX8V;YOF_+9K:[Y4S3RE3>%5.^1[0+>
MHO>!0=5K4@4_X-F&KNT2^3*$)-XK\7OT'$5/_PY^"9[&I"$'Y'\3%)13)#R8
M/])-->]S4R$#..6DLDM0GXO4T"?P2 5;Q%Q@@>=0*PDY)*.)=.R-VI=GO6'W
MD R&^\/N8*\\ GJP2_M'XS7H=B[[O6&O.R#[9X?Y7/=SY\/^V?LNZ9R?GO8&
M@][YV3-ANXQ>)%IWR=H:-'RBWA1R5-^V-O.YPU*G1*J51KVUA/<2UO>&*-D\
MCK(C((0ZN@]$?6=K\']U9T[&.GS^_3&^5V$?#O 1YF^'U* O#7S[0;;N16S9
M2S'RF2S,J'UTWC^58W'AP:@ TXE6I<%3IF+QT%8##+LQ1;U2HX0N3NV^_].U
MMFS_8+O;:@+,QX3?R3$*[6;Q>#'<CB1U].SZM<"3-.-?<"!@/ICO?O=L2/K=
MB_/^\!6(@S$O M<+J.43WX:.*M:(!,E*C=AN/J<T-K2WQ!Z_#C;^E"$6@:O[
M.D#KSM0IM4"1]E4?<"!*JU9_5D3^6*C7LE#/(R($LS64A#YS;-<G&^%W1B$2
M9YY/V TTS>=<_IYI;T&H=LBB+3M<L&47/-WKBF0PVZA5/IGVH*%<M/Z^?I!1
M$Y77=P5]YN]H -V$ME.-SN> ,;.RC%X*F4+[+VH%U)V3ZB:I9A0>7L\21D'"
M*]K;%PVEE^5!E'WZ;*)[&"GY6%?+%H<OC=/CNCUQ5-8LK(JP L=AKHJE<\Z[
MQ]>AT@@5VGU9B\WG3IFFJ]38)#U++2V+QHL%H0O\W.C.*%AHQ!N5T8WP)=0C
MGL-4+/YH1 >>^UX^!T8==--]^[JBY-.1P>"E80!+5+X05BGP[P[5M/#[@Q%)
M&.PH*U9MPZ".!]8X_(O70'TW!'_#7!\G+D19)$EAT67/U^YNF#;X/-O*2LDD
M:K7:FXS,:[VR+@KN@K+LIY0%!,]VP=;RU:6!#R:K(U95.K:V0G?Z'T;7_L6-
MTYH:CS6EN/"%%3^?.:Y]@W*7MJ5KX%9H'S*#WH(5OM.DRC]][87FIOZL<[.=
MFILCW6! U(BYV1/A^(V!-J2W)_IC _7%<7CUMUBM;6TI/Y2KSROQ:?<PI+.>
M+&BK7++N8O'?WLWH(_UV<_)Q^TDL7C%HH5UK%FLU9;M:::[)</B/^TS&"&+1
M%?Z *QOD#\2&B-XE7R&@]\!3(>)D;^3*50R"SD)/*NG;]63"U#7-8&O)!'!]
MH9(H2U3+!:HP=B?/]<]#1EXJC(VIJ1OSG?O<SP(+@/<=VS1U#S=^Y'.HF42(
MRMM$*+ >EU=/;Z\_(%W3,>PY<Y/3F191<F:7WJ9DKLQ]\ \,'Y\I$EZP#[64
M?=C7-)=YGOPXT2VF9-N&[5K0H ?]L];EUE,CQ(PQP314E'HUGQN4R"=]9IM
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MT3XE:2)(X&#A7"[I+"8X#RXRY'.+5896JZ1$=;4_]8.?0OM:SZ!]<7P\"#?
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MI6ZPH@U-PQ6:H>MZ6=<T$:<T^@G-2$FJ!OI//U_0\:.+8(9;.6_I+!590BI
M-:&IY@N0'\S>0SLQ[SF_KJ*_+LL433[/9]2M\\MJV:"CQY ^-,%[__'HR4%\
M<'#P\.!@'VW3O=9BKJ#O\ % V[I-OGOXC39- F&3L7>4O']@GH.[D8_ZE[^?
M?:E-:YG)ODVQ<2$925Q8">)M8?MOF9=HN:A*3T40N3KYG99 !#[4*=(!9+'=
M,N%^R,LO4"H<34E_@TX#'2J'-E>2NI:I/J=[>+YL21WS1BZRU]XU3;AAP],M
M(IV^C"ZJ2L3'55(LDTF1A6^3):RS:98O^)B*<D9M879) "33=V5U763I!0PE
M/@'F,C9/L*BBTSZCHU5=-S]N<4'.CWYY<1(](TWY]=$QU/?_^NK@*_[WF]='
MS\R_]:W7>=I>XK4'__DTNFL7'K35@KMA/YA4;5O-^3,Z".=G=Q\<[?4VGR:%
MV1#T"OA-?CH_OGM;.C@X*;X^/_[Y@]IX^"0OJ9WGK\A^]AIYT.3_SJ0E/OF'
M#T45Q7-_^*W<TD]O?SX^>7[Z\A1&SILX.GKV[-7;E^<PQV#6OSHG&1.=GYS]
M1F+F[<_R5KSNZ_,S_!\VP1=UY/5#LK(R-&HF'%-ZJ!WXJ']@QI[)=4E+".V:
M!>NR(=$L4E,M)9;9+&VRI"2!U!$JM$[A17CX& MBI#*-"9(\S69YR5J,".3H
MB%IF8]W<V>B$"/?QB#LQ6;:D;+B?WMBIZ()NB=+<*7I)J'+SK$HS>F$)036M
MEB7?S'@BNO4]I-^(,&SK)7U%'R<LEZ'[B*KSZ]'1:S&OJ5=T;J?+0C4.Z>@$
MWJ4T6_?3AZ1UR)UF5 'J!#V2DUBW]V"C&L%X)&V*YT+&CT;G"U+/,"@:1J9W
MH[I'&AEX(RL4X\YT?S<N%+H",G6.UMF,AD]=;-BFXD4,5,)E28W2$CE'"[0O
M]I%M\Y:]%^J?4*@_^IA"'8[9-RS"67C#6?WZZ)_BE]YI.?YH.W+\=5W-Z1B2
M_*ZBU\D*$_C0LR%%_UJ65D>$5PY.-_R(G27P@V4)"4U1TEFJ^#XU,OM('BW@
M"IY#>EH#ROG:DO0*8@TZ_7ADWTWO96&L[;*0G$Y9D.+ORW*1Y)"I)/U(YY>K
MP?@J26;)[2#O;*)TF?%@EM*62+GK2Y+Y^*8O7>$M\@77YVP"?.5\=__KP0.R
M1K,B_9$6\R)[2L__:PEY3,T^C5XM^&KY$>WJI?LT^CLI[?@Z>O!  W<_'9_^
M/0RRB5 [?#0@U;[%9Q.:NJRVG_U2D$H?'5+?FJK(4^K?!P;DQ&6YH8A]X,^"
M&?_3Z'RUH&$>U<DDGSZ-7I+5*'/TLL+(#_T??6U^A6\>_*6<- M>K9^^IID9
MF*1)G27O'DPR4FJHT05/O-_5;P>ZBLGT)\9;4=HAPZ_TNXBNRY)]EGORKK+M
MT39D&T3,>,0RAN7:9WR&-YFO0\S67K*_%77^[<^OG- >CYQTQK7ZQ<^<[+2]
M?"MS]PI1)+I49JU>?]8G'WKVXVBQK)ME4EJ?TR:.OM #QL: =W4B#FTL#T2S
M-FUUWP]PR2N2"_KR NY?=V7[%[F[OL6!HPZU<(QPZY!]-QZ)@5>)@><%6]FX
MT[!+-TYM^NUO/L\WCYBC[[%SKCS/=]?S0HM/B[42U@AX4HZKZ9)-(_%BL1M8
M7-+.4UAG"U(LZ"$UR,2;7=>T?G!-W> :BVY\XWCDJTLVU"E.+E:I:#@T#]!+
M2'-9T#L\G]W )&F0:>@;CL5+8ZG3?^(P]"J[QJW#FNG_TF4 2X#)MJ3G&0+"
M$DXB>>FIL6)SSY-W9,G3Z"ZA/LN3O%FM_EJ5] T9X_3-%*NHNW#&T;B]PY_>
MO'W]<T.MX\]]J.J\T_C,B5>4W1*] QF;6#OO J_AH 7J"&]*A6#@Q]Q9T:J-
M9*NKY<6E'A@#?N@UE=,(TIS^QG9"1FJ]/C8>'<VQE_\M/F@\[%D:;O?3[,3A
MZ(/VG9CM2E=H_7E)<H $%SN0Z4\SY7::=>Y]#P0L /BQT>:"=E>51I.LO<ZR
M00%G0[)^KQY&SWHKUQMM'/560H[>X%)TYS_N0A!X2Y&BZHW2WUA6B'>A-LEB
M4>13]M.;6:%- A.HIE?5#9[W+3I!]*AK2@+&O?CZGEP)PPZL%%(1 Z?V27HG
M$PA5ZGZ9S[ B&8VJWH\F20,W(L3OC[3?S3GEF\G>/)Y!: -\5ES%T=XC_V>9
M7;A:)]:.-^)K$Q>(WIR=:-RCAX])T=*SL_?8M)H([H,7R[J_9 GT3BJ7B$KC
M7;PFB, ":H+5]O=4;V_8*^.WI)6K6K85_)QBZ8Y'GB5]BRW,ZZR!3=,S[U;(
MQ1[&+VDTNA.BV1(^U7*H%^?![\<C -Y87DV@+&3Z\IZ'4N>TB4B_WYO:2:37
MXH-T1ZZ4Z;:NE-]HII*VJE?CT6N[[T0?CTYGM'P1Z0[L'&^F=3X9VL??\<3O
MY5;QK::D"3:12CM?4ZC9&9P5B-H!GQC<*?PS=NQRG)Q>?<*OIK\?9[-D6;0]
M\13< \!*54:)C>VN"P7-T!:"!J0;&0?Y=5U%9TF;1&\NJ<-\/HUT"(YALP0>
M@>2('3BZ-.R6ZONC%L6RV<C79*Y$B5DZV2!X'V_:\8+G;!(\S^2;X"NWO/(]
M=V OOPHZSQ+\E8=)8$@'UJUSF%F:Z_T<\S32P"/&:FI 5A="12AICHNL;-3U
M;P<I>!&SOICVK"=8&->1T,/<!?&U/8Q>5BT>=-;D'H(DIB/IDN\?%GWX;-]
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M:+J=*2L\$9>O%$@:<B[V#UYY5157G(XVKZ1,6AF]*NV%%*V]CP[=?<0OT$3
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M2]E:0OJT5D0PSWJX)\,WZ!&FS+.L[;\KJ,:50OZE-F\%=ZP8>/W"7)H1XU4
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MQ>191OP;X:CQB_.LJ84P'@7%>;#IPEH_2D$II0B4VLM9F&0C>D(&<L+$]0/
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MLW8 IDJU6CD-?EE#I]@9[-"?MQ$9+LK5'V)FZ40N)-<3SIO%TK"6*@\^6:T
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MBL(EBW3ZHLFN8AG8N2\J6F"M13L>T7>D#4K<N[GDVA,#;VR,>6%^G(DJ<IU
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MH]3[9\*KDOUK*:7IBOQ=IKF9XMP8;L\[$)P'GH?->O#I0)M2<=,3G)=@J&&
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M*V"+F\M\P=+/%OU\82+7HM([(7127BC-QB;"DJQ5\S@>,E)B//)X(SB[2+]
M,A[_@EU_/@E98F-:KVC'Y2 *Z<#4JDZ40HJ#M%+FRI>%!1LNB8%<Y4W##.U[
M_;QV[ZAI22_[VU1/!O\V[>3$,[.:E!<&WXP11[7 V6V)X:=L3%AYZ6P/CA/_
M+5NIF#5)@JSO*VY>[S1_NEKFAK9VJT]XJ0RH:S#;N<<DO1%^VY2,[:=DFBA>
M%Y8.X;*<SQE89D#G9:/A)X&=*_N&73CW0&,S^,<C5XF:151;3=]=5@4TJF#
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MM13#PP%.O$BSG0_Y'M7;O*(J?+OT%\L%<>6NF!MFDP9)Y,)L[:R.Q@<#V=[
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MJUU!O]-*A^$/V(?3YXZ&N@M.Z>Z%#96*:$]X!3V?F]8^GB!@FF:&2L_);>G
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M=ZIHB4K8K4C:HMS>.:?. TB"$MHDP0V0DKE__3>O:\T%@!3MA&U16R^)18+
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M%#$KA+K3KQ(W6L2<XOJ%%6U2S *F?*I,[K(B)Y<D&=F#A9T]\09F:?\669#
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MLY+38R8-XIO2F+> K2NQX)1D#ON#G[7<O;:RC?-!LX6/5W[]NL9>2TVOK:I
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M1DW5R':C_<B4:P/'=1-.\P;1)IS=4C L4$N6(& <S4PU31 N!!,,NFCO >P
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M Z'NK5-@^<'NP<,\;6Y8QMC9@5=KQ^V*:<^-^!PCFY*1(867RWL\MU7*S5W
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MPA[PR? A6!<#HI,KTCX>2P-#=T1B<#B5KX2ZDY3 X&:'/_WX0QRPHNJ$=)1
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MXGG(=R(9 P<.<?OP8EH$^-H9(ND3[4S#:*HXL9)R:C9'^>VS8/O[_X9KB(?
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MUD)1E<-UDM2%I(Z))D3[3GTU6TDBE!0[5M72:$>3QI6LD*8I/F@=$V(H$T!
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M_IC-=E&A\N[#U^._--_ZY\;YV<'_ U!+ 0(4 Q0    ( (,\*%@M5R@H+0,
M .P+   1              "  0    !R;71I+3(P,C0P,3 R+GAS9%!+ 0(4
M Q0    ( (,\*%C^LT#U_0H  ("&   5              "  5P#  !R;71I
M+3(P,C0P,3 R7VQA8BYX;6Q02P$"% ,4    " "#/"A803<DZUH'  #;5P
M%0              @ &,#@  <FUT:2TR,#(T,#$P,E]P<F4N>&UL4$L! A0#
M%     @ @SPH6&-#;P\J&P  '9   !$              ( !&18  '1M,C0R
M,3DU9#%?.&LN:'1M4$L! A0#%     @ @SPH6#LQ9J:#V   'IH$ !4
M         ( !<C$  '1M,C0R,3DU9#%?97@Q,"TQ+FAT;5!+ 0(4 Q0    (
M (,\*%@AQ<@#M"\  .TO 0 4              "  2@* 0!T;3(T,C$Y-60Q
M7V5X-"TQ+FAT;5!+ 0(4 Q0    ( (,\*%C88\<Q.14  !S"   5
M      "  0XZ 0!T;3(T,C$Y-60Q7V5X.3DM,2YH=&U02P4&      < !P#,
) 0  >D\!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
